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ABSTRACT
G protein-coupled receptor (GPCR) sorting into the degradative pathway is
important for attenuating signaling. Perturbations in this process can manifest in a variety
of diseases. Upon agonist activation of the chemokine receptor CXCR4, a GPCR, it is
rapidly ubiquitinated, internalized to endosomes and sorted for degradation in lysosomes
via the endosomal sorting complex required for transport (ESCRT) pathway. This process
culminates in attenuation of CXCR4 signaling. CXCR4 overexpression and increased
CXCR4 signaling have been associated with several pathologies including immune
deficiency disorders and over 23 cancers. Yet the mechanisms governing the regulation
of CXCR4 signaling remain elusive.
CXCR4 is ubiquitinated by the HECT-domain E3 ligase AIP4 at the plasma
membrane. AIP4 is also localized on early endosomes and regulates CXCR4 sorting by
modulating the activity of the ESCRT machinery. In particular, ESCRT-0 ubiquitination
has been shown to be linked to the efficiency by which CXCR4 is sorted for lysosomal
degradation. However, mechanistic insight is lacking and the precise role of AIP4 in
these processes remains poorly defined.
The objective of this project is to gain a greater understanding of the mechanisms
mediating AIP4 regulation of CXCR4 degradation. AIP4 is known to interact with other
E3 ligases, including DTX1 and Cbl-c, but whether these E3 ligases or others are
$$!"

involved in CXCR4 sorting is not known. Here, we show for the first time that the RINGdomain E3 ubiquitin ligase Deltex-3-like (DTX3L) mediates CXCR4 sorting from early
endosomes to lysosomes. Using several biochemical and immunochemical techniques
including fixed cell confocal immunofluorescence microscopy, co-immunoprecipitation
and in vitro ubiquitination assays, we show that upon CXCR4 activation DTX3L
localizes to early endosomes where it directly interacts with and inhibits the activity of
the AIP4. Thereby, limiting the extent to which ESCRT-0 is ubiquitinated while
promoting CXCR4 sorting for lysosomal degradation. Therefore, we have defined a
novel role for DTX3L in GPCR endosomal sorting and propose that DTX3L may play a
broad role in endosomal sorting. In addition, our data reveal an unprecedented link
between two distinct E3 ubiquitin ligases to control the activity of the ESCRT machinery.
Overall, these findings may prove beneficial in developing strategies to modulate CXCR4
levels and be broadly applicable to CXCR4-related pathologies.
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CHAPTER I
INTRODUCTION
OVERVIEW OF G PROTEIN-COUPLED RECEPTORS
G protein-coupled receptors (GPCRs) comprise a superfamily of proteins that
promote changes in cellular response attributable to nearly every physiological process.
GPCRs are the largest class of targets for many drugs used to treat a variety of diseases
highlighting their role pathophysiologically (Overington, Al-Lazikani, & Hopkins, 2006).
Specifically, GPCRs are integral plasma membrane proteins that consist of single
polypeptide chains containing seven transmembrane (7TM)-spanning domains that are
connected by extracellular and intracellular loops (Pierce, Premont, & Lefkowitz, 2002).
There are over 800 functional GPCRs expressed by the human genome that respond to a
diverse array of stimuli and control a multitude of physiological processes including
vision, smell, pain, neurotransmission, muscle contraction and immune responses
(Fredholm, Hokfelt, & Milligan, 2007; Jacoby, Bouhelal, Gerspacher, & Seuwen, 2006;
Pierce et al., 2002). The regulation of GPCR signaling is a tightly controlled process and
perturbations in GPCR signaling have been linked to several pathologies (Jacoby et al.,
2006; Pierce et al., 2002).
According to the International Union of Pharmacology (IUPHAR), GPCRs are
classified into five distinct groups based on amino acid sequence similarity: Class-I

1

2
rhodopsin-like (family A), Class-II secretin-like (family B), Class-III glutamate (family
C), Adhesion and Frizzled/other 7TM families (Hamann et al., 2015).

Class-I receptors comprise the largest group of GPCRs that consists of rhodopsin-like
receptors. These receptors all have similarity to the first GPCR identified, the rhodopsin
receptor and possess within their transmembrane helix a conserved Asp-Arg-Tyr (DRY)
motif. Additionally, there are 273 genes encoding this family of receptors that include 89
orphan receptors for which no known ligands have been identified so far. Members of
this family include: !1 and !2 adrenergic receptors, chemokine receptors, opioid receptors
and dopamine receptors among many more important receptors. Nearly half of class A
GPCRs are olfactory receptors that mediate responses to odor (Buck & Axel, 1991).

The second class of GPCRs include secretin-like receptors and are encoded by 48 genes
(Zalewska, Siara, & Sajewicz, 2014). This class of GPCRs bind large glycoproteins and
include secretin, calcitonin, corticotropin-releasing factor, growth-hormone releasing
hormone and parathyroid hormone receptors (B. Martin et al., 2005). Class II GPCRs
contain a large spanning N-terminal region and differ from Class I GPCRs in their amino
acid sequence. In particular, these receptors lack the DRY motif found in Class I GPCRs,
however, Class II GPCRs display the same heptahelical transmembrane structure.

The third class of GPCRs consists of metabotropic receptors encoded by 22 genes.
Receptors in this class bind to relatively small ligands such as glutamate and Ca2+.

3
Members of this group include metabotropic gamma-amino-butyric acid type B
(GABAB), calcium-sensing receptor (CaR) and glutamate receptors. Although similar in
structure, Class III GPCRs share little sequence identity within their amino acid sequence
with Class I and II (Brauner-Osborne, Wellendorph, & Jensen, 2007).

The fourth group of GPCRs is classified as adhesion receptors of which there are 33
members. These receptors are characterized by a long N terminal region containing a
GPCR-Autoproteolysis Inducing (GAIN domain) and by a distinct 7TM region
displaying little similarity with other families of GPCRs (Arac et al., 2012). Adhesion
receptors are required for cell to cell as well as cell to extracellular matrix interactions.
An interesting feature of adhesion receptors is that they undergo proteolysis within the Nterminal region mediated at the GPCR Proteolysis Site (GPS) of the GAIN domain.
Based on these characteristics, the structure of these receptors is sub-divided into a long
spanning extracellular domain (ECD), 7TM domain and intracellular domain (ICD). The
majority of adhesion receptors are classified as orphan receptors (Schulte, 2010).
However, it has been identified that several of these receptors bind to small molecules or
peptides (Hamann, Vogel, van Schijndel, & van Lier, 1996; Stacey et al., 2003; Wandel,
Saalbach, Sittig, Gebhardt, & Aust, 2012; T. Wang et al., 2005).

The final group of GPCRs are encoded by 11 genes that include Frizzled receptors
involved in Wnt signaling, Smoothened receptors involved in hedgehog signaling and
taste receptors that mediate taste responses (Kinnamon, 2012; Schulte, 2010). Taste

4
receptors are subdivided into two types, T1Rs for sweet and umami stimuli and T2Rs for
bitter stimuli (Kinnamon, 2012). Many of these receptors are important in embryonic
development and are highly homologous to the second class of GPCRs.

CHEMOKINE RECEPTORS
Chemokine receptors belong to the Class A superfamily of GPCRs. In mammals,
approximately 19 chemokine receptors have been identified and each can activate a
diverse signaling pathway (Murphy et al., 2000). Chemokine receptors bind to shared or
specific ligands known as chemokines (Allen, Crown, & Handel, 2007). Chemokines are
small proteins (8-10 kDa) whose function is associated with chemotaxis or cell migration.
Chemokines are divided into four classes based on the spacing of the N-terminal cysteine
residues within the proteins structure (i.e. C, CC, CXC, CX3C) (Allen et al., 2007;
Baggiolini, Dewald, & Moser, 1997; Fernandez & Lolis, 2002). Chemokine receptors are
named based on the class of chemokine they bind. For example, CXC receptors (CXCR)
bind to the class of CXC chemokines; CC receptors (CCR) bind CC ligands, etc.
Chemokine receptors regulate a multitude of cellular processes necessary for
development as well as hematopoiesis, angiogenesis and inflammation in the adult
(Baggiolini et al., 1997; Moser & Loetscher, 2001; Premack & Schall, 1996).
Chemokines are known to regulate immune cell trafficking (i.e. homing, extravasion,
circulation) among several other biological functions such as cell adhesion and cytokine
secretion (Zlotnik, 2006).

5
GPCR ACTIVATION
Activation of GPCRs allows for the transmission of information from the
extracellular environment into the inside of the cell. Classically, GPCR signaling is
mediated through associated guanine nucleotide binding proteins (G proteins) that are
heterotrimers composed of " and !# heterodimer (Gilman, 1987). Coupling of the
receptor to the associated G proteins allows for the transduction of information from the
outside of the cell to the inside. GPCR signaling can also be mediated via mechanisms
independent of the associated G protein. These topics are highlighted in the following
section.

GPCR SIGNALING
Upon agonist binding, GPCRs undergo a conformational change primarily within
the transmembrane regions 3 (TM3) and 6 (TM6) that facilitates the exchange of GDP for
GTP on the "-subunit of associated G protein (Gilman, 1987; Pierce et al., 2002). This
event causes dissociation of the heterotrimeric G protein into " and !# subunits which go
on to activate a diverse array of effector proteins to initiate signal transduction of the
external stimulus to the internal compartments of the cell (Fredholm et al., 2007; Oldham
& Hamm, 2008; Pierce et al., 2002). This signaling culminates in discrete changes in
cellular response (Figure 1.1). The G"-subunit coupled to a GPCR can vary based on the
type of ligand that binds to a particular GPCR. G"i inhibits adenylyl cyclase leading to a
reduction in the conversion of to adenosine triphosphate (ATP) into the second

6
messenger cyclic AMP (cAMP), whereas G"s activates adenylyl cyclase to increase
cAMP levels. The G"q subunit stimulates phospholipase C (PLC-!) that leads to
production

of

diacylglycerol

(DAG)

and

inositol

trisphosphate

(IP3)

from

phosphatidylinositol bisphosphate (PIP2). The G"12/13 subunit is involved in the activation
of Rho family GTPases that regulate the actin cytoskeleton. Additionally, the !# subunits
activate PI3K, PLC- and adenylyl cyclase signaling pathways (Oldham & Hamm, 2008).
Some GPCR signaling does not involve the heterotrimeric G proteins (Figure
1.1). This G protein independent signaling can lead to activation of several signaling
pathways including Janus kinase and signal transducer and activator of transcription
signaling pathway (JAK/STAT), mitogen-activated protein kinase (MAPK) and p38.
Taken together both G protein dependent and independent signaling downstream of
GPCR activation leads to changes in cellular responses including migration, proliferation
and survival.
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Figure 1.1 GPCR Activation and Signaling. GPCR activation can lead to both G
protein and G protein independent signaling. Ligand activation of GPCRs results in
conformational change in the receptor that promotes the exchange of GDP for GTP on
the "-subunit. This results in the dissociation of the heterotrimeric G protein into " and
!# subunits. Certain GPCRs bind preferentially to a subtype of the "-subunit. The G"subunit can be further subdivided based on the second messengers they activate.
Additionally, the !# subunits activate particular second messengers and, hence,
downstream signaling pathways. G protein independent signaling can also lead to
activation of several signaling pathways (Dorsam & Gutkind, 2007).
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REGULATION OF GPCR SIGNALING
A key component to the regulation of GPCR signaling involves desensitization,
internalization and downregulation or recycling of the receptor. Desensitization is the
process by which receptor signaling following initial activation is rapidly terminated even
in the continued presence of stimulus. Typically the removal of activated GPCRs from
the cell surface occurs via a complex process leading to their internalization and
endocytosis onto intracellular compartments known as endosomes (Marchese, Chen,
Kim, & Benovic, 2003). On endosomes, GPCRs can be sorted for long-term signaling
attenuation by degradation in the highly acidic environment of the lysosome (Marchese,
Chen, et al., 2003; Tsao & von Zastrow, 2000). Conversely, GPCRs can be recycled back
to the cell surface following dephosphorylation by an endosomal associated phosphatase,
therefore, resensitizing the GPCR to further rounds of receptor signaling (Pitcher, Payne,
Csortos, DePaoli-Roach, & Lefkowitz, 1995).

DESENSITIZATION
Regulation of GPCR signaling can occur at multiple levels including the level of
the signaling proteins and/or the receptor itself. Following the activation of the associated
G protein via the exchange of GDP for GTP within the "-subunit, GPCR signaling can be
terminated through GTP hydrolysis. This is mediated by accessory proteins such
regulators of G protein signaling (RGS) enzymes. RGS proteins are multifunctional
enzymes that facilitate GTP hydrolysis and act to turn off G protein dependent signaling
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pathways (De Vries, Zheng, Fischer, Elenko, & Farquhar, 2000). While effective at
deactivating G protein-mediated signaling, this process occurs rather slowly within a time
frame of 50 seconds (Ross & Wilkie, 2000). Alternatively, the process of signal
termination can occur directly through modification and recruitment of adaptor proteins
to the GPCR. Receptors can be desensitized intracellularly by a G protein receptor kinase
(GRK) dependent pathway or through the activities of second messenger-dependent
kinases including protein kinase A (PKA) and protein kinase C (PKC) (Moore, Milano,
& Benovic, 2007).
Stimulation of GPCRs usually results in rapid phosphorylation on serine or
threonine amino acid residues located within the third intracellular loop by GRKs
(Krupnick, Goodman, Keen, & Benovic, 1997). Mammalian GRKs are subdivided into
three groups: The first group is comprised of GRK1 and GRK7, the second GRK2 and
GRK3 and the third GRK4, GRK5, and GRK6. Early studies identified that GRK2
regulated agonist-promoted internalization of the M2 muscarinic acetylcholine (M2)
receptor (Tsuga, Kameyama, Haga, Kurose, & Nagao, 1994). In particular,
overexpression of GRK2 promoted internalization, whereas a catalytically inactive
mutant of GRK2 did not. GRK-mediated phosphorylation occurs within a few seconds
following receptor activation and provides a binding surface for the adaptor protein !arrestin, which is required to uncouple the receptor from the associated G protein
(Gurevich et al., 1995; Lohse, Benovic, Codina, Caron, & Lefkowitz, 1990; Moore et al.,
2007). !-arrestins prevent further coupling to the associated G protein through steric
hindrance and bridge the receptor to components of the internalization machinery (Lohse
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et al., 1990). !-arrestins can promote signal termination either through degradation of
second messengers (Perry et al., 2002) or internalization of the GPCR (Goodman et al.,
1996; Laporte et al., 1999). This type of GRK and !-arrestin mediated desensitization is
known as homologous desensitization (Figure 1.2).
Alternatively, GPCR signaling can be regulated by heterologous desensitization.
In this process, activation of one receptor can lead to the activation of a different receptor
through the activities of PKC or PKA. For example, CXCR4 contains many serines (Ser)
that are potential PKC phosphorylation sites within its C-terminal tail. Stimulation with
the phorbol ester phorbol-12-myristate-13-acetate (PMA) activates PKC and can promote
the phosphorylation and internalization of CXCR4 (Haribabu et al., 1997; Signoret et al.,
1997; Signoret et al., 1998). Mutational analysis of serine residues within CXCR4 Cterminal tail determined that internalization upon PMA treatment was dependent on upon
either Ser 324 and Ser 325 or Ser 338 and Ser 339 (Signoret et al., 1998). In particular
using a phospho-specific antibody, it was demonstrated that PMA treatment could
mediate phosphorylation of Ser 339. However, the precise mechanism of PMA promoted
CXCR4 phosphorylation and internalization remains to be explored. Overall, PKC
regulation of CXCR4 phosphorylation is an important mechanism that regulates also
CXCR4 plasma membrane expression.
Additional examples of GPCRs regulated by heterologous desensitization include
the dopamine receptor (D3R) (Cho et al., 2007) and metabotropic glutamate receptor 4
(mGluR4) (Mathiesen & Ramirez, 2006). The desensitization of D3R is mediated by a
PKC dependent mechanism but independent of GRK/!-arrestin (Cho et al., 2007). In
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particular, treatment with PMA induces PKC phosphorylation of Ser 229 and 257 in D3R
leading to its downregulation. In the case of mGluR4, its desensitization is also
dependent upon PMA activation of PKC (Mathiesen & Ramirez, 2006). Overall, both
homologous as well as heterologous desensitization promote downregulation of GPCR
signaling albeit by different mechanisms.
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Figure 1.2. GPCR homologous desensitization and internalization. (1) GPCRs under
basal or resting conditions are associated with heterotrimeric Guanine nucleotide-binding
proteins (G proteins) that are heterotrimers composed of " and !# heterodimer. Under
these conditions the associated "-subunit of the G protein is inactive and bound to GDP.
(2) Following activation of the receptor upon binding to its cognate ligand, the GPCR
undergoes a conformation change that leads to the exchange of GDP for GTP on the "subunit. This results in dissociation of the heterotrimeric G proteins into " and !#
subunits, which are able to activate downstream signaling pathways through activation of
a diverse array of effector molecules. (3) GPCR signaling is typically terminated through
G protein receptor kinase (GRK) recruitment to the activated receptor leading to
phosphorylation of serine or threonine residues within the C-terminal tail of the GPCR.
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(4) Arrestin can bind to the phosphorylated receptor and acts to uncouple the receptor
from the associated heterotrimeric G proteins through steric hindrance. This G protein
uncoupling promotes receptor desensitization. (5) Desensitized receptors are internalized
as a result of the interaction with Arrestin with components of the internalization
machinery, clathrin and AP2. (6) Receptor is internalized via clathrin-coated pits.

INTERNALIZATION
One of the major pathways in which a GPCR internalizes is via clathrin-coated
pits (CCPs) at the plasma membrane. Two important components of the internalization
machinery include clathrin and clathrin-associated protein (AP) complexes (Figure 1.2)
(Goodman et al., 1996). Clathrin relies upon adaptor and regulatory proteins to induce
formation and invagination of CCPs. In particular, clathrin adaptor protein 2 (AP2) is
recruited to the plasma membrane via the phospholipid PIP2. AP2 functions as an adaptor
protein and can recognize tyrosine or dileucine-based motifs within the C-terminal tail of
some GPCRs to facilitate entry into the forming CCP (as reviewed in Marchese, et al.
2008). Non-visual arrestins (!-arrestin 1 and 2) can interact with both clathrin and AP2 to
also link the GPCR into the forming CCP. Some of the first studies to demonstrate a role
for !-arrestins in GPCR internalization came from studies of the !2 adrenergic receptor
(!2 AR) (Ferguson et al., 1996; Goodman et al., 1996). It was demonstrated that !arrestins facilitate !2 AR internalization by binding with high affinity directly to clathrin
(Goodman et al., 1996). In addition, it has been shown that !-arrestins through discrete
elements in the C-terminal tail interact with both heavy chain of clathrin and !-subunit of
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AP2 (Y. M. Kim & Benovic, 2002). This interaction of !-arrestins with the assembled
CCP promotes recruitment of additional clathrin and clathrin adaptor proteins,
culminating in the invagination and release of the CCP from the plasma membrane.
Alternatively, ubiquitin modified GPCRs or those containing short linear peptide
sequences can be recognized by alternative clathrin adaptors to mediate entry into CCPs.
In addition to binding !-arrestins, AP2 can bind to receptor tyrosine or di-leucine motifs.
For example, within its C-terminal tail CXCR2 contains two di-leucine motifs. When
these motifs are mutated, CXCR2 can still bind !-arrestins, but is unable to bind AP2 and
internalize (Fan, Yang, Wang, Qian, & Richmond, 2001). Thus in the case of CXCR2, !arrestins do not play a role in internalization. Furthermore, ubiquitin can have an indirect
role in GPCR internalization via ubiquitination of !-arrestins. However, the
internalization of most GPCRs does not require direct ubiquitination but instead relies
upon !-arrestin dependent mechanisms (Kang, Tian, & Benovic, 2014).

DOWNREGULATION
Following internalization, GPCRs can be trafficked to early endocytic
compartments where they are sorted for degradation in the lysosome or recycling via
recycling endosomes (Figure 1.3). Ubiquitin modification of some GPCRs at the plasma
membrane allows for entry into the degradation pathway on early endosomes. This
ubiquitin dependent downregulation was first described for !2 AR (Shenoy, McDonald,
Kohout, & Lefkowitz, 2001) and the chemokine receptor CXCR4 (Marchese & Benovic,
2001). Upon agonist activation, B2AR was shown to be ubiquitinated, thereby, promoting
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its degradation. CXCR4 downregulation is dependent on AIP4-mediated ubiquitination
(Marchese, et al., 2003). Other GPCRs that require ubiquitin for their downregulation
include PAR2, V2 vasopressin receptor (V2R), and the kappa-opioid receptor (KOR)
(Cottrell et al., 2006; Jacob et al., 2005; N. P. Martin, Lefkowitz, & Shenoy, 2003). For
these ubiquitin modified receptors, it is thought that ubiquitin acts as a sorting signal that
allows for the receptor to be recognized by the ESCRT machinery on early endosomes
and subsequently concentrated into the invaginating domain of the endosome that buds
off to form multivesicular bodies (MVBs). These MVBs fuse with lysosomes leading to
receptor degradation (Figure 1.3).
Some GPCRs are not modified by ubiquitin upon agonist stimulation and,
therefore, require additional factors for downregulation as is the case for PAR1. In fact,
PAR1 is constitutively ubiquitinated at the plasma membrane and following agonist
activation is deubiquitinated promoting its internalization. Once localized onto early
endosomes, PAR1 is sorted on endosomes independent of endosomal sorting complex
required for transport (ESCRT) machinery components ESCRT-0 (HRS) and ESCRT-I
(Tsg101). Instead, the accessory proteins adaptor protein complex 3 (AP-3) and ALGinteracting protein X (ALIX) are required. AP-3 binds to internalized PAR1 on
endosomes and facilitates the interaction of PAR1 with ALIX. ALIX binds to the
YPX(3)L motif of PAR1 (intracellular loop 2) and recruits ESCRT-III (Dores et al.,
2012). Thus, ALIX mediates sorting of PAR1 into MVBs independent of ESCRT-0-II
and receptor ubiquitination.
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Figure 1.3. General model of GPCR endosomal trafficking. Activation of some
GPCRs does not result in receptor ubiquitination (orange receptor). These receptors upon
internalization localize to endosomes where they enter the recycling pathway allowing
for further rounds of signaling at the plasma membrane. Conversely, some activated
receptors (purple receptor) can be modified at the plasma membrane by ubiquitin (Ub)
prior to internalization. Internalized receptors localize to the endosome where the
ubiquitin modified receptor can be sorted to either degradation or recycling pathways
upon deubiquitination by an endosomally associated deubiquitinase (DUB).
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RECYCLIING
Internalized GPCRs can also be trafficked to early endocytic compartment where
they are sorted for recycling via recycling endosomes. Some ubiquitinated receptors can
have ubiquitin removed by deubiquitinating enzymes (DUBs) (Figure 1.3). These
receptors can traffic back to the plasma membrane by recycling endosomes.
Alternatively, GPCRs that are not ubiquitinated prior to internalization and localization to
endosomes directly enter the recycling pathway and are returned to the plasma membrane
to elicit further signaling.

THE UBIQUITIN PATHWAY
Post-translational modification of protein substrates by ubiquitin dictates the
cellular fate of the protein. For example, ubiquitin modification of GPCRs plays a major
role in membrane trafficking process on endosomes. In addition, ubiquitin modification
of adaptors can regulate signaling downstream of receptors. This section will focus on
the ubiquitin pathway and the factors necessary to mediate ubiquitin modification of
protein substrates.

UBIQUITIN CONJUGATION
Ubiquitin is a 76 amino acid protein that becomes covalently attached to protein
substrates through the formation of an isopeptide bond between the C-terminus of
ubiquitin and the lysine residues on target substrates. Specifically, the epsilon amino
group of a lysine residue within the protein substrate becomes covalently attached to the
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C-terminal glycine residue (Gly-76) of ubiquitin. Ubiquitin conjugation of proteins is
carried out by an enzymatic cascade involving the sequential activity of three enzymes:
E1, E2 and E3 (Fang & Weissman, 2004; Pickart, 2001). In this process, ubiquitin is first
activated in an ATP-dependent manner by the E1-activating enzyme (Figure 1.4). The E1
enzyme forms a thioester bond with activated ubiquitin, which is then transferred to the
active site cysteine of the E2-conjugating enzyme. The E2 enzyme helps link E1
activation of ubiquitin to final E3 covalent modification of protein substrates. Final
substrate ubiquitination is mediated by the E3 ligase that recruits and binds specific
substrates.
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Figure 1.4. The Ubiquitin Pathway. Ubiquitin conjugation to protein substrates is
dependent upon the activities three enzymes: E1, E2 and E3. The E1 activating enzyme
activates ubiquitin in an ATP-dependent fashion leading to the formation of a thioester
bond between activated ubiquitin to the active site cysteine (Cys) in the E1 enzymes. The
E2 conjugating enzyme accepts the activated ubiquitin forming a thioester linkage
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between ubiquitin and the active site Cys in the E2 enzyme. Final substrate ubiquitination
is mediated by the activities of one of two classes of E3 ubiquitin ligases. HECT domain
E3 ligases accept ubiquitin from the E2 enzyme and lead to direct ubiquitination of the
protein substrate. In contrast, RING and RING-like domain E3 ligases facilitate indirect
ubiquitination of protein substrates by bridging the E2 enzyme in proximity to the
substrate. Ultimately, this process leads to the covalent attachment of C-terminal glycine
reside in ubiquitin to epsilon amino group of a lysine residue within the substrate.
Substrates can either be modified by one ubiquitin (monoubiquitination) or subject to
modification with multiple ubiquitin molecules (polyubiquitination).

TYPES OF UBIQUTIN MODIFICATION
Ubiquitin modification of substrates can have multiple outcomes depending on
the type of ubiquitin modification. There are several types of ubiquitin modifications that
have been identified. The particular type of ubiquitin modification, monoubiquitination
versus

polyubiquitination,

of

a

substrate

will

dictate

its

cellular

function.

Monoubiquitination or multi-mono ubiquitination have been implicated in receptor
internalization and trafficking (Haglund, Di Fiore, & Dikic, 2003; Polo et al., 2002).
Ubiquitin itself can act as an acceptor of additional ubiquitin molecules. Within its
structure ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, Lys 48 and K63)
that can all be linked to ubiquitin to form poly-ubiquitin chains.
The most common types of poly-ubiquitin chains are those formed by linkages at
K48 and K63 (Rotin & Kumar, 2009). K48, as well as K29, linkages have been
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demonstrated to promote proteolysis of misfolded or damaged substrates mediated by the
26 S proteasome. K48 poly-ubiquitin chains are recognized by the ubiquitin interacting
motif (UIM) of proteasomal receptor S5a/Rpn1 (Pickart, 2000; Sparks et al., 2014).
Overexpression of a dominant negative form of S5a/Rpn1 lacking it UIMs or siRNA
depletion of RS5a/Rpn1 inhibits proteasomal degradation and stabilization of tumor
suppressor protein p53 (Sparks et al., 2014). The ubiquitin-associated domain (UBA)
containing protein Rad23 binds to K48 chains, thereby, inhibiting their interaction with
the 26 s proteasome and proteolysis. This demonstrates that ubiquitin binding domains
can both positively and negatively regulate the fate of ubiquitinated proteins (Raasi &
Pickart, 2003).
In contrast to K48 linkages, K63 poly-ubiquitin chains play a major role in postendocytic sorting and localization of substrates for degradation in lysosomes
(Erpapazoglou et al., 2012; Lauwers, Jacob, & Andre, 2009). In particular, K63 chains
have been linked to MVB biogenesis and UBD containing proteins such as the ESCRT-0
complex recognize K63-modified receptors on endosomes (Erpapazoglou et al., 2012). It
has also been suggested that the ESCRT-0 complex itself can be modified by K63
ubiquitination to modulate receptor sorting (Erpapazoglou et al., 2012).
The less common or atypical poly-ubiquitin linkages have been shown to function
in several cellular pathways. The function of K6 and K11 poly-ubiquitin chains has been
implicated in neurodegenerative disorders (Cripps et al., 2006). For example, loss of the
E3 ligase Mahogunin ringer finger-1 (MGRN1) has been implicated in spongiform
neurodegeneration. It has been shown that the auto-catalytic activity of the E3 ligase
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BRCA1 is dependent upon K6 to promote BRCA functioning with the E3 ligase BARD1
(Wu-Baer, Lagrazon, Yuan, & Baer, 2003). Additionally, K11 poly-ubiquitination plays a
major role in endoplasmic reticulum-associated degradation (ERAD) pathway (Xu, P et
al., 2009). K27 and K33 poly-ubiquitin chains have been identified in vitro, however,
until recently the physiological function of atypical poly-ubiquitin chains linked to K27
and K33 have started to be demonstrated (Birsa et al., 2014; David et al., 2010; Yuan et
al., 2014). Recently, it has been shown that K27 poly-ubiquitination of the outer
mitochondrial membrane protein Miro1 is dependent upon the E3 ligase Parkin following
mitochondrial damage in human dopaminergic neuroblastoma cells (Birsa et al., 2014).
Dysregulation of this K27 ubiquitination may play a role in the pathogenesis of
Parkinson’s disease. K33 poly-ubiquitin chains have been implicated in trans-Golgi
network (TGN) trafficking (Yuan et al., 2014). The ubiquitin ligase Cul30KLHL20
mediates K33 poly-ubiquitination of coronin 7 that is essential for the biogenesis of
transport carriers derived from the TGN. Future studies are needed to further shed light
on the role of these atypical poly-ubiquitin chains in the regulation of other cellular
processes including GPCR trafficking.
Importantly, it has been shown that HECT-(Homologous to the E6-AP Carboxyl
Terminus) domain E3 ligases directly contribute to the type of chain linkage formed
through its interactions with the E2 enzyme whereas for RING (Really Interesting New
Gene) domain ligases the E2 determines the chain linkage (Christensen, Brzovic, &
Klevit, 2007; H. C. Kim & Huibregtse, 2009; Li, Tu, Brunger, & Ye, 2007; Schwarz,
Rosa, & Scheffner, 1998). For example, the HECT domain of E6AP preferentially
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catalyzes K48 poly-ubiquitin chains whereas other HECT ligases such as Rsp5/Itch
catalyze K63 poly-ubiquitin chains. The type of E2 does not, however, determine chain
specificity given that Rsp5 created similar K63 poly-ubiquitin linkages regardless of the
E2 (Ubc1, Ubc5 and Ubc4). Furthermore, a chimera protein of Rsp5 swapped with the C
lobe of E6AP conferred Rsp5 the ability to form K48 poly-ubiquitin chains typified by
the HECT domain of E6AP. Replacement of the C lobe of Itch/AIP4 with that of E6AP
conferred Itch/AIP4 with the ability to form K48 poly-ubiquitin chain formation
(Huibregtse, Scheffner, Beaudenon, & Howley, 1995). Thus, the particular type of E3
ubiquitin ligase as well as E2 conjugating enzyme have a major role in dictating the
ubiquitin modification of substrates.

E3 UBIQUITIN LIGASES
E3 ligases represent a diverse family of over 600 identified proteins in the
mammalian genome (Metzger, Hristova, & Weissman, 2012; Metzger & Weissman,
2010). Given the vast number of E3 ubiquitin ligases able to interact with discrete
substrates, E3s often provide a level of specificity to the ubiquitin reaction. E3s are
generally distinguished by whether they enable indirect or direct modification of protein
substrates. E3 ligases are divided into two classes: HECT ligases that facilitate direct
ubiquitination of substrates or ligases that act as scaffolds including RING and RING-like
F-box domain ligases (Deshaies & Joazeiro, 2009; Metzger et al., 2012). Over 95% of
mammalian E3 ligases belong to the RING or RING-like domain family and
approximately 30 ligases belong to the HECT domain family (Metzger et al., 2012). Of
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the 95% of RING domain ligases, the RING-like family of F-box containing ligases
comprise eight members (Petroski & Deshaies, 2005).

RING AND RING-LIKE DOMAIN CONTAINING LIGASES
RING-domain or RING-like domain containing E3s act as scaffolds in the
ubiquitination reaction, thereby, facilitating the indirect transfer of ubiquitin from the
bound E2 enzyme to the protein substrate. Thus, RING domain and RING-like E3s lack
intrinsic catalytic activity and instead act as adaptors. The RING domain motif is
characterized by a specific sequence of evenly spaced Cysteines and Histidines residues
that are able to coordinate two zinc ions in a crossbrace fashion (Metzger et al., 2012).
This enables E2 binding and E2-mediated ubiquitination of substrates.
The crystal structure of the RING domain of c-Cbl in complex with the E2
enzyme UbcH7 and substrate (a ZAP70 kinase peptide) highlights the typical features of
a RING domain in mediating indirect transfer of ubiquitin (Zheng, Wang, Jeffrey, &
Pavletich, 2000). These studies reveal that three-stranded Beta sheets, an alpha helix and
two large loops form the structure of the RING domain, which is stabilized by two zinc
ions. UbcH7 binds the RING domain of c-Cbl and is separated by ~60 A from the
substrate also bound to the RING domain. Moreover, the specificity of the E2 enzyme for
c-Cbl RING domain lies between the interaction of Phe63 of UbcH7 and Trp408/Ile383
of c-Cbl RING domain. Interestingly, comparing RING domain of c-Cbl to the crystal
structure of the HECT domain of E6AP bound to UbcH7 reveals a common structural
theme between E2 binding to HECT or RING domains even though both are distinct in
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their structures (Huang et al., 1999). The crystal structures of the dimeric RING-like
domain ligases such as the U-box ligase CHIP display a similar interaction with the yeast
E2 Ubc13 and mammalian E2 UbcH5a (Xu et al., 2008; Zhang et al., 2005). UbcH5a
binds to the CHIP hydrophobic groove that includes Phe62 whereas Ubc13 binds to
CHIP via Met 64, a residue homologous to Ph63. This suggest that cognate E2s for their
E3s depends solely on the structural contacts made between the E2 and E3, not the type
of E3 domain.

HECT-DOMAIN LIGASES
HECT-domain ligases all possess a highly conserved ~350 amino acid C-terminal
HECT domain that directly accepts ubiquitin within a conserved cysteine residue and
facilitates substrate ubiquitination directly. The HECT domain is a bilobal domain
divided into an N and C Lobe linked by a broad catalytic cleft (Huang et al., 1999). The
N-lobe is where E2 enzyme binding occurs while the C lobe contains the catalytic
cysteine residue that forms the thioester linkages with ubiquitin. The two lobes are linked
by a flexible hinge region that is crucial for E2 transfer of ubiquitin chains to the HECT
domain catalytic cysteine (Huang et al., 1999; Verdecia et al., 2003). HECT domain
ligases have been shown to interact with E2 enzymes UbcH5, UbcH7 and UbcH8 (S.
Kumar, Kao, & Howley, 1997; Nuber, Schwarz, Kaiser, Schneider, & Scheffner, 1996;
Schwarz et al., 1998). This structure is well demonstrated for HECT domain ligase E6AP
and UbcH7 (Huang et al., 1999). Phenylalanine 63 of UbcH7 is bound to E6AP on a
hydrophobic groove within the N lobe region. This brings UbcH7 into close proximity to
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the active site cysteine within the C-lobe of E6AP. The distance between the active site
cysteine of the HECT domain and UbcH7 is 41 A. Other HECT domain ligases are
thought to display a similar structure to E6AP.
Although HECT ligases are highly homologous in their HECT domain, these
ligases differ in their N-terminal regions. The binding of substrates occurs in regions
outside of the HECT domain. HECT ligases are subdivided into three families: HERC,
Nedd4 and other HECTs (Rotin & Kumar, 2009). The HERC family of HECT ligases is
distinguished by the presence of regulator of chromosome condensation 1 (RCC1)-like
domains (RLDs). RLDs can interact with chromatin and may be a Guanine nucleotide
exchange factor (GEF) the GTPase Ran (Garcia-Gonzalo & Rosa, 2005; Rosa, CasaroliMarano, Buckler, Vilaro, & Barbacid, 1996). Nedd4 family members contain two to four
tandemly linked WW domains able to interact with proline-rich sequences and an Nterminal calcium-dependent phospholipid-binding domain. Other HECT ligases contain
only HECT domains or various unique domains. For example, E6AP contains only a
HECT domain whereas HACE1 (HECT domain and Ankyrin repeat Containing E3
ubiquitin-protein ligase 1) contains ankyrin repeats in addition to the HECT domain
(Anglesio et al., 2004; Rotin & Kumar, 2009).

HECT DOMAIN LIGASES IN GPCR TRAFFICKING
Nedd4 HECT ligases have been implicated in the regulation of plasma membrane
receptor trafficking (Marchese, Raiborg, et al., 2003; Rotin & Kumar, 2009; Shenoy et
al., 2008). The Nedd4 family comprises nine mammalian members: Nedd4, Nedd4L,
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AIP4 (Itch), WWP1, WWP2, SMURF1, SMURF2, NEDL1 and NEDL2. The Nedd4
ortholog in yeast, Rsp5, was the first Nedd4-related ligase shown to mediate endocytosis
of a receptor (Belgareh-Touze et al., 2008; Dunn & Hicke, 2001). Following agonist
activation by alpha-mating factor, it was shown that Ste2p receptor was rapidly
ubiquitinated by Rsp5. Rsp5 mediates monoubiquitination of Ste2p receptor which
promotes receptor endocytosis and recognition by UIM containing endocytic adaptors
epsin and Eps15 (Dupre, Urban-Grimal, & Haguenauer-Tsapis, 2004; Terrell, Shih,
Dunn, & Hicke, 1998). In mammalian cells, atrophin-interacting protein 4 (AIP4) has
been shown to mediate ubiquitin dependent downregulation of CXCR4 (Marchese,
Raiborg, et al., 2003). Additionally, downregulation and desensitization of B2AR
signaling is dependent on Nedd4-mediated receptor ubiquitination (Shenoy et al., 2001).

ATROPHIN-INTERACTING PROTEIN 4 (AIP4)
AIP4 was among the first ubiquitin ligases shown to be involved in agonistpromoted ubiquitination of a mammalian GPCR (Marchese, Raiborg, et al., 2003). AIP4
belongs to the NEDD4-family of HECT ligases. This ligase contains four tandemly
linked WW domains, N-terminal calcium-dependent phospholipid-binding domain and a
conserved carboxyl-terminal HECT domain (Figure 1.5A) (Rotin & Kumar, 2009). A
unique feature of AIP4 is that is has a proline-rich region (PRR) that binds a subset of
Src-homology-3 (SH3) domains. Studies have demonstrated that AIP4 can mediate
substrate ubiquitination through the interaction of the HECT domain with UbcH5 and
UbcH7 families of E2 enzymes (H. C. Kim & Huibregtse, 2009; Schwarz et al., 1998;
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Scialpi et al., 2008; Wenzel, Stoll, & Klevit, 2011). Interestingly, AIP4 has been shown
to interact with other E3 ligases such as Cbl-c, deltex-1 (DTX1) and RNF11. These three
ligases all belong to the RING domain family of E3 ligases.
The Cbl family of proteins consists of 3 related proteins: c-Cbl, Cbl-b and Cbl-c
(Fig 1.5B with domain structure). Unlike c-Cbl and Cbl-b which are ubiquitously
expressed, the expression of Cbl-c is documented as restricted to epithelial cells (Schmidt
& Dikic, 2005). These proteins all contain within their structure an N-terminal tyrosine
kinase binding domain (TKB) that mediates interactions with phospho-tyrosine modified
proteins, a RING E3 ligase domain that leads to substrate ubiquitination and a proline
rich region (PRR). In contrast to c-Cbl and Cbl-b, Cbl-c lacks the C-terminal ubiquitinbinding domain known as an ubiquitin-associated leucine zipper (UBA). The Cbl family
of ligases has been implicated in the downregulation of epidermal growth factor receptor
(EGFR) signaling (Courbard et al., 2002; Ettenberg et al., 1999; Levkowitz et al., 1999;
Levkowitz et al., 1998). Using a yeast two-hybrid screen it was identified that Cbl-c
interacts with AIP4 (Courbard et al., 2002). In this study, Cbl-c and AIP4 were shown to
co-localize in cells upon EGF stimulation, however, the identity of the subcellular
compartment where there interaction occurs was not demonstrated. Although is can be
speculated that both proteins are localized to microdomains on early endosomes where
EGFR is sorted for degradation. Biochemical assays demonstrated that the interaction
between Cbl-c and AIP4 is mediated through the proline rich region of Cbl-c and the
WW domains of AIP4. Furthermore, it was shown that AIP4 and Cbl-c act synergistically
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to downregulate EGFR signaling, although the mechanism by which this occurs remains
unknown.
AIP4 interacts directly with DTX1 on endosomes to target DTX1 for degradation
in lysosomes, modulating its cellular activity (Chastagner, Israel, & Brou, 2006). The
ortholog of AIP4 in Drosophila (Supressor of Deltex (Su(Dx)), acts as a negative
regulator of activated Notch signaling and antagonizes the activity of Deltex by
promoting post-endocytic sorting and degradation of Notch (Mazaleyrat et al., 2003). In
mammalian cells, it was demonstrated that AIP4 interacts with DTX1 on endosomes
where is mediates K29 poly-ubiquitination of DTX1 targeting it for degradation in
lysosomes. These studies conclude that AIP4 antagonizes the cellular function of DTX by
promoting K29-dependent degradation of DTX in mammalian cells (Chastagner et al.,
2006).
Another AIP4-interacting RING ligase is RNF11. RNF11 is overexpressed in
several mammalian breast tumors and has been shown to interact with several HECTdomain containing ligases including AIP4, Smurf1 and Smurf2 (Kitching et al., 2003).
However, the role of these ligase interactions physiologically remains to be defined.
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Figure 1.5. Domain structure of AIP4, Cbl family and DTX family protein
structure. A. AIP4 domain structure consists of a N-terminal C2 phospholipid binding
domain, a central proline rich region (PRR), four tandemly linked WW domains and the
C-terminal HECT E3 ligase domain. B. The Cbl family proteins of ubiquitin ligases are
comprised of three members: c-Cbl, Cbl-b and Cbl-c. All three proteins consist of a
Tyrosine Kinase Binding domain (TKB), which interacts with specific phosphotyrosines on substrates, RING ligase domain that mediates substrate ubiquitination and
PRR. Both c-Cbl and Cbl-b also possess a C-terminal ubiquitin-associated leucine zipper
(UBA) domain whereas Cbl-c lacks the N-terminal UBA domain. These proteins play
major roles in the regulation of tyrosine kinase signaling pathways through the activities
of their TKB domain. C. The deltex (DTX) family of ubiquitin ligases is comprised of
three closely related proteins (DTX1-3) in addition to the distantly related protein known
DTX3L. DTX ubiquitin ligases have a highly conserved carboxyl-terminal RING
domain and members of the DTX family of proteins were first identified for their role in
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Notch signaling. DTX1 and DTX2 contain a basic N-terminal region that binds to
intracellular Notch ankyrin repeats in addition to a central PRR and. In contrast, DTX3
and DTX3L contain a unique N-terminus and lack the central proline-rich region;
however, DTX3 and DTX3L are highly homologous to the other DTX family proteins
within the C terminal RING domain.

DELTEX-3-LIKE (DTX3L)
The DTX family of ubiquitin ligases comprises three closely related proteins
(DTX1-3) and a distantly related DTX3-like (DTX3L) (Figure 1.5C). DTX proteins were
first identified to be regulators of Notch signaling (Kishi et al., 2001). DTX proteins form
a family based on the highly homologous C-terminal RING domain. DTX1 and DTX2
possess two tandem N-terminal WWE domains that bind to Notch ankyrin repeats
whereas the N-terminus of DTX3 and DTX3L lack these WWE domains (Matsuno,
Diederich, Go, Blaumueller, & Artavanis-Tsakonas, 1995; Takeyama et al., 2003). In
contrast to other DTX members, DTX3L contains an unique N-terminus and lacks the
central proline-rich region, however, DTX3L is highly homologous to the other DTX
family proteins within the C terminal RING domain (Takeyama et al., 2003). As
described above, RING domain ligases bind to E2 enzymes acting as scaffolds to
facilitate indirect transfer of ubiquitin to substrates. In particular, DTX3L has been shown
to specifically interact with the UbcH5 family of E2 enzymes to mediate substrate
ubiquitination, but not UbcH4, UbcH6 or UbcH7. Additionally, DTX3L has been shown
to heterodimerize with DTX1 leading to enhanced DTX1 activity (Takeyama et al.,
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2003). This interaction is mediated through the unique N-terminal region of DTX3L. The
relevance of this interaction and whether DTX3L interacts with other E3 ubiquitin ligases
remains to be explored.

E2 CONJUGATING ENZYMES
In the human genome there are nearly 40 identified E2 enzymes (Metzger et al.,
2012). The E2 enzymes contain a conserved ubiquitin-conjugating (UBC) domain of
~160 amino acids that has the catalytic cysteine residue able to form a thioester with
activated ubiquitin. Recent data on the trafficking of EGFR, a receptor tyrosine kinase
(RTK), suggest that the E2 enzymes UbcH5b/c (also known as Ubc4/5) in conjunction
with the E3 ligase c-Cbl is required for degradation and ubiquitination of EGFR
(Umebayashi, Stenmark, & Yoshimori, 2008). Immunofluorescence studies demonstrated
that of the E2 enzymes screened (Ubc2, Ubc3, Ubc4, UbcH5a, UbcH5b, UbcH5c,
UbcH6, UbcH8 and UbcH13), UbcH5b and UbcH5c were the only E2 enzymes to colocalize with c-Cbl at the plasma membrane as well as the early endosomes following
EGF stimulation. Furthermore, siRNA-mediated knockdown of UbcH5b/c, but not
UbcH7, prevented EGF promoted ubiquitination of EGFR (Umebayashi et al., 2008).
These data highlight the potential importance of specific subsets of E2 enzymes through
their activities with respective E3s ligases in the regulation of receptor trafficking. While
it is intriguing that subsets of E2s may regulate RTK ubiquitination and trafficking,
whether this idea applies directly or indirectly to GPCR trafficking remains to be
investigated.
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DEUBIQUITINATING ENZYMES (DUBs)
Modification of protein substrate with ubiquitin is usually transient and reversible
by ubiquitin specific proteases (USPs) or deubiquitinating enzymes (DUBs). DUBs
mediate cleavage of the isopeptide bond between Ub and its substrates through protease
activity. Several studies have identified important DUBs in regulating GPCR trafficking.
A role for DUBs in GPCR trafficking was first defined in yeast. The deubiquitinating
enzyme Doa4 was found to localize to the pre-vacuolar compartment where it has a role
in recycling ubiquitin from cargos destined for degradation in the vacuole (Amerik,
Nowak, Swaminathan, & Hochstrasser, 2000).
In mammals, DUBs and USPs modulate the trafficking of several GPCRs. The
DUB AMSH has been shown to interact with and regulate ESCRT-0. In particular, both
AMSH and USP8 have been shown to regulate the ubiquitination and degradation of the
GPCRs protease activated receptor 2 (PAR2) and delta-opioid receptor (DOR)
(Hasdemir, Murphy, Cottrell, & Bunnett, 2009; Hislop, Henry, Marchese, & von
Zastrow, 2009). Depletion of either AMSH or USP8 using siRNA prevented PAR2
ubiquitin dependent degradation, trapping the receptor in early endosomes (Hasdemir et
al., 2009). DOR downregulation is also dependent upon deubiquitination activities of
AMSH and USP8. Overexpression of catalytically inactive mutants of either enzyme
prevented WT DOR downregulation, whereas downregulation of lysine-less mutant of
DOR still downregulated in the presence of mutant AMSH and USP8 (Hislop et al.,
2009).
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USP8 and AMSH indirectly promote CXCR4 sorting by antagonizing the ubiquitin
modification of ESCRT-0 mediated by the E3 ligase AIP4 (Berlin, Higginbotham, Dise,
Sierra, & Nash, 2010). Unlike PAR2, both USP8 and AMSH do not regulate
deubiquitination of CXCR4 itself. Instead, the DUB USP14 has been implicated as a
direct regulator of CXCR4 ubiquitination (Mines, Goodwin, Limbird, Cui, & Fan, 2009).
Upon CXCL12 stimulation, USP14 associates with CXCR4 to promote deubiquitination.
Depletion of USP14 by siRNA or overexpression of USP14 prevented CXCR4
ubiquitination, thereby, blocking receptor degradation.
USP8 has recently been shown to control the sorting of lysosomal enzymes necessary
for lysosomal degradation (MacDonald, Urbe, & Clague, 2014). Lysosomal
enzymes/hydrolases are sorted away from the Trans-Golgi network to the endocytic
pathway and are ultimately delivered to the lysosome. Ultimately, delivery of acidic
hydrolases to the pre-lysosomal compartment allows for degradation of receptors
delivered to the lysosome. Thus, USP8 plays a role in both sorting at the endosome as
well as delivery of enzymes to the degradative lysosomal compartment.
The highly related DUBs USP20 and USP33 have been implicated as regulators
of !2AR recycling. Downregulation and desensitization of !2AR is dependent upon
receptor ubiquitination by Nedd4. On early endosomes, deubiquitination of !2AR by
USP20 and USP33 promotes receptor recycling (Berthouze, Venkataramanan, Li, &
Shenoy, 2009). This results in resensitization of receptor signaling at the plasma
membrane. Altogether the balance of ubiquitination versus deubiquitination in GPCR
trafficking is important in controlling the magnitude and duration of receptor signaling.
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FUNCTIONAL ROLE OF GPCR UBIQUITINATION
GPCR trafficking and endocytosis is also controlled by covalent modification of
lysine residues within the receptor or adaptor proteins by ubiquitin. Ubiquitination of
GPCRs regulates cell surface expression and, thus, the level of signaling. The ubiquitin
moiety can act as a sorting signal that promotes trafficking of the receptor at the
endosomal compartment. Ubiquitin modification of GPCRs can occur constitutively or be
promoted by agonist stimulation. Typically, agonist dependent ubiquitination of GPCRs
occurs at the plasma membrane as is the case for the chemokine receptor CXCR4.
Although this ubiquitin-dependent trafficking is not exclusive to all GPCRs. Some
GPCRs themselves are not modified by ubiquitin, however, their endocytic sorting is
dependent upon additional factors. Proteins can also possess ubiquitin recognition motifs
that can bind ubiquitinated substrates. In particular, ubiquitination of plasma membrane
receptors can dictate endocytic sorting via interactions of ubiquitin with endocytic sorting
machinery. At the endosome the receptor can be recognized by a number of ubiquitin
interacting proteins that possess ubiquitin binding domains (UBDs) or ubiquitin
interacting motifs (UIMs). Overall, ubiquitin regulation of GPCRs can have pleiotropic
effects.

UBIQUITIN IN ESCRT-DEPENDENT SORTING
Ubiquitinated receptors are targeted at the endosome into forming MVBs by the
endosomal sorting complex required for transport (ESCRT) machinery, which comprise
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four conserved protein complexes (ESCRT0-III) (Table 1.1). The ESCRTs together with
the AAA-ATPase Vsp4 complex and other accessory proteins act in a concerted fashion
to recognize and concentrate the ubiquitinated receptor into the invaginating membrane
of the endosome and facilitate formation of intraluminal vesicles of MVBs (Hurley,
2008; Marchese, Paing, Temple, & Trejo, 2008; Williams & Urbe, 2007). Thus, ESCRT
proteins not only concentrate receptors into the invaginating membrane of the endosome,
but also facilitate the formation of the MVB. MVBs fuse with highly acidic lysosomes
leading to receptor degradation and, hence, desensitization of receptor signaling.
The ESCRT proteins were first identified in yeast Saccharomyces cerevisiae as
class E genes of vacuolar protein sorting (Vps) that associate with endosomes. These
studies employed indirect immunofluorescence microscopy in which the vacuole was
indirectly visualized by antibodies against either the vacuolar integral membrane protein,
ALP, or the subunit of the vacuolar H+-ATPase, V-ATPase (Raymond, HowaldStevenson, Vater, & Stevens, 1992). It was demonstrated that class E Vps mutants change
the morphology of the yeast vacuole (the equivalent of the mammalian lysosome) and
result in the accumulation of cargoes (i.e. A-ALP and CPY; Ste3p) to a pre-vacuolar
organelle. This accumulation of cargo in these mutants was attributed to defects in the
delivery cargo from the limiting membrane of the vacuole to the lumen for degradation
(Piper, Cooper, Yang, & Stevens, 1995; Raymond et al., 1992).
Further studies in mammalian cells demonstrated that the ESCRT machinery is
highly conserved. In mammalian cells, ESCRT comprises four multimeric protein
complexes (ESCRT-0 – III) in addition to activities of AAA-ATPase-Vps4 (Table 1.1).
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ESCRT complexes are recruited sequentially to the endosome membrane to mediate
cargo targeting into the limiting membrane of endosomes leading to the generation of
ILVs that comprise the MVB. Three of the four ESCRT complexes (ESCRT-0-II)
contain UBDs that recognize/interact with the surface of ubiquitin on cargo to facilitate
sorting into the ILVs of MVBs. UBD containing proteins can be ubiquitinated themselves
and disruption of individual ESCRT-UBDs results in defective sorting of certain cargoes
into the MVBs. It is thought that ubiquitin supports ESCRT function by mediating
changes in the intramolecular interactions between ESCRT proteins or facilitates cargo
release by changing intramolecular interactions between UBDs and Ubiquitin on cargo.

Table 1.1 Proteins in the ESCRT pathway
Complex

Mammalian
Protein
ESCRT-0 HRS
STAM-1, STAM-2
ESCRT-I Tsg101
Vps28
Vps37A, B, C, D
MVB12A, B
UBAP1
ESCRT-II EAP30
EAP25
EAP45
ESCRT-II CHMP2A, B
CHMP6
CHMP3
CHMP4A, B, C
CHMP5
CHMP1A,B
Accessory ALIX
Proteins
VPS4A, B
LIP5
IST1

Yeast Protein
Vps27
Hse1
Vps23
Vps28
Vps37
Mvb12
Vps22
Vps25
Vps36
Vps2
Vsp20
Vps24
Vps32/Snf
Vps60
Did2
Bro1
Vps4
Vta1
Ist1

Domains
FYVE, UIM, VHS, PSAP
UIM, SH3, VHS
UEV
Coiled-coil
SOUBA
Coiled-coil, WH
PPXY, WH
GLUE, NZF, WH
Coiled-coil
Coiled-coil
Coiled-coil, MIR
Coiled-coil
Coiled-coil
Coiled-coil
Bro1
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RECOGNITION
ESCRT-0, composed of HRS and STAM-1/STAM-2, initially recognize
ubiquitinated cargo at the endosome. HRS and STAM exist as a 1:1 complex on
endosomes through the association of their coiled coil region, however, HRS and STAM
may also form a heterotetrameric complex (Mayers et al., 2011). Localization of ESCRT0 to endosomes is mediated in part through selective binding of the FYVE (Fab1, YOTB,
Vac1 and early endosome antigen-1) domain in HRS to phosphatidylinositol 3-phosphate
(PI-3P), an endosomally enriched phospholipid (Raiborg et al., 2001; Stenmark, Aasland,
& Driscoll, 2002). In addition, HRS and STAM-1/STAM-2 both contain ubiquitin
binding domains (UBDs) (Bilodeau, Urbanowski, Winistorfer, & Piper, 2002; Henne,
Buchkovich, & Emr, 2011; Prag et al., 2007; Raiborg et al., 2002; Ren & Hurley, 2010)
able to interact with several ubiquitin moieties at once (Mayers et al., 2011). In particular,
the ubiquitin interacting motif (UIM) of HRS interacts with and recruits ubiquitinated
cargo to be sorted on the endosome (Stringer & Piper, 2011). In addition to interacting
with ubiquitinated cargoes, HRS can bind to internalized cargo on endosomes contained
in clathrin coated pits via an interaction of clathrin with the clathrin binding box motif
(Leu-Ile-Ser-Phe-Asp) within the C-terminus of HRS. The UIM of STAM also
recogonizes ubiquitinated cargo by binding to both monoubiquitin and polyubiquitin
chains. Furthermore, the proline rich (PSAP) motif in HRS acts to recruit and link
ESCRT-0 to ESCRT-I through binding to the UEV (ubiquitin E2 variant) domain in the
ESCRT-I subunit Tsg101 (Pornillos et al., 2002; Ren & Hurley, 2011). Together HRS
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and STAM bind to ubiquitinated cargo and initiate the sorting of proteins at the
endosome.

SORTING
Following binding and recognition of cargo on endosomes, ESCRT-0 then
recruits ESCRT-I via binding of the PSAP motif in HRS to the UEV domain in Tsg101
(Katzmann, Babst, & Emr, 2001). In mammalian cells, ESCRT-I can comprise several
subunits including Tsg101, VPS28, VPS37A-D and the recently identified UBAP1
(Agromayor et al., 2012; Chu, Sun, Saksena, & Emr, 2006; Morita et al., 2007; Stefani et
al., 2011; Tsunematsu et al., 2010). In addition to interacting with HRS, the UEV domain
of Tsg101 is involved in the further sorting and recognition of ubiquitinated cargo
(Stuchell et al., 2004). Together with Vps28, Tsg101 recruits ESCRT-II to the endosome.
In mammalian cells, ESCRT-II is composed of EAP30, EAP25 and EAP45. These
proteins all contain protein-protein interacting winged-helix (WH) domains. In particular,
the WH domain of the ESCRT-II subunit EAP25 acts to recruit ESCRT-III to the
endosome (Babst, Katzmann, Snyder, Wendland, & Emr, 2002; Teo, Perisic, Gonzalez,
& Williams, 2004). The subunit EAP45 possesses a Gram-like ubiquitin-binding in
EAP45 (GLUE) domain able to interact with ubiquitin in addition to endosomally
enriched phosphoinositides (Hirano et al., 2006; Slagsvold et al., 2005).
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MVB FORMATION AND ESCRT DISASSEMBLY
The final step in ESCRT-dependent sorting involves recruitment of ESCRT-III to
endosomes by ESCRT-II. This recruitment ESCRT-III facilitates the concentration of
receptor into the ILVS of MVBs and the disassembly of the ESCRT-complex by the
AAA-ATPase Vps4 (Williams & Urbe, 2007). ESCRT-III is composed of the
mammalian subunits CHMP1A-B, CHMP2A-B, CHMP3, CHMP4A-C, CHMP5 and
CHMP6 along with the Ist-1 (Rue, Mattei, Saksena, & Emr, 2008). Each subunit of
ESCRT-III is recruited to the endosomal membrane from the cytosol. On the endosome,
ESCRT-III subunits are able to bind to microtubule interacting and trafficking (MIT)
domains of accessory proteins including the deubiquitinating enzyme AMSH and the
AAA-ATPase Vps4 to facilitate disassembly of the ESCRT- complex. Together, the
subunits of ESCRT-III act together to cleave the endosomal membrane resulting in the
formation of intraluminal vesicles. The AAA-ATPase, Vps4, acts to form MVBs. MVBs
are composed of many ILVs and are considered vesicular intermediates between early
and late endosomes (Gruenberg & Stenmark, 2004; Piper & Katzmann, 2007). In the
final sorting step, AAA-ATPase Vps4 disassembles the ESCRT complex, thereby,
allowing for recycling of the ESCRT components to initiate additional rounds of ESCRTmediated sorting.

CXCR4
The chemokine receptor 4 (CXCR4) is a class A rhodopsin-like G protein coupled
receptor (GPCR), previously known as CD184 or Fusin (Berson et al., 1996; Moriuchi,
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Moriuchi, Turner, & Fauci, 1997; Wegner et al., 1998). CXCR4 was first identified as
one of the co-receptors that together with the T cell receptor CD4 facilitate HIV fusion
and entry into T cells (Berson et al., 1996). Later it was identified in the normal cellular
context that CXCR4 binds to the chemokine ligand CXCL12 (a.k.a. SDF-1!) and
together it was shown that CXCR4/CXCL12 are essential for development of the heart,
brain, and vasculature during embryogenesis (Nagasawa, Tachibana, & Kishimoto, 1998;
Tachibana et al., 1998). In addition to binding CXCL12, CXCR4 was recently identified
to also bind to the highly conserved small molecule ubiquitin as well as to the cytokine
MIF (macrophage migrating inhibitory factor) (Bernhagen et al., 2007; Klasen et al.,
2014; Saini, Marchese, & Majetschak, 2010). Studies have highlighted that CXCR7 also
binds to CXCL12. In contrast to CXCR4, CXCR7 binding to CXCL12 does not promote
activation of classical CXCR4 signaling. It is thought that CXCR7 acts as a scavenger by
binding to CXCL12 and, thereby, regulates CXCL12 gradients. Taken together, CXCR7
antagonizes CXCR4 activation and cellular responses (Dambly-Chaudiere, Cubedo, &
Ghysen, 2007; Naumann et al., 2010). Of the 7 identified CXC-receptors, CXCR4 is the
most widely studied and highly conserved phylogenetically among different species
(Arnolds & Spencer, 2014; Knaut, Werz, Geisler, & Nusslein-Volhard, 2003; Nagasawa,
2014; Schabath et al., 1999; Willett et al., 1997; Zou, Redmond, Qi, Dooley, &
Secombes, 2015). Yet, detailed information on the regulation of CXCR4 is continuing to
be delineated.
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PHYSIOLOGICAL ROLES OF CXCR4
CXCR4 as well as its ligand CXCL12 have important roles during embryonic
development and in the adult. The knockout (KO) animals of both genes display identical
phenotypes. Mice deficient in CXCL12 or CXCR4 die at a late stage of embryogenesis
(E 17.5) ( Nagasawa, Tachibana, & Kishimoto, 1998; Tachibana et al., 1998). The death
is due mainly to a defect in formation of the ventricular septum in the heart. In addition to
displaying defects in heart development, these mice also have defects in vascularization
of the gastro-intestinal tract, cerebellum formation and hematopoiesis (Ara, Tokoyoda,
Okamoto, Koni, & Nagasawa, 2005; Q. Ma et al., 1998; Nagasawa et al., 1996;
Nagasawa et al., 1998; Tachibana et al., 1998).
In the adult, the CXCL12/CXCR4 signaling axis has a role in tissue repair,
hematopoiesis and cell homing. Following myocardial infarction, the ischemia produced
within the heart mediates CXCR4/CXCL12 dependent homing of endothelial progenitor
cells to initiate cardiac tissue repair (Askari et al., 2003; Heeschen et al., 2004). In
hematopoiesis, CXCR4 mediates the homing of immature and mature bone marrow cells
to peripheral sites where CXCL12 gradients are established (Broxmeyer et al., 2003;
Lataillade, Domenech, & Le Bousse-Kerdiles, 2004; Q. Ma et al., 1998; Moser &
Loetscher, 2001; Nagasawa et al., 1996). Aberrant CXCR4 signaling due to dysregulated
CXCR4 expression has been implicated pathophysiologically in many diseases including
breast cancer, cardiovascular disease, immunodeficiency disorders and lymphomas
(Balkwill, 2004; Busillo & Benovic, 2007; Hernandez et al., 2003; Muller et al., 2001;
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Walter et al., 2005; Ahn, Seo, Weinberg, & Arber, 2013; Burger & Kipps, 2002;
Corcione et al., 2006; Trentin et al., 2004; Zlotnik, 2006).

CXCR4 IN BREAST CANCER
Dysregulated CXCL12/CXCR4 signaling has also been implicated in metastasis
of a variety of epithelial carcinomas. CXCR4 is overexpressed in at least 23 types of
cancer including cancers of the breast, ovary and prostate (Balkwill, 2004; Busillo &
Benovic, 2007). Cancer cells with upregulated CXCR4 receptor levels can home in on
distance sites where the CXCL12 ligand is expressed. Additionally, CXCR4 is involved
in several cellular pathways that regulate invasion, chemotaxis as well as adhesion. As a
result of these effects, the overexpression of CXCR4 in many cancer types promotes
metastasis and progression (Balkwill, 2004). In particular, breast cancer subtypes that
have high expression levels of CXCR4 can metastasize to regions where high levels of
CXCL12 are expressed such as the lung, liver, lymph nodes and bone marrow (Muller et
al., 2001). In breast cancer cells, CXCR4 mediated signaling promotes both chemotactic
and invasive responses. In particular, CXCR4 signaling leads to changes in actin
polymerization as well as pseudopodia formation that facilitate migratory responses of
breast cancer cells in vitro. In vivo in a MDA-MB-231 breast cancer xenograft model,
treatment with a neutralizing anti-human CXCR4 monoclonal antibody was able to
significantly reduce metastasis to the lymph node and lung (Muller et al., 2001). This
study overall highlights the importance of CXCR4/CXCL12 in mediating breast cancer
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metastasis and was one of the first studies to demonstrate that targeting this signaling
pathway can reduce metastasis.

CXCR4 IN CARDIOVASCULAR DISEASE
The CXCL12/CXCR4 signaling axis is highly important to the development as
well as tissue repair within the heart (Askari et al., 2003; Dong et al., 2012; Nagasawa et
al., 1996; Penn, 2009). Conditional CXCR4-endothelium knockout mice show abnormal
vascularization demonstrating a requirement for CXCR4 in normal endothelial
vascularization (Ara et al., 2005; Tachibana et al., 1998). In the adult, the
CXCL12/CXCR4 signaling axis has a role in tissue repair of the damaged myocardium
following cardiac ischemia (Penn, 2009; Tang et al., 2009) and in providing protection to
cardiomyocytes from myocardial reperfusion injury (Cai et al., 2015). During myocardial
infarction, the resulting ischemia promotes release of CXCL12 from the damaged tissue.
This leads to an increase in endothelial progenitor cells released from the bone marrow
and their homing to the damaged myocardium to initiate tissue repair (Abbott et al., 2004;
Askari & Penn, 2003; Askari et al., 2003; Nagasawa et al., 1996). Perturbations in
CXCL12/CXCR4 signaling that arise, for example by aberrant CXCR4 expression, may
lead to impaired homing of endothelial progenitor cells thereby impairing tissue repair
(Walter et al., 2005). The therapeutic value of CXCR4/CXCL12 in mediating cardiac
tissue repair remains to be explored.
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CXCR4 IN WHIM SYNDROME
Aberrant CXCL12/CXCR4 signaling has been associated with the rare
immunodeficiency disorder known as WHIM syndrome (Hernandez et al., 2003).
Specifically, WHIM syndrome is caused by an autosomal dominant mutation in the
CXCR4 gene. The acronym WHIM denotes the four most common symptoms of this
syndrome,

which

include

Warts,

Hypogammaglobulinemia,

Infections,

and

Myelokathexis. These patients exhibit warts as a result of increased susceptibility to
HPV-infection, a low level of circulating gamma globulins (hypogammaglobulinemia),
retention of neutrophils in the bone marrow (myelokathexis) and the resulting immune
deficiency leads to increased infections. Additionally, due to the retention of neutrophils
in the bone marrow patients exhibit neutropenia (low number of circulating neutrophils)
(Hernandez et al., 2003; Kawai & Malech, 2009).
The identified mutations in CXCR4 involve either nonsense (R334X, G336X,
S338X, E343X) or frame shift (S339fs342X) mutations (Hernandez et al., 2003; Liu et
al., 2012). Any of these mutations result in truncation of the C-terminal tail of CXCR4
preventing its internalization and, thus, desensitization. As a result, the receptor is
hyperfunctional in mediating downstream signaling. This results in disruption of
chemokine gradients in the bone marrow and results in retention as well as apoptosis of
neutrophils and other immune cells. Interestingly, one patient diagnosed with WHIM
syndrome did not display a genetic mutation in the CXCR4 gene per se, however, it has
been suggested that disruption of downstream regulators of CXCR4 signaling may be
involved. Mice deficient in GRK6 and arrestin-3 exhibit symptoms similar to WHIM
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syndrome patients such as neutropenia (Fong et al., 2002; Vroon et al., 2004) indicating
that defects in CXCR4 desensitization may contribute to WHIM syndrome in the patient
lacking the CXCR4 genetic mutation.
Treatment of WHIM syndrome usually involves infusion with gamma globulins
(IV-Ig) and/or administration of the mobilizing therapy granulocyte-colony stimulating
factor (G-CSF). Additionally, these patients are often treated prophylactically with
antibiotics and undergo surgery to remove HPV-associated warts. Unfortunately, these
current therapies come at a high cost to the patient and do not prevent recurring infection.
Given the identified hyperfunctional CXCR4 genetic mutation in the majority of WHIM
patients, current clinical trials are testing the efficacy of low-dose treatment with the
CXCR4 antagonist Plerixafor (AMD3100) (McDermott et al., 2014). While directly
targeting CXCR4 may prove efficacious in WHIM patients, the adverse side effects that
may be associated with direct CXCR4 antagonism may require the development of
alternative therapeutic targets to inhibit CXCR4 indirectly.

CXCR4 IN LYMPHOMAS (DLBCLs)
Aberrant CXCR4 expression has been correlated several hematological
malignancies that lead to improper trafficking and migration of malignant B cells. While
CXCR4 has been implicated in several hematological malignancies (Ahn, Seo, Weinberg,
& Arber, 2013; Burger & Kipps, 2002; Corcione et al., 2006; Trentin et al., 2004;
Zlotnik, 2006), the significance of CXCR4 in the progression of diffuse large B cell
lymphomas (DLBCLs) remains unclear. A recent study of 94 biopsies in patients with
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DLBCLs has demonstrated that CXCR4 expression in these patients can be used as a
prognostic marker (Moreno et al., 2015). In this study, CXCR4 expression correlated to
shorter overall survival as well as progression-free survival. Additionally, CXCR4 was
shown to mediate dissemination of DLBCL cells in a mouse xenograft model. This
dissemination was inhibited by administration of the CXCR4 antagonist, AMD3100.
Recently another study of de novo germinal-center B-cell-like (GCB)-DLBCLs has
demonstrated that an increase in CXCR4 is also associated with increased dissemination
(Chen et al., 2015). Conversely, a study of gastric extranodal DLBCLs originating from
mucosa-associated lymphoid tissue (MALT) established that loss of CXCR4 expression
is a prognostic marker for the development and progression (Deutsch et al., 2013). Thus,
the expression and role of CXCR4 in DLBCLs varies between different subtypes of
DLBCLs. Taken together, these studies highlight the therapeutic potential of targeting the
CXCR4 pathway in DLBCLs.

CXCR4 SIGNALING
Activation of CXCR4 signaling occurs upon binding to CXCL12. The binding
region for CXCL12 on CXCR4 lies within the N-terminal domain of CXCR4 (residues 136) (Doranz et al., 1999). Upon activation of CXCR4 by CXCL12, the receptor
undergoes a conformational change. Ultimately, CXCR4 activation leads to either G
protein dependent or independent signaling as described in the below sections.
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CXCR4 SIGNALING: G PROTEIN DEPENDENT
Following CXCL12 binding to CXCR4, several signaling pathways can be
activated (Figure 1.6). The majority of signaling that occurs following CXCR4 activation
is dependent upon the downstream activities of the associated G proteins. CXCR4
couples canonically to the Pertussis toxin (PTX)-sensitive G"i subunit although coupling
to Gq, Gs, and G12/13 have also been demonstrated (A. Kumar et al., 2006; Tan, Martin, &
Gutkind, 2006). Although the vast majority of CXCR4 mediated signaling pathways are
PTX-sensitive and, therefore, are G"i dependent.
Binding of CXCL12 to CXCR4 results in the exchange of GDP for GTP in the
G"i subunit and subsequent dissociation of G"i from the !# subunits of the
heterotrimeric G protein. G"i functions to inhibit adenylyl cyclase and activate the kinase
Src. Inhibition of adenylyl cyclase inhibits the production of cyclic AMP (cAMP) which
in turn affects the activity of the PKA (Yang et al., 2007). Activation of Src by G"i
results in MAPK pathway activation (Ganju et al., 1998; Y. C. Ma, Huang, Ali, Lowry, &
Huang, 2000) and can regulate the activities of focal adhesion proteins including FAK
and paxillin (Dutt, Wang, & Groopman, 1998; J. F. Wang, Park, & Groopman, 2000)
The liberated !# subunits can activate phospholipase C-! (PLC-!) leading to the
cleavage of inositol-4,5-bisphosphate (PIP2) to form inositol-1,4,5-triphosphate (IP3) and
diacylglycerol (DAG). IP3 increases the levels of intracellular Calcium (Ca2+) while DAG
activates protein kinase C (PKC). Additionally, downstream activation of PI3K leads to
the formation of PIP3 and subsequent activation of the rho family of GTPases, Rac and
Cdc42. Ultimately, the activation of second messengers downstream of CXCR4 lead to
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changes in biological processes including migration, adhesion, proliferation and gene
transcription.
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Figure 1.6. Signaling pathways activated downstream of CXCR4. Binding of
CXCL12 to CXCR4 leads to the activation of both G protein dependent and G protein
independent signaling pathways. The downstream effects of these signaling pathways
regulate several cellular responses including migration, gene transcription, adhesion and
proliferation.

A recent study has demonstrated a novel role for AIP4 and ESCRT-0 subunit STAM-1 in
regulating CXCR4 signaling (Malik, Soh, Trejo, & Marchese, 2012). Using siRNA
against AIP4 and STAM-1, it was shown that CXCR4 activation of ERK-1/2 signaling
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was prevented. This phenotype was dependent upon the ability of AIP4 and STAM-1 to
interact as well as the catalytic activity of AIP4. Thus, ubiquitination activity of AIP4 is
important in mediating ERK signaling in conjunction with STAM-1. It was further shown
that AIP4 and STAM-1 activate ERK signaling in microdomains of the caveolar
compartment. Overall, this study reveals that ubiquitination of STAM-1 by AIP4 is
important in mediating ERK signaling downstream of CXCR4 activation.

CXCR4 SIGNALING: G PROTEIN INDEPENDENT
CXCR4 activation can also lead to the activation of signaling pathways
independent of the G protein. CXCR4 activates Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signaling pathway in T cell (MOLT4) lysates.
Pharmacological inhibition of G"i by PTX treatment does not prevent JAK/STAT
signaling suggesting this signaling is independent of CXCR4 coupling to G"i (Vila-Coro
et al., 1999). Furthermore, in this study it was demonstrated that CXCL12 treatment did
not promote association G"s with CXCR4. Although this study suggest a G protein
independent mechanism, these studies do not rule out whether JAK/STAT signaling
downstream of CXCR4 activation can be attributed to coupling to other G proteins
including Gq or G12/13.
Non-visual arrestins (!-arrestin-1/2) have also been suggested to mediate CXCR4
G protein independent signaling. It has been demonstrated that !-arrestin-1and !-arrestin2 can increase MAPK signaling downstream of CXCR4 activation through activation of
ERK and p38. In addition, mice deficient in !-arrestin-2 or GRK6 display defective
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lymphocyte chemotaxis in response to CXCL12 (Fong et al., 2002). It is thought that the
defective chemotactic response in these mice is attributed to !-arrestin-2-mediated
signaling and is independent of G protein activation. Thus, these study suggest that !arrestin-2 not only functions in CXCR4 desensitization but may also play a vital role in
mediating chemotaxis through G protein independent activation of MAPK/p38 signaling
pathway (Y. Sun, Cheng, Ma, & Pei, 2002). While these study suggest an intriguing role
for G protein independent signaling, more comprehensive studies will be required to
determine whether these are truly G protein independent processes.

REGULATION OF CXCR4 SIGNALING
In order to maintain the proper level of CXCR4 signaling both in magnitude and
duration, attenuation of CXCR4 signaling is a highly regulated process (Figure 1.7).
Following activation, CXCR4 signaling is tightly controlled by three processes:
desensitization, internalization and downregulation as detailed in the following sections.

CXCR4 DESENSITIZATION AND INTERNALIZATION
Activation of CXCR4 by CXCL12 results in a rapid desensitization process. In
this process, CXCR4 is first phosphorylated by GRKs on serine and threonine residues
within the C-terminal tail (Krupnick & Benovic, 1998). In particular GRK2, GRK3 and
GRK6 have all been implicated in mediating this phosphorylation event (Balabanian et
al., 2008; Busillo et al., 2010; Jimenez-Sainz et al., 2006). GRK-mediated
phosphorylation recruits !-arrestin-1/2, which uncouple the receptor from the associated
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G protein preventing further G protein activation (Gurevich et al., 1995; Lohse et al.,
1990). In addition to uncoupling the receptor from the associated G protein, !-arrestins
promote proximal degradation of cAMP and DAG through the recruitment of the
respective phosphodiesterases or DAG enzymes (Nelson et al., 2007; Perry et al., 2002).
It has also been demonstrated that !-arrestin-1 (a.k.a Arrestin-2) interacts with AIP4 on
endosomes upon CXCR4 activation, however, siRNA depletion of either !-arrestin-1 or
AIP4 does not prevent CXCR4 internalization. This data suggest that the interaction
between !-arrestin-1 and AIP4 has a role in the post-endocytic sorting of CXCR4
separate from a function at the plasma membrane (Bhandari, Trejo, Benovic, &
Marchese, 2007).

CXCR4 UBIQUITIN DEPENDENT DOWNREGULATION
CXCR4 is rapidly internalized from the plasma membrane onto early endosomes
upon binding to its cognate ligand CXCL12 (Figure 1.7) (Marchese & Benovic, 2001).
Prior to internalization, CXCR4 can be ubiquitinated by E3 ubiquitin ligase AIP4.
Phosphorylation of two serine residues (S324 and S325) within CXCR4 (Bhandari,
Robia, & Marchese, 2009; Marchese & Benovic, 2001; Marchese, Raiborg, et al., 2003)
promotes the recruitment of AIP4. This phosphorylation event is mediated by GRK6
and/or PKC$ (Busillo et al., 2010). AIP4 recruitment to CXCR4 promotes
monoubiquitination of the CXCR4 at the plasma membrane (Bhandari et al., 2009).
Interaction studies have highlighted that the interaction between AIP4 and CXCR4
involves a non-canonical interaction between WW I-II domain of AIP4 with the
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phosphorylated S324 and S325 within the C-terminal tail of CXCR4 (Bhandari et al.,
2009). Typically, the WW domains of AIP4 interact with proline rich sequences (PPXY
or PPPY motifs) (Ingham et al., 2005; Sudol, Chen, Bougeret, Einbond, & Bork, 1995),
however, CXCR4 lacks these sequences. Thus, these studies demonstrate a novel
interaction between the WW domains of AIP4 with CXCR4.
Ubiquitin modification of CXCR4 acts as a sorting signal that localizes the
receptor to early endosomes, however, ubiquitination of CXCR4 is not required for
internalization. On early endosomes, ubiquitinated CXCR4 is localized to microdomains
containing ESCRT-0 and sorted for trafficking towards lysosomes where the receptor is
degraded (Bhandari et al., 2007; Marchese & Benovic, 2001; Marchese, Raiborg, et al.,
2003). Studies have shown that expression of ubiquitination-deficient mutants of CXCR4
display a significant reduction in agonist-promoted degradation (Marchese & Benovic,
2001). Agonist-promoted degradation of CXCR4 is a highly efficient process although a
small amount is recycled back to the plasma membrane via Rab11-positive recycling
endosomes (A. Kumar, Kremer, Dominguez, Tadi, & Hedin, 2011; Malik & Marchese,
2010; Marchese & Benovic, 2001). These studies highlight the importance of CXCR4
ubiquitination in facilitating receptor downregulation.
Not only does AIP4 mediate ubiquitination of CXCR4 at the plasma membrane, it
also acts on early endosomes to regulate the sorting machinery, such as ESCRT-0 protein
HRS, to control CXCR4 sorting to lysosomes (Malik & Marchese, 2010; Marchese,
Raiborg, et al., 2003). Previous studies have demonstrated that the ESCRT-0 protein
STAM-1 and Arrestin-2 (!-arrestin-1) act to recruit AIP4 to the endosome where AIP4
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ubiquitinates HRS (Malik & Marchese, 2010). Ubiquitination of HRS is thought to
inhibit its ability to target CXCR4 for degradation. Thus AIP4 acts at multiple sites to
control CXCR4 trafficking, but detailed molecular insight into its function is lacking.
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Figure 1.7 Current model of CXCR4 trafficking within the endocytic pathway. Upon
CXCL12 binding to CXCR4, the receptor is rapidly phosphorylated on serine residues
324 and 325 within the C-tail by a G protein-coupled receptor kinase (GRK). This
promotes direct binding to the E3 ubiquitin (Ub) ligase AIP4, which mediates Ub
conjugation of CXCR4 on nearby lysine residues. The ubiquitin moieties on CXCR4 act
as a sorting signal recognized by the ESCRT machinery, which is located on endosomes.
This machinery recognizes and interacts directly with the ubiquitin moieties attached to
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CXCR4 and acts in a sequential and concerted fashion to deliver ubiquitinated CXCR4
into ILVs of MVBs. MVBs fuse with lysosomes where their contents are degraded. In
addition the STAM-1/Arrestin-2 complex on endosomes acts to recruit AIP4 which in
turn ubiquitinates HRS and limits the extent of CXCR4 that is targeted for degradation.

RATIONALE AND RESEARCH OBJECTIVES
Despite the fact that dysregulated CXCR4 expression contributes to aberrant
signaling, very little is known about the molecular processes regulating CXCR4
expression in cells. Understanding how CXCR4 levels are regulated is critical for two
reasons. First, understanding CXCR4 regulation will allow future studies to further
pinpoint the contribution of CXCR4 and its usefulness as a biomarker in disease.
Secondly, understanding the molecular mechanisms regulating CXCR4 levels will
provide alternative strategies to target CXCR4. The goal of this dissertation project is to
understand the molecular mechanisms regulating CXCR4 expression, with a specific
emphasis on understanding how CXCR4 levels are controlled by membrane trafficking
within the endocytic pathway.
CXCL12-activation of CXCR4 results in its rapid ubiquitination and
internalization from the plasma membrane. Once on endosomes, ubiquitinated CXCR4 is
sorted for lysosomal degradation through an ubiquitin-dependent pathway (Marchese,
Raiborg, et al., 2003), although the mechanism remains poorly characterized. CXCR4 is
ubiquitinated by the HECT-domain E3 ligase AIP4 at the plasma membrane. AIP4 is also
localized on early endosomes and regulates CXCR4 sorting by modulating the activity of
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the endosomal sorting complex required for transport (ESCRT) machinery(Malik &
Marchese, 2010; Marchese, Raiborg, et al., 2003). However, the precise role of AIP4 in
these processes remains poorly defined. The objective of this project is to gain a greater
understanding of the mechanisms mediating AIP4 regulation of CXCR4. AIP4 is known
to interact with other E3 ligases, including DTX1 and Cbl-c (Chastagner et al., 2006;
Courbard et al., 2002), but whether these E3 ligases or others are involved in CXCR4
sorting is not known. Our preliminary data indicate that the DTX protein, Deltex-3-like
(DTX3L) regulates CXCR4 degradation. We hypothesize that the E3 ubiquitin ligase
DTX3L regulates CXCR4 trafficking within the degradative pathway through an
interaction with AIP4 and other key proteins involved in the CXCR4 sorting pathway.
To achieve the overall objective of this project we addressed two specific aims:

AIM # 1. To characterize the role of DTX3L in CXCR4 trafficking to
lysosomes. Our preliminary data indicates that DTX3L mediates CXCR4
lysosomal degradation. In this aim we will elucidate the step at which DTX3L
functions in the endocytic pathway to regulate CXCR4 targeting to lysosomes.

AIM # 2. To elucidate the role of DTX3L on CXCR4-induced ubiquitination.
In this aim we will test the hypothesis that DTX3L interacts with AIP4 and the
endocytic machinery on endosomes to modulate CXCR4 lysosomal sorting.
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The results from this study will further the knowledge on the regulation of CXCR4
signaling and trafficking. Furthermore, the results of this study can be correlated to
CXCR4 related pathologies and will provide valuable information that may lead to the
identification of novel pharmacological targets within the CXCR4 pathway.

CHAPTER II
MATERIALS AND METHODS
CELL LINES AND TRANSFECTION REAGENTS
Human cervical cancer (HeLa) cells were obtained from the American Type
Culture Collection (Manassas, VA) and human embryonic kidney (HEK) 293 cells were
from Microbix (Toronto, ON, Canada). Cells were maintained in Dulbecco's modified
Eagle's medium (DMEM; Hyclone Laboratories (Logan, UT)) supplemented with 4 mM
L-glutamine, 4500 mg/L glucose and 10% fetal bovine serum (FBS; Hyclone
Laboratories or Fisher Scientific) and incubated in a 37°C humidified chamber containing
5% CO2.
Transfection of cells with plasmid DNA and siRNA were performed using the
transfection reagents Polyethylenimine (PEI) and Lipofectamine® 2000 or 3000
(Invitrogen, Carlsbad, CA), respectively. Transfections with Lipofectamine® 2000 or
3000 were done per the manufacturers instructions and optimized for experiments
performed as outline below. Additionally, all transfections were performed within the
biological safety cabinet to maintain sterility.

TRANSFECTION OF DNA USING POLYETHYLENIMINE (PEI)
Transfection of cells with DNA was performed on cells cultured in 10-cm, 6-cm
or 6-well culture dishes using polyethylenimine (PEI). The cells were typically at 70-80%
56
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confluency at time of transfection. The protocol was kindly provided by Dr. JoAnn Trejo
(UCSD) (Grimsey, Lin, & Trejo, 2014). PEI was made as a stock of 1 mg/ml
(Polysciences, Inc., Warrington, PA) in 30% ethanol (Decon Laboratories, Inc., King of
Prussia, PA)), as described in Appendix I. PEI was used for DNA transfection at a ratio
of 2 µl PEI stock: 1 µg of DNA. Specifically, for a 10-cm dish, 10 µg of total plasmid
DNA was combined with 20 µl of PEI in 1 mL DMEM supplemented with 20 mM
HEPES pH 7.5. For a 6-cm dish, 5 µg of total plasmid DNA was combined with 10 µl of
PEI in 1 mL DMEM supplemented with 20 mM HEPES pH 7.5. Lastly, for DNA
transfections in 6-well dishes, 2.5 µg of total plasmid DNA was incubated with 5 µl of
PEI in 1 mL DMEM supplemented with 20 mM HEPES pH 7.5.
The PEI/DMEM mixture was incubated at room temperature for 5 min and then it
was added drop wise to a second microcentrifuge tube containing the DNA. The
DNA:PEI mixture was incubated for 20 min at room temperature, during which time the
media was aspirated and replaced with fresh DMEM plus 10% FBS (10 ml for 10 cm
dish, 4 ml for 6 cm dish and 1 ml for 6-well plate) prior to adding DNA complexes.
DNA was then added drop wise to cells. To evenly distribute DNA:PEI complexes, cells
were gently rocked back and forth several times before placement into a 37°C incubator.
DNA transfections were allowed to incubate at 37°C for 24-48 h depending on particular
experiment and amount of DNA transfected.
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INTERFERING

RNA

(siRNA)

USING

Lipofectamine® 2000 or 3000 REAGENTS
Transfection of cells with siRNA were performed on cells cultured in 10-cm, 6cm and 6-well culture dishes using Lipofectamine® 2000 or 3000 transfection reagents.
siRNA transfections were performed at a ratio of 2.5 µl Lipofectamine® 2000/3000 to 50
pmol of siRNA.
For transfection set up in a biological safety cabinet, the desired amount of siRNA
was aliquoted into a microcentrifuge tube containing 500 µl of DMEM supplemented
with 20 mM HEPES pH 7.5. In a second microcentrifuge tube, 500 µl of DMEM
supplemented with 20 mM HEPES pH 7.5 was aliquoted. The corresponding amount of
(2.5 – 30 !l) Lipofectamine® was aliquoted directly into this tube. The two
microcentrifuge tubes were left in the biological safety cabinet at room temperature for 5
min. After 5 min, the siRNA/DMEM mixture were added drop wise to the tube
containing the Lipofectamine®/DMEM mixture and incubated for an additional 20 min at
room temperature. In the mean time, media on 70-80% confluent cells was replaced with
warm DMEM plus 10% FBS after which siRNA complexes were added drop wise to
cells. To evenly distribute siRNA:Lipofectamine® complexes, cells were gently rocked
back and forth several times before placement into a 37°C incubator. Cells were allowed
to transfect for 24-72 h depending on siRNA used and experiment.
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ANTIBODIES AND REAGENTS
Primary antibodies used in this dissertation work are listed in Table 2.1 while
reagents are listed in Table 2.2. siRNA sequences are listed in Table 2.4. DNA constructs
and primers used in this work are in Tables 2.5 and 2.6, respectively.

CLONING
Basic steps used to clone DNA into desired vectors are listed below in Sections
2.3.1 -2.3.7. Primers used in PCR reactions are listed in Table 2.6 and construct maps of
each DNA are in Appendix II.

POLYMERASE CHAIN REACTION (PCR) SET UP
PCR reactions were set up using the Expand High Fidelity PCR system (Roche) as
follows. To a sterile PCR tube each of the following ingredients was added: Expand High
Fidelity Buffer (10") containing 15 mM MgCl2 (2 µl), 10 mM dNTP mixture (1 µl),
DMSO (2 µl), Forward primer (1 µl), Reverse primer (1 µl), template DNA (1 µg) and
Expand High Fidelity Enzyme mix (1 µl; 3.5 units/µl) and sterile, autoclaved dH2O to a
final volume of 50 µl. Tubes were placed in a GeneAMP! PCR system Thermocycler
(Model 9700; Applied Biosystems) using the following parameters: 94°C for 45 sec- 2.5
min), 40-55°C for 45 sec – 10 min and 72°C for 2 min for 30 cycles with a 2 min hold
before the start at 94°C and final elongation hold at 72°C for 7 min.
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GENERATION OF THE FLAG-DTX3L-3C/A MUTANT
To generate the FLAG-DTX3L-3C/A mutant three conserved cysteine residues
(561, 596 and 599) within the catalytic RING domain of DTX3L were mutated to
alanine. Mutation of these residues is predicted to inhibit E2 enzyme binding to the RING
domain based on previously described RING mutant of DTX1 (Chastagner, Israel, &
Brou, 2006). These same residues are conserved in the DTX3L sequence as determined
by manual comparison of the DTX1 and DTX3L sequences. To make this mutant we
used two-step PCR mutagenesis. Two constructs were generated with the first using
DTX3L DNA that was PCR amplified and extended with primers designed to incorporate
one mutation (C561A). The second construct was generated using the C561A DNA as the
template in our PCR reaction in order to add the second and third mutations (C596A and
C599A).
We first generated the single mutant (C561A). Briefly, FLAG-DTX3L-C561A
was PCR amplified using sequential PCR. Reaction one amplified FLAG-DTX3L
template DNA using FLAG-DTX3L-Forward and FLAG-DTX3L-C561A-Reverse
primer in one tube and FLAG-DTX3L-Reverse and FLAG-DTX3L-C561A Forward
primer in tube two. The product of PCR reaction one was then used as a template to
anneal the C561A mutant strands. PCR conditions used for this annealing step were:
denaturation 94°C (2 min), annealing 40°C (10 min) and elongation 72°C (2 min) for 1
cycle. The annealed product was then extended for 30 cycles using FLAG-DTX3LForward/Reverse primers at the following PCR conditions: denaturation 94°C (45 sec),
annealing 50°C (45 sec) and elongation 72°C (2 min). The forward primer carried a NotI
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restriction site and started at amino acid residue Ala2, in frame with the 3xFLAG epitope.
The reverse primer carried a XbaI site and an in frame stop codon and ended at E740.
The PCR fragment was digested with NotI and XbaI and cloned into the NotI and XbaI
sites of 3xFLAG-CMV10.
In the second PCR reaction, FLAG-DTX3L-3C/A was amplified by PCR using
FLAG-DTX3L-C561A (single mutant) template DNA extended with FLAG-DTX3LC596A/C599A-Forward primer in PCR reaction 1. Product of reaction 1 was then
subjected to a second round of PCR using the FLAG-DTX3L- C596A/C599A-Reverse
primer in tube two. The product of PCR reaction one was used as a template to anneal the
DTX3L-3C/A triple mutant strands and extended using FLAG-DTX3L-Forward/Reverse
primers using the same PCR conditions as above to generate the single mutant. The
forward primer carried a NotI restriction site and started at amino acid residue Ala2, in
frame with the 3xFLAG epitope. The reverse primer carried a XbaI site and an in frame
stop codon and ended at E740. The PCR fragment was digested with the restriction
enzymes NotI and XbaI and sub-cloned into the NotI and XbaI sites of 3xFLAGpCMV10. Incorporation of the three mutations was confirmed by sequencing using the
FLAG-DTX3L forward and reverse primers, essentially following steps described below
in Sections 2.3.2-2.3.7. The FLAG-DTX3L-3C/A was also sub-cloned into the His vector
(pET-21a (+)) and used in binding (Section 2.10.2) and in vitro ubiquitination assays
(Section 2.13)
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PCR PRODUCT GEL EXTRACTION
Amplified products were separated by agarose gel electrophoresis and purified by
gel extraction. Amplified products diluted in 6X loading dye were loaded onto a premade 1% agarose gel (containing 10 µl of ethidium bromide) along with a 1 kb DNA
ladder (Promega). Gel was electrophoresed at 130 V for approximately 1-2 h or until dye
front neared bottom of gel. Samples were viewed under a UV light and the predicted
product band was cut out using a sterile razor. The gel fragment was placed in a sterile
1.75 ml microcentrifuge tube. DNA was extracted from the gel using the Qiagen
QIAquick Gel Extraction kit according to the manufacturer’s protocol. DNA was eluted
in 30 µl EB buffer (10 mM Tris#Cl, pH 8.5) and amount of DNA eluted was quantified
using a Nanodrop 8000 spectrophotometer (Thermo Scientific).

RESTRICTION DIGEST
Both the vector and amplified DNA insert were individually subject to restriction
enzyme digest using the desired restriction sites that were amplified in the DNA product
and compatible with the multiple cloning region of the vector. Restriction enzymes used
in this project are listed in Table 2.7. Digestion reactions were set up as follows: 10"
BSA (2 µl), 10" NEB buffer 1-3 (2 µl), vector and/or insert DNA, Restriction enzyme 1
(1 µl), Restriction enzyme 2 (1 µl) and sterile, autoclaved dH2O in a final volume of 20
µl. Samples were incubated overnight at 37°C. NEB buffers were utilized due to low
cutting efficiency when using Promega buffers and based on parallel analysis that
suggested better compatibility of enzymes in a double restriction digest reactions with
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NEB buffers than Promega buffers. Samples were then run on 1% agarose gel (containing
10 µl ethidium bromide) and subjected to Gel Extraction using the Qiagen Kit mentioned
previously. DNA was eluted in 30 µl of EB buffer and the amount of DNA purified was
quantified using a Nanodrop 8000 spectrophotometer (Thermo Scientific).
Specifically to generate DTX3L, the pCMV-SPORT6-DTX3L cDNA (ThermoScientific) purified from bacteria using the Qiagen mini-prep kit per manufacturer’s
protocol was amplified by PCR and the product was sub-cloned into the Not I and Xba I
sites of 3"FLAG-pCMV-10 (Sigma-Aldrich, St. Louis, MO), the BamHI and XhoI sites
of pGEX-6P-1 (GE Healthcare) or the Bam HI and XhoI sites of pET-21a (+).
To generate the GST-N-terminal (NT) and GST-C-terminal (CT) truncations of
DTX3L, primers were made based on the DTX3L truncations previously published
(Takeyama et al., 2003). Briefly, the NT truncation of DTX3L spans amino acids 1-464,
while the CT truncation covers amino acids 528-740. Full-length GST(pGEX6p1) DTX3L was used as a template in the PCR and PCR products were sub-cloned into the
BamHI and XhoI sites of pGEX-6P-1.
The DTX3L-3C/A mutant was designed based on the DTX1 mutant previously
reported (Chastagner et al., 2006), as detailed in Section 2.4.1.1. Briefly, cysteine
residues 561, 596 and 599 within the RING domain were mutated to alanine residues
using two-step PCR and sub-cloned into 3"FLAG-pCMV-10 or pET-21a (+) vectors as
described for wild-type DTX3L.
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The 3"FLAG-pCMV-10-AIP4-C830A mutant was made by digesting myc-AIP4C830A-pRK5 with XhoI and BamHI and sub-cloning and replacing the equivalent
fragment in 3"FLAG-pCMV-10-AIP4.
To make GST-AIP4-C830A, the FLAG-AIP4-C830A cDNA was used as a
template for PCR and the product was sub-cloned into the BamHI and NotI sites of
pGEX-6P-1.
The yellow fluorescent protein tagged 2"FYVE domain (YFP-2"FYVE) was
made by a previous student, Rohit Malik, by amplifying amino acid residues 147-223
from HRS by two-step PCR and sub-cloning in tandem into the XhoI and EcoRI sites of
pEYFP-C1 (Clontech).

LIGATION AND TRANSFORMATION
Restriction enzyme digested samples were subject to ligation using different
molar ratios of vector to insert (i.e. 1:1, 1:3, 3:1, etc.). The desired ratios of vector to
insert DNA were combined in a sterile 0.6 ml microcentrifuge tube with 10" T4 ligase
buffer (2 µl; Promega), T4 DNA ligase (1 µl; Promega) and sterile, autoclaved dH2O to a
final volume of 20 µl. As a negative control, a ligation reaction using only the vector but
no insert (Vector only control) was set up in parallel. The ligation was incubated
overnight (15 h) at 4°C. The next day, competent DH5#’ bacterial cells (100 µl) were
combined with ligated DNA (5 µl) in a 1.7 ml sterile, microcentrifuge tube and incubated
on ice for 30 min. Cells were then placed in a 42°C water bath for 2 min and then back on
ice for 2 min. Next, 600 µl of LB broth was added to the transformed bacteria and
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incubated for 40-60 min at 37°C. Transformed cells were then plated onto LB agar plates
containing 100 µg/mL ampicillin (LB-amp agar). Briefly, transformed cells were
centrifuged at 4,000 rpm for 1 min. Excess LB broth was aspirated to the 100 µl mark on
the tube and pelleted bacteria were re-suspended. Cells (25-50 µl) were added to the LBamp agar plate. To spread cells onto plate, a metal cell spreader was dipped in 70%
ethanol and flamed using a Bunsen burner. The spreader was cooled for a 1-2 min and
then used to spread the bacterial cells back and forth covering the agar dish. Plate was
then inverted (lid downward) and placed at 37°C overnight.

SELECTION OF COLONIES
Colonies of transformed bacterial cells plated overnight on LB-amp agar were
counted manually and compared to vector only control. The amount of colonies selected
was based on the ratio between vector-only and vector plus insert transformations.
Briefly, individual colonies were selected and inoculated in 3 ml of LB broth containing
100 µg/mL ampicillin (LB-amp broth). Samples were allowed to grow overnight in an
orbital shaker (Forma Scientific, Model 4518) set at 250 rpm and a temperature of 37°C.

SCREENING FOR INSERTS
Small scale plasmid DNA was isolated from bacterial cultures using the Qiagen
QIAprep Spin Miniprep kit, according to the manufacturer’s protocol. DNA was eluted in
a volume of 50 µl EB buffer. Plasmid DNA (500 ng - 1µg) was subjected to a restriction
enzyme digest using the same restriction enzymes used in the ligation reaction, as
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described in Section 2.3.3. Following digestion, 2 !l of 6X loading dye was added to
each sample and loaded onto a 1% agarose gel (containing 10 µl of ethidium bromide)
along with a 1 kb DNA ladder (Promega). Gel was electrophoresed at 130 V for
approximately 1 h or until dye front neared bottom of gel. Samples were viewed under a
UV light box (Fisher Scientific) to determine positive clones for insert incorporation. A
clone was determined to be positive for the insert if following digestion two bands
appeared that migrated in the proper kb range determined for both vector and insert.

SEQUENCING
DNA of positive clones was sent for Single Pass DNA Sequencing off site at
ACGT, Inc. (Wheeling, IL). Specifically, 5-10 µl of desired mini-prep DNA was
aliquoted into a 0.6 ml sterile, microcentrifuge tube. In a separate tube, desired primers
(5-10 µl; forward and reverse) were aliquoted into a 0.6 ml sterile, microcentrifuge tube
or alternatively banked primers on the ACGT website were indicated to be used in
sequencing reactions. Typically, data from reactions was uploaded within 2-3 days and
sequence files were opened in Serial Cloner software (version 1.3-11) to determine
whether correct insert was cloned into desired vector. Briefly, sequences obtained were
compared manually to original sequence to determine whether the sequences matched or
whether a certain mutation was incorporated. Purity of sequence was determined using
Finch TV software (version 1.4.0, Geospiza Inc.).
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MAXI PREP
Following confirmation of sequence, large scale plasmid DNA was isolated using the
Qiagen HiSpeed Plasmid Maxi kit. Specifically, transformed bacterial cells were
inoculated in 5 ml of LB-amp broth. Samples were incubated for 8 h in an orbital shaker
(Forma Scientific, Model 4518) set at 250 rpm and a temperature of 37°C. The 5 ml
culture was then added to 500 ml of LB-amp broth allowed to grow overnight (18 h) in
the same orbital shaker set at 250 rpm and a temperature of 37°C. Bacteria were pelleted
by centrifugation at 4,000 rpm for 25 min (Beckman Coulter J6-HC centrifuge). DNA
was then purified from bacterial pellet as per manufacturer’s protocol and eluted in a
volume of 500-750 µl TE buffer. Concentration of DNA was determined using a
Nanodrop 8000 spectrophotometer (Thermo Scientific).

SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL (SDS-PAGE) AND
WESTERN BLOT TRANSFER
Samples were collected in 2" sample buffer (8% SDS, 10% glycerol, 0.7 M betamercaptoethanol, 37.5 mM Tris HCl, pH 6.5, 0.003% bromophenol blue) as detailed in
each protocol below. Samples were resolved along with pre-stained molecular weight
standards (BioRad) on SDS-polyacrylamide gels (containing 7%, 10% or 12%
acrylamide, as detailed in the Appendix I). Gel was electrophoresed at 150-160 volts in
1" SDS running buffer (0.25 mM Tris-HCl pH 7.5, 1% SDS and 0.192 M glycine) for 1 h
-1.5 h. Separated proteins were transferred by Western blot onto nitrocellulose membrane
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(0.45 !M or 0.20 !M, GE Healthcare or BioRad) for 1 h at 100 volts in 1" transfer buffer
(0.25 mM Tris-HCl pH 7.5, 0.192 M glycine and 20% (vol/vol) methanol).

IMMUNOBLOT ANALYSIS
Membranes containing Western blot transferred proteins (immunoblots) were
incubated in 5% non-fat milk in Tris-buffered saline (20mM Tris pH 7.5, 150 mM NaCl)
containing 0.05% TWEEN-20 (TBS-T) for 30 min rocking at room temperature on a
rocking platform (VWR, model 200). Blocked immunoblots were incubated with specific
primary antibodies (dilution range 1:500 to 1:3000) in the same buffer overnight at 4°C.
The following morning, primary was saved and frozen at - 20°C for later re-use or
discarded. Primary incubated immunoblots were washed three times for 5 min with TBST and then incubated with appropriate horseradish peroxidase (HRP) conjugated
secondary antibody (Vector Labs) at a dilution of 1:10,000 in blocking buffer (5% nonfat milk dissolved in TBS-T) for 30 min rocking at room temperature. Immunoblots were
washed five times with TBS-T with one 5 min quick wash and four subsequent 10 min
longer washes at room temperature. Proteins were visualized using enhanced
chemiluminescence (ECL) reagents (DURA extended duration substrate, Thermo
Scientific or homemade short duration substrate). Short duration substrate was made as
detailed in Appendix I. DURA was generally used on immunoblots for samples obtained
from co-immunoprecipitation and degradation experiments for endogenous protein or for
primary antibodies of low affinity such as DTX3L, HRS and CXCR4. Short duration
substrate was used on immunoblots of samples with DNA overexpression, for loading
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controls (Tubulin or Actin), using primary antibodies of high affinity such as AIP4 and
STAM-1 or obtained from in vitro ubiquitination assays. Immunoblot membranes were
incubated with 1:1 ratio of ECL for 1-5 min prior to developing. Signal was captured on
autoradiography film (Dot Scientific high contrast blue or MIDSCI Classic blue
autoradiography film BX) and exposed films were developed using an automated film
processor.

LIGAND STIMULATION
CXCL12 was made as a stock of 10 µM in 0.1% BSA in PBS and stored at 20°C. For stimulation with CXCL12, the amount/concentration of desired ligand made in
0.1% BSA in PBS was diluted in DMEM incomplete supplemented with 20mM HEPES.
For vehicle stimulation, cells were treated with 0.1% BSA in PBS without ligand. Media
was removed from cells by aspiration prior to the addition of pre-mixed, diluted ligand in
DMEM incomplete supplemented with 20mM HEPES. To evenly distribute the ligand,
plates were gently rocked back and forth twice and placed at 37°C for desired time course
(15 min-3 h).

CXCR4 DEGRADATION ASSAY
Agonist promoted degradation of CXCR4 was assessed by immunoblot analysis,
similar to previously described (Malik & Marchese, 2010; Marchese et al., 2003).
Specifically, HeLa cells grown to 70-80% confluency in 6-well plates were transfected
with 50 pmol siRNA directed against DTX family members, c-Cbl, Cbl-b, AIP4 or
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GAPDH or Luciferase using Lipofectamine® 2000/3000 (Invitrogen, Carlsbad, CA), as
we have previously described (Marchese et al., 2003). The next day after transfection,
cells were split 1:2 into 12- well plates and grown for another 24 hours. At the time of
experiment cells had grown to 90-100% confluency. Cells were washed with DMEM
complete and then incubated with complete media (500 µl) containing 50 µg/mL
cyclohexamide to prevent protein synthesis for 15 min at 37°C. Media was aspirated and
replaced with media containing vehicle (0.1% BSA in PBS) or 10 nM CXCL12 for total
of 3 h in the continued presence of cyclohexamide. After treatment, media was aspirated
and replaced with 500 !l PBS at room temperature, followed rapidly by aspiration. Three
hundred µl of 2" sample buffer was added to each well and cells were removed by gently
scraping with a rubber policeman and transferred to a 1.7 ml microcentrifuge tube.
Lysates were sonicated once for 10 sec at 15 % amplitude using a Branson Digital
Sonifier (Model 450). Equal amounts (10 µl) of samples were analyzed by 10% SDSPAGE and immunoblotting with antibodies directed against CXCR4, DTX3L, AIP4,
actin or tubulin. We were unsuccessful in determining DTX1-3, c-Cbl and Cbl-b
knockdown by immunoblot due to lack of good reagents that could distinguish these
proteins. Future study will require qPCR to determine degree of knockdown for these
proteins. Receptor degradation was determined by densitometric analysis of similar
enhanced chemiluminescent exposures from multiple experiments and calculated as the
percent receptor degraded in CXCL12 treated cells compared to vehicle.
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CONFOCAL FLUORESCENCE MICROSCOPY: SAMPLE PREPARATION
HeLa cells grown in 6-well plates were transfected with siRNA targeting DTX3L,
AIP4 or control Luciferase using Lipofectamine® 2000/3000, as described above in
Section 2.1.2. Alternatively, cells were transfected with 1 µg FLAG-AIP4 DNA using
PEI, as detailed in Section 2.1.1. Twenty-four hours later cells were plated onto 22 x 22
mm No. 2 coverslips (Fisher) coated with poly-L-lysine (PLL; 0.1 mg/mL; SigmaAldrich, St. Louis, MO). To coat coverslips, in a biological safety cabinet coverslips were
placed in 6-well plate and incubated with PLL for 10 min. PLL was aspirated and
coverslips were incubated in the biological safety cabinet for 40 min at room temperature
to dry prior to passing cells directly onto coverslips.
The following day, cells were washed once with DMEM supplemented with 20
mM HEPES pH 7.5. For serum starvation, media was replaced with 1ml DMEM
supplemented with 20 mM HEPES pH 7.5 for 3 h at 37 °C before stimulating with
ligand. To stimulate cells, the desired volume of CXCL12 was pre-diluted in DMEM
supplemented with 20 mM HEPES pH 7.5 to a final concentration of 10 nM. Media was
aspirated from cells and media containing vehicle or CXCL12 (10 nM) was added
directly to cells. Cells were stimulated at 37˚C for various times (15 min-3h). Cells were
then washed twice on ice with ice-cold 1" PBS (500 !l - 1000 !l; Hyclone Laboratories).
To fix cells, 1 ml of 3.7% paraformaldehyde-PBS was added to each well followed by
incubation for 10 min at room temperature. Cells were washed twice again with 1 ml
1"PBS. To permeabilize cells a solution containing 0.05% (w/v) saponin in 1 ml 1"PBS
was added for 10 min at room temperature, as described previously (Malik, Soh, Trejo, &
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Marchese, 2012). To block non-specific binding sites 1000 !l blocking buffer (1"PBS
plus 1% BSA and 0.05% w/v saponin) was added to each well and incubated for 30 min
at 37°C. Primary antibodies (1:25 - 1:100 dilution) directed against either CXCR4,
DTX3L, EEA1, LAMP2, HRS, STAM-1 or FLAG in 100 !l were aliquoted on parafilm
that was placed on top of moistened filter paper to create a moist chamber. Coverslips
were inverted onto the aliquoted primary for 1 h at 37 °C and followed by washing with
0.05% (w/v) saponin in 1 ml 1"PBS. Briefly, coverslips were placed back into the 6 well
dish (cell side up), washed quickly four times at room temperature and then washed for a
longer time period for 15 min at 37°C. Samples were then incubated for 30 min at 37°C
with Alexa-Fluor-conjugated secondary antibodies (1:100) in a similar fashion as the
primary. Secondary antibodies included: Alexa-Fluor 635-conjugated goat anti-mouse,
Alexa-Fluor 633-conjugated goat anti-rat, Alexa-Fluor 488-conjugated goat anti-mouse,
Alexa-Fluor 555-conjugated donkey anti-goat, and Alexa-Fluor 488-conjugated goat antirabbit antibodies (Table 2.3), Molecular Probes (Eugene, OR)). Controls for staining
included samples stained with secondary only, primary with opposite (different species)
secondary or staining sample with single primary and secondary combination followed
by scanning in opposite channel (i.e. stain with 488 nm conjugated secondary and view in
555 nm for any bleed-through). Cells were washed as before and mounted on glass slides
using mounting medium containing DAPI (Vector Laboratories, Burlingame, CA or
ProLong Gold Invitrogen, Carlsbad, CA). The edges of the slips were sealed using nail
polish and stored either at room temperature or 4°C in the dark prior to viewing.
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DTX3L CO-LOCALIZATION WITH EEA1 AND LAMP2
To examine co-localization between DTX3L and EEA1 or LAMP2, HeLa cells
plated onto coverslips were serum starved in 1ml DMEM supplemented with 20 mM
HEPES pH 7.5 for 3 h at 37 °C, treated with 10 nM CXCL12 for 30 min and co-stained
for DTX3L and EEA1 or LAMP2.

CXCR4 DEGRADATION BY IF
To characterize the effect of DTX3L silencing on CXCR4 trafficking, HeLa cells
plated on coverslips were transfected with DTX3L or control siRNA for a total of 48 hrs.
Cells were then serum starved in 1ml DMEM supplemented with 20 mM HEPES pH 7.5
for 3 h at 37 °C prior to stimulation with 10 nM CXCL12 or vehicle for 3 h. Cells were
processed as described above and were co-stained for CXCR4 and EEA1 or LAMP2 or
DTX3L.

CO-LOCALIZATION OF DTX3L AND AIP4
To examine co-localization of DTX3L with AIP4, HeLa cells plated on coverslips
were first transfected with 1 µg of FLAG-AIP4. The following morning cells were serum
starved in 1ml DMEM supplemented with 20 mM HEPES pH 7.5 for 3 h at 37 °C and
stimulated with 10nM CXCL12 or vehicle for 0-60 min. Cells were processed essentially
as stated above and co-stained for DTX3L, FLAG-AIP4 and EEA1.
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ASSESSING CO-LOCALIZATION WITH ESCRT-0
To assess the effect of DTX3L on ESCRT-0 components, HeLa cells plated on
coverslips were transfected with control or DTX3L siRNA for a total of 48 hrs. Cells
were serum starved in 1ml DMEM supplemented with 20 mM HEPES pH 7.5 for 3 h at
37 °C and then stimulated with 10 nM CXCL12 or vehicle for 1 h. Cells were processed
as above and co-stained for HRS or STAM-1 and DTX3L or EEA1.

YFP-FYVE CO-LOCALIZATION STUDIES
To determine the effect of DTX3L silencing on endosomal phosophoinositol 3phosphate (PI-3P) levels, HeLa cells plated on coverslips were co-transfected with 1 µg
YFP-2"FYVE and control or DTX3L siRNA for 48 hrs. Cells were serum starved in 1ml
DMEM supplemented with 20 mM HEPES pH 7.5 for 3 h at 37 °C. Cells were then pretreated with DMSO or wortmannin (100 nM) for 30 min before stimulation with 10 nM
CXCL12 for 1 h. Cells were processed as described above, however, cells were
immunostained for DTX3L and EEA1.

CONFOCAL FLUORESCENCE MICROSCOPY: IMAGE ACQUISITION AND
PROCESSING
Slides were viewed using a Zeiss LSM 510 laser-scanning confocal microscope
equipped with a Plan-Apo " 63/1.4 numerical aperture oil DIC M27 lens objective.
Images were acquired using a 1.4-megapixel cooled extended spectra range RGB digital
camera set at 512 " 512 resolution. Specifically, the following parameters detailed below
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were used to acquire images and did not vary unless stated otherwise. Scan mode was set
at plane, original data, multitrack, 8 bit. Stack size was set at 512 x 512 x 1. Wavelengths
used were 633 nm (17%), 561 nm (12%) and 488 nm (4.1%). Channel (Ch) filters were
as follows: Ch 1 LP650, Ch 2 BP 505-550 and Ch 3 LP 575. Pinhole was set to 134 µM
for each channel and images were scanned at a speed of 8. The software used to view
acquired images was Carl Zeiss Laser Scanning System LSM 510. Images were also
viewed using Zeiss LSM Image Browser version 4.2.0.121. Equal acquisition settings
were used between parallel samples within each experiment. Specifically, control
samples were first viewed for each experiment to determine optimal parameters for
staining with each primary used and those same settings were used to view subsequent
treated samples during the same sitting on the microscope. Gain and intensity values
varied based on each primary and secondary combination used, but remained constant
between each experiment repetition.
Images were analyzed using ImageJ software (National Institutes of Health,
version 1.37v) and processed using Adobe Photoshop (CS4). Pearson product-moment
correlation coefficient was determined using the ImageJ plug-in “Colocalization Finder.”
Pixels were restrained to the minimum ratio of 75% to reduce noise from channel bleed
through. Analysis results in values ranging from 0 to 1, where 0 represents ‘no colocalization’ and 1 represents ‘absolute co-localization’. Puncta analysis was performed
using the “Analyze Particles” macro in ImageJ. Images (8-bit) were manually thresholded
to minimum (130-150) and maximum (255) values to exclude background noise.
Particles counted were restrained to a size of 0.05-1.0 and circularity of 0.5-1.0.
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GST- AND His-FUSION PROTEIN PURIFICATION
Escherichia coli BL21 cells transformed (similar to protocol used in Section
2.3.4) with cDNA encoding GST-fusion proteins in pGEX-6p1 or His-tagged proteins in
pET-21a (+) vectors were inoculated in 5 ml LB-amp broth from glycerol stocks.
Constructs used for GST and His purifications are listed in Table 2.8. Specifically, 10 µl
of thawed glycerol stock was pipetted into LB-amp using sterile techniques. Sample was
grown overnight at 37°C in an orbital shaker (Forma Scientific, Model 4518) set at 250
rpm. The following morning, 30 ml cultures were diluted (3.7% dilution) into a 50 ml
conical tube and grown to OD600 0.35–0.40 at 37°C in an orbital shaker (1-3 h). Protein
expression was induced by adding isopropyl-1-thio-$-D-galactopyranoside (IPTG) to a
final 0.1-0.3 mM concentration (IPTG; Sigma-Aldrich, St. Louis, MO) for 3 h at 18°C.
Following induction, cells were pelleted by centrifugation (Beckman Coulter J6-HC
centrifuge set at 4,000 rpm for 20 min at 4°C). Pellets were re-suspended in 0.7 mL lysis
buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol,
10 µg/mL each of leupeptin, aprotinin, and pepstatin-A). For purification of His-tagged
proteins DTT was omitted in the lysis buffer. Cells were lysed by sonication (Branson
Digital Sonifier Model 450 set at 15% amplitude, 10 sec twice) on ice and clarified by
centrifugation at 14,000 rpm for 20 min at 4°C (5417r-Eppendorf microcentrifuge).
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EQUILIBRATION OF GLUTATHIONE-SEPHAROSE AND TALON METAL
AFFINITY BEADS
For GST-fusion or His-fusion protein purifications, glutathione-Sepharose 4B
(GE Healthcare) or Talon Metal Affinity Beads (Clontech, Mountain View, CA) resin
were first equilibrated in lysis buffer. This was done by washing three times with 750 !l
of lysis buffer. Specifically for each wash, following the addition of wash buffer beads
were rocked back and forth three times, subject to centrifugation for 15 sec at 10,000 rpm
and excess buffer was aspirated between washes. The volume of the pelleted resin was
determined by reading the graduations on the microcentrifuge tube. The resin was resuspended in an equal volume of lysis buffer to make a 50% slurry.

IMMOBLIZATION OF GST- AND His-PROTEINS
Clarified lysates were incubated with 25 !l of a 50% slurry of equilibrated
glutathione-Sepharose 4B (GE Healthcare) or 20 !l of a 50% slurry of equilibrated Talon
Metal Affinity Beads (Clontech, Mountain View, CA) resin for His-fusion proteins while
rocking at 4˚C for 15-17 h. The next day immobilized proteins were washed three times
with 750 !l of lysis buffer, pelleted by centrifugation at 10,000 rpm for 15 sec and resuspended in 100 !l of lysis buffer. For washes, following the addition of wash buffer
samples were manually rocked back and forth three times, wash buffer was pelleted by
microcentrifugation for 15 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120)
and excess buffer was aspirated between washes.
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QUANTIFICATION OF IMMOBILIZED GST- AND HIS- FUSION PROTEINS
To determine the amount of purified protein, the immobilized protein was
compared to known amounts of BSA. To accomplish this 10 !l of the total immobilized
sample (100 !l) was combined with 10 !l of 2" sample buffer. Bound protein was eluted
from the beads by boiling the sample at 100 ˚C for 5 min. Eluted proteins (10 !l) were
resolved by 7% or 10% SDS-PAGE along with bovine serum albumin (BSA, Roche
Diagnostics, Indianapolis, IN) standards (0.1 !g- 3 !g). Gel was place in a tray and
washed in 100 ml distilled water for 30 min. Proteins were stained by incubating gel in
approximately 50 ml of GelCode Blue stain while rocking at room temperature. GelCode
Blue was decanted and the gel was then destained by washing with distilled water 2-3
times for 15-30 min. Protein amounts were estimated by comparing the staining
intensities of purified proteins to the BSA standards of known concentration.
Concentration was confirmed by analyzing gel bands using densitometry and comparing
values of purified proteins to the densities of the BSA standards to determine
quantitatively the purified protein concentration. An example of typical purification yield
for GST (0.2 !g/ !l), GST-DTX3L (0.1 !g/ !l) and GST-AIP4 (0.1 !g/ !l) is shown in
Figure 2.1.
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Figure 2.1 Example of a gel stained with GelCode Blue used to quantify amounts of
GST-fusion proteins purified for this study. Representative image of GelCode Blue
staining of a gel ran for GST-protein purification of GST, GST-DTX3L and GST-AIP4.
Ten microliters of immobilized protein were eluted in 10 !l of 2" sample buffer. Sample
was boiled, centrifuged and 10 !l of each eluted protein was subsequently run on 10%
SDS-PAGE gel along with known BSA standards (0.1 !g, 0.5 !g, 1.0 !g and 3.0 !g).
The gel was then washed in distilled H2O, stained with GelCode Blue and briefly
destained with distilled H2O. Fusion protein concentration was then estimated by
comparing intensities of fusion protein band to the BSA standards. As shown here, the
protein concentration were estimated to be: GST = 0.2 !g/ !l; GST-DTX3L=0.1 !g/ !l
and GST-AIP4 = 0.1 !g/ !l.
ELUTION OF HIS-TAGGED PROTEINS
His-tagged proteins bound to Talon Metal Affinity resin were eluted by
incubating samples in elution buffer containing 100 mM imidazole. Specifically,
immobilized proteins (20-50 !l) were eluted in 0.5 mL His purification lysis buffer
containing 100 mM imidazole, while rocking overnight at 4˚C. The next day, samples
were centrifuged for 30 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120)
and supernatant was then subject to buffer exchange. Eluted proteins were dialyzed in
10K MWCO, 20mm SnakeSkin dialysis tubing (Life Technologies) in 2 L of dialysis
buffer (50 mM Tris-HCl, pH 7.4) stirring, overnight and concentrated using Spectra/Gel
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absorbent
(Spectrum Labs, Rancho Dominguez, CA). Twenty !l aliquots were aliquoted
%$
%$
into microcentrifuge tubes and samples were immediately snap frozen on a mixture of
&%
dry ice plus 1:;<=>:*';,:*(?@AB
methanol for 5 min. Samples were stored at -80˚C until use in &%
experiments.
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Samples were quantified by resolving on 10% SDS-PAGE, followed by staining of gel
with GelCode Blue. An example of a typical yield for the purification of His-DTX3L (0.1

'
$0# $0

5/

342

DAE

DAE

'()*+C-.
$0% #0$ /0$

342

5/

6

63/

<F)

!g/ !l) and His-DTX3L-3C/A (0.075 !g/ !l) is shown in Figure 2.2.
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Figure 2.2 Example of a gel stained with GelCode Blue used to quantify amounts of
His-fusion proteins purified for this study. Representative image of GelCode Blue
staining of a gel ran for His-protein purification of His-DTX3L and His-3C/A. Ten
microliters of imidazole eluted protein was diluted in 10 !l of 2" sample buffer and 10 !l
of each sample was subsequently run on 10% SDS-PAGE gel along with known BSA
standards (0.5 !g, 1.0 !g and 3.0 !g). The gel was then washed in distilled H2O, stained
with GelCode Blue and briefly destained with distilled H2O. His-fusion protein
concentration was then estimated by comparing intensities of fusion protein band to the
BSA standards. Asterisk’s (*) denotes degradation products left over from purification.
As shown here, the protein concentration were estimated to be: His-DTX3L=0.1 !g/ !l
and His-DTX3L-3C/A = 0.075 !g/ !l.
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LARGE SCALE PURIFICATION AND PreScission PROTEASE CLEAVAGE OF
GST-AIP4 AND GST-AIP4-C830A
To generate purified cleaved AIP4 or AIP4-C830A, BL21 E. coli cells
transformed with GST-AIP4 or GST-AIP4-C830A cDNA were inoculated into 30 ml of
LB-amp broth at 37˚C overnight. The following morning, cultures were diluted into 500
mL and grown at 37˚C for 3hr. Protein expression was induced with 0.3 mM IPTG
(Sigma-Aldrich, St. Louis, MO) for 24 h at 18°C. Cells were then pelleted by
centrifugation (4000 rpm for 30 min at 4˚C using a Beckman Coulter J6-HC centrifuge)
and re-suspended in 10 mL of cold GST purification lysis buffer. Lysates were incubated
for 30 min, while rocking at 4˚C. Samples were sonicated and then pelleted by
microcentrifugation (4000 rpm for 30 min at 4˚C). To remove any small degradation
products, supernatants (~10 ml) were placed in a 30 ml syringe and passed through a 0.2
!M filter and were combined with 600 !l of a 50% slurry of glutathione-Sepharose 4B
(GE Healthcare) resin overnight at rocking at 4˚C. Samples were washed three times with
1000 !l lysis buffer. For washes, following the addition of wash buffer samples were
rocked back and forth three times manually, beads were pelleted by microcentrifugation
for 15 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120) and excess buffer
was aspirated between washes. Samples were re-suspended in 1000 !l of lysis buffer.
To cleave the GST (pGEX6P1) tag from GST-AIP4 and GST-C830A,
immobilized proteins in lysis buffer (1000 !l) were directly incubated with 10 units of
PreScission Protease (GE Life Sciences) for 12 h, while rocking at 4˚C. Eluted samples
were dialyzed in 10K MWCO, 20mm SnakeSkin dialysis tubing (Life Technologies) in 2
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L of dialysis buffer (50 mM Tris-HCl, pH 7.4) stirring, overnight and concentrated using
Spectra/Gel absorbent (Spectrum Labs, Rancho Dominguez, CA). Samples were
quantified by resolving on 10% SDS-PAGE, followed by staining of gel with GelCode
Blue, similar to sections 2.9.3 and 2.9.4. An example of typical purification yield for
cleaved AIP4 (0.2!g/ !l) and cleaved AIP4-C830A (0.2!g/ !l) is shown in Figure 2.3.
Twenty-five !l aliquots were made into microcentrifuge tubes and samples were
immediately snap frozen on a mixture of dry ice plus methanol for 5 min. Samples were
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stored at -80˚C until used in experiments.
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Figure 2.3 Example of a gel stained with GelCode Blue for cleaved AIP4 and AIP4C830A purification. Representative image of GelCode Blue staining of a gel ran for the
'()*+,-.
purification and PreScission protease cleavage of (A.) GST-AIP4
and (B.) GST-AIP4$0# $0% #0$ /0$
C830A. Five microliters of each sample was diluted in 6 !l of 2" sample buffer and1(23)789
5 !l
of each sample was subsequently run on 10% SDS-PAGE
gel along with known 1(23425/6
BSA
#$#
!" sample represents GST-fusion
standards (0.1 !g, 0.5 !g, 1.0 !g and 3.0 !g). ‘Cleaved’
'()
'()*+C-.
protein that was
cleaved with PreScission Protease and%&‘Bound’ sample represents GST$0% #0$ /0$
fusion protein
that remain in DAE3425/6
bead volume after cleavage. The gel was then washed in
#$#
! DAE3425/63/<F)
distilled H2O, stained with
GelCode Blue and briefly
H2O.
&! destained with distilled 1(2
"&
! '()
Protein concentration was then estimated by comparing intensities of fusion protein band
!
to the %&
BSA standards. Asterisk’s
(*) denotes degradation1:;<=>:*';,:*(?@AB
products left over from
purification.1:;<=>:*';,:*(?@AB
As shown here, the protein concentration of cleaved proteins was estimated
to be: AIP4=0.2 !g/ !l and AIP4-C830A= 0.2!g/ !l.
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GST- AND HIS-FUSION BINDING ASSAYS
Binding assays were used to determine protein-protein interactions by affinity
purification.

GST- AND HIS-FUSION BINDING ASSAYS : LYSATE COLLECTION
Typically for a binding reaction using HeLa cell lysates, HeLa cells were first
plated onto 6-cm dishes. HeLa cells were either left untransfected or transfected with
empty vector or desired DNA constructs for 24 h. Cells were washed two times with 3 ml
1"PBS on ice and collected by gently scraping cells in 0.4 ml of binding buffer (20 mM
Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol, 20 mM Nethylmaleimide (NEM) and 10 µg/mL each of leupeptin, aprotinin, and pepstatin-A).
Samples were rocked for 30 min at 4˚C and lysed by sonication (15 % amplitude, 10 sec)
on ice. Lysates were cleared by microcentrifugation at 14,000 rpm for 20 min at 4°C
(5417r-Eppendorf microcentrifuge). Protein concentrations of supernatants were
determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). A total of 100-500
!g of supernatant was incubated with immobilized protein overnight while rocking at 4
˚C.

GST- AND HIS-FUSION BINDING ASSAYS : BINDING ASSAYS
For GST-binding assays, immobilized fusion proteins were incubated with cleared
HeLa lysates either transiently transfected without or with 1!g of FLAG-AIP4. Between
100 !g -500 !g of cleared lysate was used in binding assays as detailed below. Samples
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were incubated at 4˚C for 15-17 h while gently rocking. Samples were washed three
times with 750 !1 of lysis buffer. Specifically, following the addition of wash buffer
samples were manually rocked back and forth three times, beads were pelleted by
microcentrifugation for 15 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120)
and excess buffer was aspirated between washes. Samples were eluted with 25 !1 2"
sample buffer and followed by immunoblot analysis.

GST-DTX3L TRUCATIONS
For binding reaction involving the GST-DTX3L N-terminal and C-terminal
truncation mutants, equimolar amounts of GST, GST-DTX3L-full length, -NT or –CT
(100 nmol) were incubated with cleared HeLa lysates (100 !g) transiently transfected to
express FLAG-AIP4 or empty vector. Samples were incubated overnight and collected as
described above. Lysates were subjected to immunoblot analysis for anti-FLAG-HRP
(AIP4) and blot was stained with Ponceau to show amount of purified protein used the
reaction.

GST-AIP4 TRUNCATIONS
For binding reaction involving the GST-AIP4 truncation mutants, equimolar
amounts of GST, GST-AIP4, GST-C2, GST-WWI-IV or GST-HECT (200 nmol) were
incubated with His-DTX3L (5nM). Samples were incubated overnight and collected as
described above. Lysates were subjected to immunoblot analysis for DTX3L and GST.
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AIP4 AND DTX3L BINDING
To determine binding between GST-AIP4 and endogenous DTX3L, HeLa lysates
(500 µg) were collected as described above and incubated overnight with immobilized
GST or GST-AIP4 (100 nmols). DTX3L binding was determined by immunoblot
analysis. To determine direct binding between AIP4 and DTX3L, increasing amounts of
purified, eluted His-DTX3L (1-10 nM final concentration) were incubated with equal
amounts of immobilized GST-AIP4 (100 nmol) in a volume of 100 !l for 1 h while
gently rocking at 4˚C. Samples were washed three times with 750 !1 lysis buffer.
Specifically, following the addition of wash buffer samples were manually rocked back
and forth three times, beads were pelleted by microcentrifugation for 15 sec at 10,000
rpm (Thermo microcentrifuge 5519, model 120) and excess buffer was aspirated between
washes. Samples were eluted with 25 !1 2" sample buffer and followed by immunoblot
analysis to determine His-DTX3L binding to GST-AIP4.

GST- AND HIS-FUSION BINDING ASSAYS : DATA QUANTIFICAITON
Data were quantified by densitometric analysis for each experiment. Values were
averaged between experiments and represented as a fraction of GST or empty vector
control.
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CO-IMMUNOPRECIPITATION
Co-immunoprecipitation assays were utilized to determine protein-protein
interactions in cells using specific antibodies to capture target proteins as detailed in the
following sections.

TIME COURSE CO-IMMUNOPRECIPITATOIN
To determine whether the interaction between DTX3L and AIP4 is dependent on
CXCL12 treatment, we performed a time course co-immunoprecipitation. Specifically,
HeLa cells plated in 10-cm dishes were serum starved for 4 h and then treated for 0-60
min with 10 nM CXCL12 at 37°C. Cells were placed on ice, washed once with ice-cold
PBS and lysed in immunoprecipitation buffer [20 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1% Triton X-100, 20 mM N-ethylmaleimide (NEM), protease inhibitors (10 !g/mL each
of aprotinin, leupeptin and pepstatin A (Roche))]. Lysates were cleared by centrifugation
at 14,000 rpm for 20 min in a 5417r-Eppendorf microcentrifuge. Clarified lysates (500
!g) were incubated with an antibody (2 !g) directed against DTX3L or goat IgG control
for 16 h at 4 ˚C. Twenty !l of a 50% slurry of protein A agarose was then added and
samples were incubated for an additional 1 h. Samples were then washed three times as
follows: following the addition of wash buffer samples were rocked back and forth three
times, beads were pelleted by microcentrifugation for 15 sec at 10,000 rpm (Thermo
microcentrifuge 5519, model 120) and excess buffer was aspirated between washes.
Immunoprecipitated proteins were denatured by the addition of 25 !l 2" sample buffer,
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resolved by 7% SDS-PAGE and analyzed by immunoblotting using antibodies directed
against AIP4, DTX3L, and actin.

CO-IMMUNOPRECIPITATION OF ENDOGENOUS PROTEINS
For the immunoprecipitation of endogenous proteins, lysates were collected in a
similar fashion as Section 2.10.1, however, left untreated. Specifically, to determine the
effect of DTX3L depletion on the binding between ESCRT-0 components HRS and
STAM-1, HeLa cells were transfected with control siRNA or DTX3L siRNA (25 nM
final concentration) for 24 h before immunoprecipitation of cleared lysates (300 !g) with
2 !g of either anti-HRS or mouse IgG control and anti-STAM-1 or rabbit IgG control for
1 h at 4 ˚C. Twenty !l of a 50% slurry of protein A agarose was then added and samples
were incubated for an additional 1 h. Immunoblots were probed with antibodies against
AIP4, DTX3L, HRS, STAM1 or actin.
For endogenous DTX3L co-immunopecipitation experiments lysates were
collected as stated above, however, cleared lysates (500!g) were immunoprecipitated
with 3 !g of anti-DTX3L or goat IgG control. Samples were resolved by 7% SDS-PAGE
and immunoblots were probed with antibodies against AIP4, DTX3L, HRS, STAM1 or
actin.

CO-IMMUNOPRECIPITATION DATA QUANTIFICATION
Data were quantified by densitometric analysis for each experiment. For the time
course co-immunoprecipitation analysis, values were averaged between experiments and
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vehicle values were set to 1 and treatment times were represented as a fraction of vehicle.
In the ESCRT-0 co-immunoprecipitations, the average of control siRNA values were set
to 1 and DTX3L siRNA samples were calculated as a fraction of the control siRNA.

UBIQUITINATION ASSAYS
Ubiquitination assays were used to determine the ubiquitination of substrates in
cells or in purified in vitro systems.

HRS AND STAM UBIQUITINATION
HeLa cells grown on 6-cm dishes were transfected with 1 !g FLAG-ubiquitin, 4
!g T7-HRS or T7-STAM-1 and control siRNA or siRNA directed against DTX3L, AIP4
or a combination (25 nM final concentration for each siRNA) using Lipofectamine® 3000
(Invitrogen, Carlsbad, CA), as described in Section 2.1.2. Specifically, cells were first
transfected with siRNA in the morning and then transfected with DNA seven hours later.
The following morning, cells were placed on ice, washed twice with ice-cold PBS and
collected into 2 mL microcentrifuge tubes with 200 !l of denaturing ubiquitination buffer
[20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% SDS, 1% Triton X-100, 5 mM EDTA, 20
mM N-ethylmaleimide (NEM), and protease inhibitors [10 !g/mL each of aprotinin,
leupeptin and pepstatin A (Roche, Indianapolis, IN)] by gently scraping with a rubber
policeman. Collected samples were boiled for 5 min at 100˚C on a heat block, sonicated
(15%, 10 sec) on ice and diluted with 1.8 mL dilution buffer [20 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% Triton X-100, 5 mM EDTA]. Cells were allowed to lyse for 1 h while
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rocking at 4 ˚C. Samples were cleared by centrifugation (14,000 rpm, 25 min at 4 ˚C) and
protein concentrations of supernatants were determined using the BCA Protein Assay Kit
(Pierce, Rockford, IL). A total of 300 !g of supernatant was incubated with 2 !g of an
anti-T7 goat polyclonal antibody overnight while rocking at 4 ˚C. The next day, samples
were then incubated with 20 !l of a 50% slurry of Protein G agarose (Roche) for 1 h
while rocking at 4 ˚C. Samples were washed twice with 500 !l dilution buffer as follows.
Following the addition of wash buffer samples were rocked back and forth three times,
beads were pelleted by microcentrifugation for 15 sec at 10,000 rpm (Thermo
microcentrifuge 5519, model 120) and excess buffer was aspirated between washes.
Bound proteins were eluted in 25 !l of 2" sample buffer, resolved by 7% or 12% SDSPAGE and then analyzed by immunoblotting with antibodies directed against the FLAG
and T7 epitopes, DTX3L AIP4 or actin.

CXCR4 UBIQUITINATION
To examine CXCR4 ubiquitination, HEK293 cells grown on 10-cm dishes were
first transfected with siRNA against control, DTX3L or AIP4 (25 nM final concentration)
using Lipofectamine® 3000 as described in Section 2.1.2. Seven hours later cells were
transfected with 3 !g FLAG-ubiquitin and 7 !g HA-CXCR4. The next morning cells
were split 1:2 into 6-cm dishes. Twenty-four hours later cells were serum starved in
DMEM incomplete plus 20 mM HEPES for 3 h at 37 ˚C, followed by stimulation with 30
nM CXCL12 or vehicle for 30 min. Cells were placed on ice and washed twice with 3 ml
ice-cold 1"PBS. Samples were collected with 200 !l of denaturing ubiquitination buffer
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by gently scraping with a rubber policeman. Samples were then boiled for 5 min at 100˚C
on a heat block, sonicated (15%, 10 sec) on ice and diluted with 1.8 mL dilution buffer.
Cells were allowed to lyse for 1 h while rocking at 4 ˚C. Samples were cleared by
centrifugation (14,000 rpm, 25 min at 4 ˚C) and protein concentrations of supernatants
were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). Supernatants
(300 !g) were incubated with 2 !g of an anti-HA rabbit polyclonal antibody
(Covance/Biolegend) while rocking overnight at 4 ˚C. Samples were then incubated with
20 !l of a 50% slurry of Protein A agarose (Roche) for 1 h while rocking at 4 ˚C.
Samples were washed twice with 500 !l dilution buffer. Bound proteins were eluted in 25
!l of 2" sample buffer, resolved by 10%, 7% or 12% SDS-PAGE and then analyzed by
immunoblotting with antibodies directed against the FLAG and HA epitopes, DTX3L,
AIP4 or tubulin.

IN VITRO UBIQUITINATION ASSAYS
AIP4 AND DTX3L IN VITRO UBIQUITINATION
To determine effect of DTX3L on AIP4 ubiquitination, in vitro ubiquitination
assays were performed using 500 ng of GST-purified/cleaved AIP4 or AIP4-C830AHECT mutant and 1 !g His-DTX3L or DTX3L-3C/A RING mutant alone or in
combination. Briefly, purified E3s were incubated alone or together with a master mix of
E1 (0.5 !g), E2 (UbcH5c, 0.5 !g), and ubiquitin (2.5 !g) and ATP in a final volume of
20 !l for 1 h 30 min at room temperature. Reactions were stopped by the addition of 20
!l of 2" sample buffer. Samples were resolved by 7% or 12% SDS-PAGE and then
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analyzed by immunoblotting with antibodies directed against the AIP4, DTX3L,
ubiquitin or GST.

AIP4, DTX3L AND PARKIN IN VITRO UBIQUITINATION
To examine the effect of AIP4, DTX3L and Parkin ubiquitination alone and in
combination, purified MBP-Parkin (500 ng), AIP4 (500 ng) and His-DTX3L (1 !g) were
allowed to react alone and in combination for 1 h 30 min at room temperature similar to
previous section. Samples were separated by 7% SDS-PAGE and analyzed by
immunoblotting with antibodies directed against DTX3L, AIP4, Parkin and ubiquitin.

STATISTICAL ANALYSIS AND FINAL FIGURE PREPARATION
Data were analyzed by Student's t-test, one-way analysis of variance (ANOVA)
using GraphPad Prism 4.0 for Macintosh (GraphPad Software, San Diego, CA). Figures
were created using Adobe! Illustrator CS4.
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Table 2.1 List of Primary Antibodies used in this project
Antibody
Clone/N Type
Vendor
Name
ame

Catalog
Number

Anti-T7

goat polyclonal

Abcam

ab9138

Anti-T7

mouse monoclonal

Novagen

69522-3

Anti-HA.11

16B12

mouse monoclonal

BioLegend/Covance

mms-101p

Anti-HA

101R

rabbit polyclonal

BioLegend/Covance

prb-101p

Anti-FLAGHRP

M2

mouse monoclonal

Sigma

A8592-1MG

Anti-FLAG

M2

mouse monoclonal

Sigma

F3165-1MG

rabbit polyclonal

Sigma

F7425
F3040-1MG

Anti-FLAG
Anti-FLAG

M1

mouse monoclonal

Sigma

Anti-LAMP2

H4B1

mouse monoclonal

Developmental
H4B4
Studies
Hybridoma
Bank at the University
of Iowa
BD
610457

Anti-EEA1

mouse monoclonal

Anti-tubulin

mouse monoclonal

Anti-actin

mouse monoclonal

goat polyclonal

Developmental
12G10
Studies
Hybridoma
Bank at the University
of Iowa
Developmental
JLA20
Studies
Hybridoma
Bank at the University
of Iowa
Santa Cruz
sc-102497

Anti-UbcH5c

mouse monoclonal

Abcam

Anti-UbcH5c

rabbit monoclonal

Cell
Signaling #4330
Technologies

Anti-DTX3L

N-16

ab58251
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Anti-UbcH7

rabbit monoclonal

Abcam

ab108936

Anti-Itch
(AIP4)

rabbit monoclonal

Abcam

ab108515

Anti-Itch
(AIP4)

rabbit monoclonal

Abcam

ab109018

Anti-Itch
(AIP4)

mouse monoclonal

BD

611198

mouse monoclonal

Santa Cruz

sc-271455

Anti-HRS

rabbit polyclonal

Proteintech

10390-1-AP

Anti-STAM-1

rabbit polyclonal

Proteintech

12434-1-AP

Anti-Ubiquitin P4D1

mouse monoclonal

Santa Cruz

sc-8017

Anti-CXCR4

rat

BD

558644

Anti-HRS

C-7

2B11

Table 2.2 List of reagents used in this dissertation work
Reagent
Vendor
Dulbecco's modified Eagle's medium
(DMEM)
Hyclone Laboratories
Phosphate Buffered Saline (1"PBS)
Hyclone Laboratories
Trypsin EDTA 1"
Gibco by Life Technologies
HEPES, pH 7.5
Hyclone Laboratories
paraformaldehyde (PFA)
Sigma-Aldrich
Poly-L-lysine (PLL)
Sigma-Aldrich
Lipofectamine$ 2000
Invitrogen
Lipofectamine$ 3000
Invitrogen
Polyethylenimine (PEI)
Polysciences, Inc.
DEPC RNAase/DNAase free water
Invitrogen
Ethanol, 200 proof
Decon Laboratories Inc.
Methanol
Fisher Scientific
Isopropanol
Sigma-Aldrich
Talon Metal Affinity Resin
Clontech
Glutathione Sepharose 4B
GE Healthcare
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Sodium chloride (NaCl)
Tris Base
Tween-20
Glycine
D-Dithiothreitol (DTT)
Triton X-100
N-Ethylmalemide (NEM)
Hydrochloric acid (HCl)
Isopropyl-B-D-1-thiogalactopyranoside
(IPTG)
Ampicillin
Kanamycin
Sodium Dodecyl Sulfate (SDS)
Dimethyl Sulfate (DMSO)
DURA extended duration substrate
luminal (3-aminophathalhydrazide)
p-coumaric acid
hydrogen peroxide
Imidazole
CXCL12
EGF
AMD3100
Leupeptin (for IF-M)
VECTASHIELD Mounting Media with DAPI
ProLong GOLD Mounting Media with DAPI
Protein A agarose
Protein G agarose
Saponin
Bovine serum albumin fraction V
Non Fat Dry Milk
Acrylamide/Bisacrylamide, 37.5:1
TEMED
Ammonia persulfate (APS)
Nitrocellulose, 0.45 µm
Nitrocellulose, 0.2 µm
Ponceau-S
Aprotinin
Pepstatin-A
Leupeptin
Gel Code® Blue Stain Reagent

Sigma-Aldrich
Fisher Scientific
Sigma-Aldrich
Sigma-Aldrich
Roche
Sigma-Aldrich
Sigma-Aldrich
Acros
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Roche
Sigma-Aldrich
Thermo Scientific
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
PeproTech
PeproTech
Sigma-Aldrich
Sigma-Aldrich
Vector Labs
Invitrogen
Roche
Roche
Sigma-Aldrich
Roche
Baker's Corner, ALDI
Roche
Thermo Scientific
Sigma-Aldrich
BioRad; GE Healthcare
BioRad
Sigma-Aldrich
Roche
Roche
Roche
Thermo Scientific
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X-ray Film, high contrast blue
X-ray Film, Classic blue autoradiography film
BX
Microscope coverglass 22x22 mm No. 2
Premium microscope slides, frosted
Mini-prep kit
Maxi-prep kit
NEB Buffer 3
Agarose
beta-mercaptoethanol
bromophenol blue
T4-DNA ligase and buffer

Dot Scientific
MIDSCI
Fisher Scientific
Fisher Scientific
Qiagen
Qiagen
NEB
dot scientific Inc.
Sigma-Aldrich
Fisher Scientific
Promega
Hyclone
Laboratories
Scientific
GE Healthcare

;

Fisher

Fetal bovine serum (FBS)
PreScission Protease
Wortmannin
Luria Broth
Fisher Scientific
Agar
Fisher Scientific
Glycerol
Sigma-Aldrich
10K MWCO, 20mm SnakeSkin dialysis
tubing
Life Technologies
Spectrum Labs, Rancho Dominguez,
Spectra/Gel absorbent
CA
BCA Protein Assay Kit
Pierce, Rockford, IL
EDTA
Sigma-Aldrich
E1
Boston Biochem
E2, UbcH5c
Boston Biochem
Mg-ATP Activating Solution
Boston Biochem
10" ubiquitination buffer
Boston Biochem
ubiquitin
Boston Biochem
Expand High Fidelity PCR System
Roche
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Table 2.3 List of secondary antibodies used in this project
Secondary
AntiCatalog
body
Species
Vendor
Number
anti-goat-HRP
horse
Vector Labs
PI-95000
anti-mouse-HRP
goat
Vector Labs
PI-2000
anti-rabbit-HRP
goat
Vector Labs
PI-1000
anti-rat-HRP
goat
Calbiochem
DC01L
Alexa-Fluor-488
rabbit
Invitrogen
A11070
Alexa-Fluor-488
mouse
Invitrogen
A11029
Alexa-Fluor-488
rat
Invitrogen
A11006
Alexa-Fluor-555
goat
Invitrogen
A21432
Alexa-Fluor-555
mouse
Invitrogen
A21424
Alexa-Fluor-568
rabbit
Invitrogen
A11036
Alexa-Fluor-635
mouse
Invitrogen
A31575
Alexa-Fluor-633
rat
Invitrogen
A21094
Alexa-Fluor-633
rabbit
Invitrogen
A21071
Alexa Fluor-EGF-488
Invitrogen
E13345
Table 2.4 List of siRNA used for this dissertation work
Name
Sequence
Source
AIP4
GGUGACAAAGAGCCAACAGAG
Dharmacon
RNA
Technologies
(Lafayette,
CO) Cat. No. MARAD000018
DTX3L
1. GGAGAAAGGAGGCGAAUUA
SMARTpool,
Dharmacon
2. GGAGUUGAAUCACCAGUUU
RNA
Technologies
3. GAAAGAGGGUCAUGAAACA
(Lafayette, CO)
4. CAAGAUACCUGUGAAACUA
Cat. No. M-007143-01-003
DTX1
1. GAAGAUACAUGCAGAAGGU
SMARTpool,
Dharmacon
2. GAUAUGGACAUCUGCAUCA
RNA
Technologies
3. GAAGAAGUUCACCGCAAGA
(Lafayette, CO)
4. CCAAGAAGAAGCACCUUAA
Cat. No. M-006525-00-003
DTX2
1. GGACCAUCCUCAUAGUUUA
SMARTpool,
Dharmacon
2. CAACUACACUGUCAACUAC
RNA
Technologies
3. CAGGACCGCUUCUGUGUUU
(Lafayette, CO)
4. GAUACAGCGAUGUGACUGA
Cat. No. M-007114-02-003
DTX3
1. GCACCAUUGUCAUCCAGUA
SMARTpool,
Dharmacon
2. GGCGGAUGCUGGUCUCUAA
RNA
Technologies
3. UCAAGGGGCUGCUAAAAGA
(Lafayette, CO)
4. CCUCAUAGAUGGCGAGACU
Cat. No. M-007156-01-003

Cbl

UbcH5a

1. GGAGACACAUUUCGGAUUA
2. GAUCUGACCUGCAAUGAUU
3. GACAAUCCCUCACAAUAAA
4. CCAGAAAGCUUUGGUCAUU
1. GACCAUACCUCAUAACAAG
2. UGAAAGACCUCCACCAAUC
3. GAUGAAGGCUCCAGGUGUU
4. UAUCAGCAUUUACGACUUA
GGUGUAGUCAUUAGCAAA

UbcH5b

GGAUAACCUCUACAAAUA

UbcH5c

UGCAUGUCAAUAAAGGAAUGACCTG

UbcH7

ACUAGAUCCUGUGGAGAAGAUGACT

Cbl-b

UbcH9

1.
2.
3.
4.

GCAUAGCCACUCAGUAUUU
GCUAAGUUAUCCACUAGUG
AUAUGAAGGUGGUGUGUUU
GGAGCUAGCUGAAAUAACC
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SMARTpool,
Dharmacon
RNA
Technologies
(Lafayette, CO)
Cat. No. M-003003-02-0003
SMARTpool,
Dharmacon
RNA
Technologies
(Lafayette, CO)
Cat. No. M-003004-02-0003
Integrated
DNA
Technologies
(Coralville,
Iowa) Cat. No. 87294301
Integrated
DNA
Technologies
(Coralville,
Iowa) Cat. No. 87294304
Integrated
DNA
Technologies
(Coralville,
Iowa) Cat. No. 121392347
Integrated
DNA
Technologies
(Coralville,
Iowa) Cat. No. 121392344
SMARTpool,
Dharmacon
RNA
Technologies
(Lafayette, CO)
Cat. No. M-008845-00

Table 2.5 DNA constructs used for this dissertation work
Construct Name
Vector
Reference
AIP4 constructs
FLAG-AIP4
GST-AIP4
GST-AIP4-C830A
GST-AIP4-C2
GST-AIP4-dPRR
GST-AIP4-WWI-IV
GST-AIP4-dWWI-IV
GST-AIP4-HECT
Myc-AIP4

pCMV10
pGEX-4T2
pGEX-6P1
pGEX-4T2
pGEX-4T2
pGEX-4T2
pGEX-4T2
pGEX-4T2
pRK5

Marchese and Benovic, 2001
Bhandari et al., 2007
Holleman and Marchese, 2014
Bhandari et al., 2007
Malik et al., 2011
Bhandari et al., 2007
Bhandari et al., 2007
Bhandari et al., 2007
Marchese et al., 2003

CXCR4 constructs
HA-CXCR4
FLAG-CXCR4

pcDNA3.0
pCMV-10

Marchese and Benovic, 2001
Malik and Marchese, 2010
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DTX3L constructs
DTX3L

Thermo Scientific

FLAG-DTX3L
GST-DTX3L
GST-DTX3L-NT
GST-DTX3L-CT
His-DTX3L
His-DTX3L-3C/A

pCMVSPORT6
pCMV-10
pGEX6p1
pGEX6p1
pGEX6p1
pET-21a(+)
pET-21a(+)

Other constructs
HA-Ubiquitin
FLAG-Ubiquitin
FLAG-HRS
FLAG-STAM-1
FLAG-Arrestin-1
FLAG-Arrestin-2
FLAG-UbcH5c
FLAG-UbcH7
GST-STAM-1
T7-HRS
T7-STAM-1
YFP-HRS-2"FYVE
His

pcDNA3.0
pCMV-10
pCMV-10
pCMV-10
pCMV-10
pCMV-10
pcDNA3
pcDNA3
pGEX-4T2
Unknown
Unknown
pEYFP-C1
pET-21a(+)

Bhandari et al. 2007
Marchese and Benovic, 2001
Malik and Marchese, 2010
Malik and Marchese, 2010
Source unknown
Source unknown
Gift from Dr. Noriyuki Matsuda
Gift from Dr. Noriyuki Matsuda
Malik and Marchese, 2010
Marchese et al., 2003
Malik and Marchese, 2010
Holleman and Marchese, 2014
Gift from Katherine L. Knight

Holleman and Marchese, 2014
Holleman and Marchese, 2014
Holleman and Marchese, 2014
Holleman and Marchese, 2014
Holleman and Marchese, 2014
Holleman and Marchese, 2014

Table 2.6 Primers used to generate constructs for this dissertation
Construct
Name
FLAGDTX3L
(1-740)
FLAGDTX1
(1-620)
FLAGDTX2
(1-622)
FLAGDTX3L-

Primers (5’ to 3’)
F: 5’ATATGCGGCCGCGCCTCCCACCTGCGCCCGCCGTC
R: 5’ATATTCTAGATTACTCAATTCCTTTGGCTTTC
F: 5’ATAT AAGCTTTCACGGCCAGGCCACGGTGGGC
R: 5’ATAT TCTAGATCAAGCCTGGTGTCGACTCCGGC
F: 5’ATAT AAGCTTGCCATGGCCCCAAGCCCTTCCC
R: 5’ ATAT TCTAGACTGCTGCTCCAGGCAGTC
F: 5’ GAAGGAAAAGGGCATCGCTGTCATCTGTATGGACACC
R: 5’ GGTGTCCATACAGATGACAGCGATGCCCTTTTCCTTC
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C561A
FLAGDTX3LC596/599A
GSTDTX3L
(1-740)
GSTDTX3L3C/A
GSTDTX3LNT
(1-464)
GSTDTX3L-CT
(528-740)
HisDTX3L
(1-740)
HisDTX3L3C/A
GST-AIP4C830A

F: 5’CATGTCATATAAGCCAATGCTCCCACAGCCCAGACTTCCTATGGTATTC
R:
5’GAATACCATAGGAAGTCTGGGCTGTGGGAGCGATTGGCTTATATGACATG
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC
R: 5’ATATCTCGAGTTACTCAATTCCTTTGGCTTTC
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC
R: 5’ATATCTCGAGTCAGATGCCCTTTTCCTTCTTGTCCAGTTCAAAGC
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC
R: 5’ATATCTCGAGTCAGATGCCCTTTTCCTTCTTGTCCAGTTCAAAGC

F: 5’ATATGGATCCGACATTGATAGCGATGATTCC
R: 5’ATATCTCGAGTTACTCAATTCCTTTGGCTTTC
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC
R: 5’ATATCTCGAGCTCAATTCCTTTGGCTTTCAGCTC
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC
R: 5’ATATCTCGAGCTCAATTCCTTTGGCTTTCAGCTC
F: ATATGGATCCGGTAGTCTGACCATGAAATCTCAACTTCAG
R: ATATGCGGCCGCTTACTCTTGTCCAAATCCTTCTGTTTCTTCTAG

Table 2.7 Restriction enzymes used for cloning in this dissertation
Enzyme
NotI
XbaI
BamHI
XhoI
EcoRI
ApaI

Recognition
Sequence
GC%GGCC GC
CG CCGG&CG
T%CTAG A
A GATC&T
G%GATC C
C CTAG&G
C%TCGA G
G AGCT&C
G%AATT C
C TTAA&G
G GGCC%C
C&CCGG G

Vendor

Cat. No.

Promega

R643A

Promega

R618A

Promega

R602A

Promega

R6161

Promega

R6011

Promega

R636A
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Table 2.8 GST- and His-fusion proteins used in this study
Number
Fusion protein
1.

GST

2.

GST-AIP4

3.

GST-AIP4-C830A

4.

GST-AIP4-C2

5.

GST-AIP4-dC2/dPRR

6.

GST-AIP4-WWI-IV

7.

GST-AIP4-dWWI-IV

8.

GST-AIP4-HECT

9.

GST-DTX3L

10.

GST-DTX3L-NT

11.

GST-DTX3L-CT

12.

GST-STAM-1

13.

His-DTX3L

14.

His-DTX3L-3C/A

CHAPTER III
RESULTS
ROLE OF DTX3L IN CXCR4 DEGRADATION
Endosomal sorting of the chemokine receptor 4 (CXCR4) into the degradative
pathway is important for controlling both the duration and magnitude of CXCR4
signaling (Malik, Soh, Trejo, & Marchese, 2012; Marchese et al., 2003). Ubiquitin is
known to regulate CXCR4 sorting into the degradative pathway, however, the precise
mechanisms by which this occurs remains poorly understood (Bhandari, Trejo, Benovic,
& Marchese, 2007; Malik & Marchese, 2010; Marchese & Benovic, 2001; Marchese et
al., 2003). Agonist activated CXCR4 is rapidly ubiquitinated at the plasma membrane by
the E3 ligase AIP4 and once internalized onto endosomes is sorted towards lysosomes by
the endosomal sorting complex required for transport (ESCRT) machinery. AIP4 also
ubiquitinates ESCRT-0, negatively impacting its sorting function to control the amount of
CXCR4 that is targeted for lysosomal degradation (Malik & Marchese, 2010; Marchese
et al., 2003). These data indicate that AIP4 is a central player in governing CXCR4
degradation and yet the mechanism regulating AIP4 remains poorly understood.
Given previous literature that suggest that AIP4 can interact with RING domain E3
ligases including Cbl-c and deltex-1 (DTX1), we tested the hypothesis that the DTX
and/or Cbl ligases are involved in CXCR4 trafficking (Chastagner, Israel, & Brou, 2006;
Courbard et al., 2002). Initially, we performed a preliminary small interfering RNA
(siRNA) screen to determine the role of deltex (DTX) and Casita B-lineage Lymphoma
(Cbl) proteins in regulating agonist promoted degradation of CXCR4. To determine this
101
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we examined agonist promoted degradation of endogenous CXCR4 in HeLa cells by
immunoblot analysis, similar to previously described (Bhandari et al., 2007; Malik &
Marchese, 2010; Marchese et al., 2003). HeLa cells were transfected with siRNA against
control, AIP4, DTX1-3, DTX3L, c-Cbl or Cbl-b. Twenty-four hours later cells were split
into single wells of a 24 well plate and grown overnight at 37˚C. The following day, cells
were treated with vehicle (0.1% BSA + PBS) or 10 nM CXCL12 for 3 h in the presence
of the protein synthesis inhibitor cyclohexamide. Cyclohexamide is used in order to
prevent de novo CXCR4 synthesis during the 3 h treatment period. Cells were harvested
in 2x sample buffer and subjected to SDS-PAGE followed by immunoblot analysis for
CXCR4. As shown in Figure 3.1, siRNA against AIP4 and DTX3L results in depletion of
AIP4 and DTX3L, respectively. Similar to our previously published results, siRNA
mediated knockdown of AIP4 significantly attenuates CXCR4 agonist-promoted
degradation when compared to control (Marchese et al., 2003). (Figures 3.1, 3.2 and 3.3).
Additionally, agonist-promoted degradation of CXCR4 was significantly inhibited in
cells transfected with siRNA against DTX3L as compared to cells transfected with
control siRNA (Figure 3.1).

Figure 1. Holleman and Marchese
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Figure 3.1 DTX3L regulates CXCR4 degradation. A. HeLa were transiently transfected with control

(Ctrl), AIP4 or DTX3L siRNA and treated with vehicle (0.1% BSA + PBS) or 10 nM CXCL12 for 3 h.
Figure 1. A role for DTX3L in CXCR4 degradation. (A) HeLa cells transfected with siRNA directed against GAPDH
Whole
cell
for the+ level
endogenous
CXCR4,
AIP4,
or actin
AIP4
orlysates
DTX3Lwere
werecollected
treated and
withanalyzed
vehicle (PBS
0.1%ofBSA)
or 10 nM
CXCL12
for 3DTX3L
h. Whole
cell lysates were ana
for the levels of endogenous CXCR4 and the indicated proteins by immunoblotting (IB). (B) CXCR4 levels normalized
by immunoblot
(IB) analysis.
B. The percent
of CXCR4
normalized
to actinpercent
were determined
by
actin were determined
by densitometric
analysis.
Datalevels
represent
the average
CXCR4 degraded
in CXCL12
treated cells as compared to vehicle treated cells from 8 independent experiments. Error bars represent the standard
densitometric
analysis.
Data analyzed
are representative
of theANOVA(p
average percent
of CXCR4
following
of the mean.
Data were
by a one-way
< 0.0001),
followed degradation
by Bonferroni's
post-hoc test. CXCR4
AIP4 (p < 0.001) and DTX3L (p < 0.001) siRNA treated cells was significantly different from siRNA control (siCtrl).
CXCL12 treatment from 8 independent experiments. Data were analyzed by one-way ANOVA (p<0.001),
followed by Bonferroni’s post-hoc test for multiple comparison amongst the groups. Compared to control
siRNA-treated cells, AIP4 (p<0.001) and DTX3L (p<0.001) siRNA depletion significantly attenuated
CXCR4 degradation.

In contrast, depletion of Cbl and DTX1-3 proteins had no effect on CXCR4 degradation
(Figures 3.2 and 3.3). Although no phenotype was displayed, we were unable to
determine knockdown of DTX1-4 and Cbl proteins due to lack of suitable reagents.
Future studies will be required to confirm knockdown either of protein or mRNA by
immunoblot or qPCR analysis, respectively. Overall, these data suggest a novel role for
the DTX protein DTX3L in mediating CXCR4 degradation.
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Figure 3.2 Cbl proteins in CXCR4 degradation. A. HeLa were transiently transfected with Ctrl, AIP4, cCbl or Cbl-b siRNA and treated with vehicle or 10 nM CXCL12 for 3 h. Whole cell lysates were collected
and analyzed for the level of endogenous CXCR4 and tubulin by IB analysis. B. The percent of CXCR4
:>?@:!0!A!(2((BC

levels normalized to actin were determined by densitomeric analysis. Data are representative of the average
percent of CXCR4 degradation following CXCL12 treatment from two independent experiments. Data
were quantified by densitomeric analysis and analyzed by one-way ANOVA (**p = 0.0067) followed by
Bonferroni’s post-hoc test. Error bars represent the standard deviation.
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Figure 3.3 DTX proteins in CXCR4 degradation.
A. HeLa were transiently transfected with Ctrl, AIP4, DTX3L or DTX1-3 siRNA and treated with vehicle
;?@A;!0!B!(2((CD

or 10 nM CXCL12 for 3 h. Whole cell lysates were collected and analyzed for the level of endogenous
CXCR4 and tubulin by IB analysis. B. The percent of CXCR4 levels normalized to actin were determined
by densitometric analysis. Data are representative of the average percent of CXCR4 degradation following
CXCL12 treatment. Data were quantified by densitomeric analysis and analyzed by one-way ANOVA
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(***p = 0.0004). Data represent three independent experiments for Ctrl, AIP4 and DTX3L or two
independent experiments for DTX1-3. Error bars represent the standard deviation.

CXCR4

ACTIVATION

PROMOTES

DTX3L

DISTRIBUTION

TO

THE

SURFACE OF EARLY ENDOSOMES
Given the novel role identified for DTX3L in regulating CXCR4 degradation, we
next assessed the subcellular distribution of endogenous DTX3L in HeLa cells following
CXCL12 treatment. To determine whether CXCL12 could regulate DTX3L localization
to either early endosomes or late endosomes/lysosomes, we employed fixed cell
confocal immunofluorescence microscopy. HeLa cells plated onto coverslips were
serum starved for 3 h and treated with CXCL12 or vehicle for 30 min. Cells were then
co-stained for endogenous DTX3L along with early endosomal and lysosomal markers
EEA1 and LAMP2, respectively. As shown in Figure 3.4, endogenous DTX3L staining
appears mostly diffuse in vehicle-treated cells with some punctate staining that colocalizes little with the early endosomal marker EEA1 and the lysosomal marker
LAMP2 (Figure 3.4C). In contrast, upon CXCL12 treatment, DTX3L puncta were
significantly increased (Figures 3.4A and B). Additionally, in contrast to vehicle,
CXCL12 treatment significantly increased the degree of co-localization of DTX3L with
EEA1-positive early endosomes (Figures 3.4A and C) compared to control whereas
DTX3L co-localization to LAMP2-positive lysosomes was only modestly increased
(Figures 3.4A and D).
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Figure 3.4 CXCR4 activation promotes DTX3L distribution on early endosomes. A. HeLa cells grown
on coverslips were serum starved for 3hrs. Media was replaced with media containing vehicle or 10 nM
CXCL12 for 30 min placed at 37˚C. HeLa cells were treated with vehicle or 10 nM CXCL12 for 30 min.
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Cells were fixed, permeabilized and immunostained for endogenous DTX3L and EEA1 or LAMP2. Yellow
in the “merge” panel indicates co-localization between DTX3L and EEA1 or LAMP2. Differential
interference (DIC) contrast images are shown. B. Quantification of DTX3L puncta in vehicle or CXCL12
treated cells using the ImageJ Function “Analyze Particles.” Threshold was set at a minimum of 130 and
maximum of 255. CXCR4 activation significantly increases DTX3L puncta. C,D. Quantification of
average co-localization between DTX3L and EEA1 (C) or LAMP2 (D) using the Pearson product moment
correlation co-efficient. Correlation was determined using the ImageJ plug-in “Colocalization Finder.”
Error bars represent the standard error of the mean. Data are representative of four independent
experiments and analyzed by a Student’s t test.

DTX3L REGULATES CXCR4 TRAFFICKING
Because CXCR4 is sorted for degradation by trafficking from early endosomes to
lysosomes (Bhandari et al., 2007; Marchese & Benovic, 2001; Marchese et al., 2003) and
since CXCL12 treatment promotes DTX3L localization on to early endosomes (Figures
3.4A and C), we next sought to determine whether DTX3L regulates the trafficking of
CXCR4 from early endosomes to lysosomes. In order to address this question, we used
confocal immunofluorescence microscopy to monitor the distribution of CXCR4 in HeLa
transiently transfected with control or DTX3L siRNA. Images were acquired under equal
acquisition settings between parallel experiments as detailed in Methods Section 2.7. In
control siRNA cells, treatment with CXCL12 significantly increased CXCR4 localization
to LAMP2-labeled lysosomes with little CXCR4 co-localizing to the early endosomal
marker EEA1 (Figures 3.5A and 3.6A) indicating that CXCR4 has trafficked from early
endosome to lysosomes. In contrast to control, depletion of DTX3L significantly
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increased the amount CXCR4 puncta (Figures 3.5A and 3.6B) and the co-localization of
CXCR4 with EEA1-positive early endosomes (Figures 3.5A and 3.6A), indicating that
CXCR4 sorting to lysosome is impaired. Overall, these data indicate that DTX3L is
important in mediating CXCR4 sorting from early endosomes to lysosomes.
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Figure 3.5 DTX3L promotes CXCR4 endosomal to lysosomal degradation. A. HeLa cells grown on
coverslips transiently transfected with either control or DTX3L siRNA were serum starved for 3hrs. Media
was replaced with media containing vehicle (PBS + 0.1% BSA) or 10 nM CXCL12 for 30 min placed at
37˚C. Cells were fixed, permeabilized and co-stained for endogenous CXCR4, DTX3L and EEA1 or
LAMP2. CXCR4 is shown in green, DTX3L is shown in blue and EEA1 or LAMP2 are shown in red.
Yellow puncta in the “merge” image indicate co-localization between CXCR4 and EEA1 or LAMP2.
Images represent four independent experiments, 45-60 cells. Differential interference (DIC) contrast
images are shown.
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Figure 3.6 DTX3L is required for CXCR4 localization to and degradation in lysosomes. A.
Quantification of average co-localization between CXCR4 and EEA1 or LAMP2 using the Pearson product
moment correlation co-efficient. Correlation was determined using the ImageJ plug-in “Colocalization
Finder.” Data were analyzed by one-way ANOVA (p<0.001), followed by Bonferroni’s post-hoc test. B.
Quantification of CXCR4 puncta in control and DTX3L siRNA-treated cells. Puncta were analyzed using
the ImageJ function “Analyze Particles.” Data are representative of the average puncta from four
independent experiments, 45-60 cells. Threshold was set at a minimum of 130 and maximum of 255. Error
bars represent the standard error of the mean. Data were analyzed by a Student’s t test.

AIP4 AND DTX3L DIRECTLY INTERACT
Since DTX3L not only co-localizes with CXCR4 upon activation, but also
regulates the extent to which CXCR4 degrades, we next wanted to determine the
mechanism by which DTX3L controls CXCR4 endosomal sorting. Given the role of
DTX3L in CXCR4 degradation (Figures 3.1 and 3.5) we hypothesize that DTX3L may
interact with key CXCR4 regulators, including AIP4 and ESCRT-0. In particular, prior
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studies have shown that AIP4 interacts with other E3 ligases including DTX1 and Cbl-c
(Chastagner et al., 2006; Courbard et al., 2002). Therefore, we tested whether DTX3L
could interact with AIP4 and the ESCRT-0 subunits, HRS and STAM-1 by coimmunoprecipitation. We immunoprecipitated endogenous DTX3L from HeLa cells and
assessed whether endogenous AIP4 or ESCRT-0 were present in the immunoprecipitates
by immunoblot analysis. As seen in Figure 3.7A, endogenous AIP4 and ESCRT-0
subunits, HRS and STAM-1 immunoprecipitated with DTX3L, but not immunoglobulin
G (IgG), used here as an isotype control. These data indicate that DTX3L can interact
with AIP4 and ESCRT-0, suggesting that potentially through these interactions DTX3L
may regulate endosomal sorting of CXCR4.
In order to determine the mechanism by which DTX3L controls CXCR4
endosomal sorting, we first focused on the interaction between AIP4 and DTX3L. First,
we determined whether AIP4 and DTX3L directly interact by performing binding
experiments using purified proteins. As shown in Figure 3.7B, recombinant His-DTX3L
interacts directly with recombinant GST-AIP4 in a concentration-dependent manner.
Second, we tested whether the interaction of AIP4 and DTX3L is promoted by CXCL12
treatment. HeLa cells were treated with or without CXCL12 for various times (0 - 60
min) and endogenous DTX3L was immunoprecipitated, followed by immunoblot
analysis using an anti-AIP4 antibody. As shown in Figure 3.7C, AIP4 coimmunoprecipitates with DTX3L at all time-points, with a significant increase in this
interaction at 15 min.
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Figure 3.7 AIP4 and DTX3L directly interact. A. HeLa cells lysates (500 µg) were subject to
immunoprecipitation for endogenous DTX3L or immunoglobulin G (IgG) isotype control and coimmunoprecipitation of proteins was determined by immunoblot analysis. Data represent three independent
experiments. B. Equimolar amounts of purified recombinant GST-AIP4 (100 nmols) were incubated with
increasing concentrations of His-DTX3L (1-10 nM). Samples were analyzed by 10% SDS-PAGE and
immunoblotting for DTX3L and GST. Bands in the GST-AIP4 purification lower than 100 kDa represent
degradation products from the purification. Data were quantified as the fold change in binding to AIP4
using densitometric analysis. Specifically, average values were subtracted from the GST only values and
then normalized to the 1 nM His-DTX3L sample. Data show a significant increase in His-DTX3L to AIP4
with increasing concentration. Data represent three independent experiments. Data were analyzed by oneway ANOVA, followed by Bonferroni’s post-hoc test. C. HeLa cells were serum starved for 3 h, followed
by treatment with 10 nM CXCL12 for 0-60 min. Cleared lysates (500 µg) were subject to
immunoprecipitation

using

the

goat

polyclonal

anti-DTX3L

and

isotype

control

antibodies.
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Immunoprecipitates and inputs were resolved by SDS-PAGE and immunoblotting to detect endogenous
AIP4, DTX3L or actin. AIP4 binding to DTX3L was significantly increased at 15 min of CXCL12
treatment. Immunoblots from four independent experiments were subject to densitomeric analysis and the
bar graph represents average AIP4 binding. Data were analyzed by one-way ANOVA followed by
Bonferroni’s post-hoc test (p<0.05). Error bars represent the standard error of the mean.

Third, we examined the localization of endogenous DTX3L and FLAG-AIP4
upon CXCR4 activation by fixed cell confocal immunofluorescence microscopy. Images
were acquired under equal acquisition settings between parallel experiments as detailed
in Methods Section 2.7. Overexpression of AIP4 was required in these experiments due
to a lack of suitable antibodies directed against AIP4 that could detect endogenous AIP4
by confocal microscopy. As seen in Figure 3.8, FLAG-AIP4 and DTX3L co-localize
upon CXCL12 treatment. Pearson analysis for co-localization reveals that AIP4 and
DTX3L significantly co-localizes at 15 - 60 min time points compared to cells treated
with vehicle (Figure 3.8B). This co-localization persisted up to the 60 min at which time
point there was a slight reduction in DTX3L and AIP4 co-localization (Figures 3.8A and
B). Additionally, the average amount of FLAG-AIP4 puncta increased upon CXCL12
treatment and decreased back towards vehicle by 60 min time point. (Figure 3.8C). In
contrast, DTX3L puncta levels increased upon CXCL12 treatment and persisted above
vehicle levels up to the 60 min time point (Figures 3.8D). The return of AIP4 puncta to
baseline at 60 min may be due to AIP4 cytosolic re-distribution rather than degradation
given that AIP4 levels in inputs at 60 min are not reduced (Figure 3.7C). Altogether these
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data indicate that DTX3L and AIP4 directly interact and CXCR4 activation promotes this
interaction.
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Figure 3.8 CXCL12 promotes DTX3L co-localization with AIP4. A. HeLa transfected with 1 µg FLAGAIP4 were serum starved for 3 h and stimulated with vehicle or 10 nM CXCL12 for 15-60 min. Cells were
fixed, permeabilized and co-stained for FLAG epitope, endogenous DTX3L and EEA1. FLAG-AIP4 is
shown in green, DTX3L is shown in red and EEA1 in blue. White puncta in the “merge” image represent
co-localization between AIP4, DTX3L and EEA1. Differential interference (DIC) contrast images are
shown. B. Quantification of average co-localization between DTX3L and FLAG-AIP4 using the Pearson
product moment correlation co-efficient. Correlation was determined using the ImageJ plug-in
“Colocalization Finder.” Data were analyzed by a Student’s t test and error bars represent the standard error
of the mean. (C, D). Quantification of FLAG-AIP4 (C) and DTX3L (D) puncta. Puncta were analyzed
using the ImageJ function “Analyze Particles.” Threshold was set at a minimum of 130 and maximum of
255. Data are representative of the average puncta from four independent. Error bars represent the standard
error of the mean. Data were analyzed by a Student’s t test. E. Immunoblot depicting the level of FLAGAIP4 overexpression in lysates from IF in (A).

MAPPING THE AIP4 BINDING SITE ON DTX3L
We have shown so far that DTX3L regulates the lysosomal degradation of
CXCR4 at the level of the endosome and that DTX3L interacts directly with AIP4. To
gain insight into the role of DTX3L interaction with AIP4 on CXCR4 trafficking, we
performed interaction studies to determine the binding regions. First, we performed
GST-pull down experiments using GST-AIP4 and HeLa cell lysates endogenously
expressing DTX3L. Endogenous DTX3L is able to bind to full-length recombinant GSTAIP4, but not GST-only control (Figure 3.9A).
In order to determine the binding region through which DTX3L binds to AIP4, we
generated GST-fusion proteins of the N-terminal (NT) and C-terminal (CT) regions of
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DTX3L based on the DTX3L truncation mutants previously characterized by Takeyama
et al. 2003. The NT truncation of DTX3L spans amino acids 1-464 of the unique region,
while the CT truncation covers amino acids 528-740 which includes the CT RING
domain (Figure 3.9B). These truncation mutants were compared along with GSTDTX3L-Full length (FL) for binding to FLAG-AIP4 expressed in HeLa cells. As shown
in Figure 3.9, FLAG-AIP4, but not empty vector binds strongly to GST-DTX3L-FL as
compared to GST alone. In addition, FLAG-AIP4 binds to a lesser degree to the NT and
CT DTX3L truncations when compared to FL DTX3L (Figure 3.9C). However,
densitomeric analysis demonstrates that FLAG-AIP4 binds stronger to DTX3L-NT and
weakly to the DTX3L-CT truncation (Figure 3.9B and D). Altogether these data
demonstrate that DTX3L and AIP4 bind and that the N-terminal unique region of DTX3L
binds strongly to AIP4.
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Figure 3.9 DTX3L binds AIP4 via the N-terminal domain. A. Equimolar amounts (100 nmols) of
immobilized GST or GST-AIP4 were incubated with HeLa lysates (500 µg). Binding of endogenous
DTX3L was determined by immunoblot analysis. Ponceau staining of blot depicts the loading of GST and
GST-AIP4 used in the binding reactions. B. Schematic representing the DTX3L truncation constructs used
in binding experiments described in panels C and D. Summary of AIP4 binding to each truncation mutant
is indicated. +++ = high binding; ++ = intermediate binding; + = low binding. C. Equimolar amounts (100
nmol) of immobilized GST, GST-DTX3L-Full length (FL), GST-DTX3L-N-term (NT) or GST-DTX3L-Cterm (CT) were incubated with HeLa lysates (100 µg) transiently transfected with FLAG-AIP4 or empty
vector control. Binding of FLAG-AIP4 was detected by immunoblotting with the anti-FLAG-HRP
antibody. Amount of FLAG-AIP4 binding was determined by densitomeric analysis and normalized to FL.
Ponceau staining depicts the loading of the GST-fusion proteins. D. Shown are representative data analyzed
from a total of three independent experiments. Data is represents fold AIP4 binding to each DTX3L

118
construct normalized to control (empty vector). Data were analyzed by one-way ANOVA and error bars
represent the standard error of the mean.

MAPPING THE DTX3L BINDING SITE ON AIP4
In order to gain further insight into the interaction between DTX3L and AIP4, we
next sought to determine the region on AIP4 that could be binding to DTX3L. In order to
do this, we performed binding experiments using immobilized GST-AIP4-full length
(FL) as well as several GST-AIP4 truncation mutants (Figure 3.10C). Equimolar amounts
of the GST fusion proteins were incubated with HeLa lysates to determine binding to
endogenous DTX3L. As shown in Figure 3.10, endogenous DTX3L bound strongly to
GST-AIP4-FL and to a lesser extent to GST-C2 and GST-HECT truncations relative to
GST only control. Little to no binding was detected for GST-WW I-IV samples. These
data suggest that DTX3L is able to bind strongly to both the N-terminal C2 domain as
well as the C-terminal HECT domain of AIP4 and potentially to regions containing the
PRR domain. However, future experiments will need to be performed to determine
importance of the two AIP4 binding regions in mediating the interaction with DTX3L.
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Figure 3.10 AIP4 binding to DTX3L involves the C2 and HECT domains. A. Equimolar amounts (200
nmols) of immobilized GST, GST-AIP4, GST-C2, GST-WW I-IV or GST-HECT were incubated with HisDTX3L (5 nM) overnight. Binding of His-DTX3L was determined by immunoblotting with the anti-T7
monoclonal antibody. His-DTX3L binds strongly to GST-AIP4 and weaker to GST-C2 and GST-HECT. B.
Data from two independent experiments were quantified by densitometry. Data represents fold DTX3L
binding to each AIP4 construct as a fraction of control (GST). Error bars represent the standard deviation.
D. Cartoon depicting the recombinant GST-AIP4 constructs used in binding reactions and summary of the
relative binding of His-DTX3L to each construct denoted as follows: +++ = high binding; ++ =
intermediate binding; + = low binding. Data represent two independent experiments.
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DTX3L REGULATES ESCRT-0 UBIQUITINATION
Previous work from our lab has shown that the extent to which CXCR4 is
degraded is dependent on both CXCR4 and ESCRT-0 ubiquitination mediated by AIP4.
Agonist-stimulation of CXCR4 promotes ubiquitination of both ESCRT-0 components,
HRS and STAM-1 (Malik & Marchese, 2010; Marchese et al., 2003). Recent data from
our lab has also highlighted that the interaction of STAM-1 with the adaptor arrestin-2
(a.k.a. !–arrestin-1) on early endosomes acts to potentially regulate the ubiquitination
status and sorting function of HRS (Malik & Marchese, 2010). In this complex, Arrestin2 is thought to recruit AIP4 to endosomes where it ubiquitinates HRS and, thereby,
triggers a conformational change in HRS structure that prevents its sorting function with
STAM-1. Importantly, CXCR4 degradation is enhanced when HRS ubiquitination is
inhibited (Malik & Marchese, 2010). Essentially, the extent of CXCR4 degradation is
dependent upon the ubiquitination status of ESCRT-0 (Malik & Marchese, 2010;
Marchese et al., 2003). We sought to determine whether DTX3L also has an effect on
ESCRT-0 ubiquitination. We examined the degree of ubiquitination of ESCRT-0
subunits HRS and STAM in HeLa cells following DTX3L or control siRNA depletion.
As seen in Figure 3.11, in DTX3L siRNA-treated cells there was significantly increased
amounts of ubiquitinated HRS (Figure 3.11A) and STAM-1 (Figure 3.11B) compared to
control. There was also an increase in total ubiquitination in lysates treated with DTX3L
siRNA compared to control, indicating that depletion of DTX3L may result in a global
accumulation of ubiquitinated proteins and does not result in a reduction in the protein
stability of either HRS or STAM-1. Based on these experiments this data suggest that
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DTX3L negatively regulates the ubiquitination process. This is surprising given the role
that ubiquitin ligases often have in promoting substrate ubiquitination. To the best of our
knowledge, this is first study to show that depletion of a particular E3 ubiquitin ligase
actually promotes global ubiquitination of substrates and opens the door to idea that E3
ubiquitin ligases may have both positive as well as negative roles in mediating

!"#$%&'()'*+,,&-./'./0'1.%23&4&
ubiquitination.
Taken together, these data suggest that DTX3L regulates CXCR4
degradation through regulation of ESCRT-0 ubiquitination.
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Figure 3.11 DTX3L regulates ESCRT-0 ubiquitination and complex formation. A, B. HeLa cells were
first transfected with control or DTX3L siRNA, followed by co-transfection with FLAG-ubiquitin and T7HRS (A) or T7-STAM-1 (B). Lysates were collected under denaturing conditions and subject (300 µg) to
immunoprecipitation using the anti-T7 polyclonal antibody. Immunoprecipitates and lysates were resolved
by 7% SDS-PAGE and immunoblotted with the indicated antibodies. Data are representative of 3
independent experiments and were quantified by densitomeric analysis. Asterisks (*) indicate HRS or
STAM attached to a single or multi-mono ubiquitin. The amount of ubiquitination in control siRNA-treated
cells was normalized to one and ubiquitination in DTX3L siRNA-treated cells was represented as a fold
over control. Data were analyzed by a Student’s t test and error bars represent the standard error of the
mean. Data were analyzed by a Student’s t test.

DTX3L REGULATES ESCRT-0 COMPLEX STABILITY
Previous studies have suggested that ubiquitination of HRS can regulate the
ability of ESCRT-0 to form a stable complex on early endosomes due to the inability of
HRS to adopt an active conformation and be recruited to early endosomes (Hoeller et al.,
2006; Malik & Marchese, 2010; Marchese et al., 2003). Specifically, the sorting activity
of HRS is predicted to be inhibited upon ubiquitination due to the adoption of an autoinhibitory conformation in which the ubiquitin moiety on HRS binds to its own ubiquitin
binding domain (UBD). This conformation inhibits HRS from binding to STAM-1 and,
thus, prevents ESCRT-0 from sorting ubiquitinated cargo on the endosome (Hoeller et
al., 2006). In support of this idea, recent data from our lab has demonstrated that when
HRS poly-ubiquitination is inhibited, the amount of CXCR4 sorted to lysosomes is
increased (Malik & Marchese, 2010). Having determined that DTX3L functions to
regulate ESCRT-0 ubiquitination, we next examined the effect that DTX3L has on the
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ability of HRS and STAM-1 to form an active sorting complex on early endosomes. In
HeLa cells immunoprecipitated for endogenous HRS or STAM-1, DTX3L siRNA
depletion resulted in a significant reduction in co-immunoprecipitation of STAM-1 or
HRS, respectively, compared to control (Figures 3.12A and B). Therefore, DTX3L
positively regulates ESCRT-0 complex integrity. Overall, these data indicate that DTX3L
is an important regulator of ESCRT-0 ubiquitination and complex formation as means to
regulate the extent of CXCR4 sorting into the degradative pathway.
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Figure 3.12 DTX3L regulates ESCRT-0 ubiquitination and complex formation. A, B. HeLa lysates
transfected with control or DTX3L siRNA were subject to immunoprecipitation for endogenous HRS (A)
or STAM-1 (B). Immunoprecipitates and lysates were subject to SDS-PAGE and immunoblotting for

124
indicated antibodies. Data represent 3-4 independent experiments. The amount of co-immunoprecipitation
was determined by densitomeric analysis. Briefly, the amount of the associated protein was calculated as a
fraction of the total immunoprecipitated protein for each respective siRNA sample. Average control values
were normalized to one and then compared to DTX3L siRNA-treated samples. Data were analyzed by a
Student’s t test.

DTX3L PROMOTES ESCRT-0 ACTIVITY ON EARLY ENDOSOMES
Given that ubiquitin modification of ESCRT-0 may prevent the formation of
active complex, we hypothesize that DTX3L through regulating the degree of ESCRT-0
ubiquitination could, therefore, also regulate the ability of ESCRT-0 to be recruited to
endosomes (Hoeller et al., 2006; Marchese et al., 2003). In order to address this question,
we used confocal immunofluorescence microscopy to monitor the distribution of HRS
and STAM-1. HeLa cells grown on coverslips transiently transfected with either control
or DTX3L siRNA were serum starved for 3h. Media was replaced with media containing
vehicle (PBS + 0.1% BSA) or 10 nM CXCL12 for 30 min placed at 37˚C. Cells were
then fixed, permeabilized and immunostained for DTX3L and HRS or STAM-1. Images
were acquired under equal acquisition settings between parallel experiments as detailed
in Methods Section 2.7. In control siRNA-treated cells, DTX3L co-localizes with both
HRS (Figures 3.13A and 3.14B) and STAM-1 (Figures 3.13B and 3.14D). Furthermore,
siRNA depletion of DTX3L resulted in a reduction in the level of both HRS (Figures
3.13A and 3.14A) and STAM-1 (Figures 3.13B and 3.14C) puncta compared to control.
These data indicate that DTX3L modulates the ability of ESCRT-0 to localize onto
endocytic structures following CXCR4 activation and, therefore, the degree of CXCR4
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endosomal to lysosomal sorting into the degradative pathway. Taken together, these data
provide mechanistic insight into DTX3L regulation of CXCR4 degradation through
positively regulating ESCRT-0 complex formation and integrity.
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Figure 3.13 DTX3L promotes ESCRT-0 aggregation on early endosomes. A, B. HeLa cells were
transiently transfected with control or DTX3L siRNA. Cells were serum starved for 3hr and then stimulated
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with 10 nM CXCL12 for 1 h and then fixed, permeabilized and co-stained for HRS (A) or STAM-1 (D)
and DTX3L. HRS or STAM are shown in green and DTX3L is shown in red. Yellow in the “merge” image
represents co-localization of HRS or STAM with DTX3L. Differential interference (DIC) contrast images
are shown. Data represent 4 and 3 independent experiments, respectively. For HRS 110-145 cells were
analyzed whereas 45-50 cells were analyzed for STAM-1. Data were analyzed by a Student’s t test.
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Figure 3.14 DTX3L localizes with and regulates the aggregation of ESCRT-0 on endosomes. A, C.
Quantification of the average HRS (A) and STAM-1 (C) puncta per cell using the ImageJ function
“Analyze Particles.” Threshold was set at a minimum of 150 and maximum of 255. Data were analyzed by
a Student’s t test and error bars represent the standard error of the mean. B, D. Quantification of average
co-localization between DTX3L and HRS (B) or STAM-1 (D) using the Pearson product moment
correlation co-efficient. Correlation was determined using the ImageJ plug-in “Colocalization Finder.” Data
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represent 4 and 3 independent experiments, respectively. For HRS 110-145 cells were analyzed whereas
45-50 cells were analyzed for STAM-1. Data were analyzed by a Student’s t test.

PHOSPHATIDYLINOSITOL 3-PHOSPHATE IS NOT REGULATED BY DTX3L
The localization of ESCRT-0 to the surface of early endosomes is dependent
partly on the interaction of the FYVE (Fab1, YOTB, Vac1 and early endosome antigen1) -domain of HRS with phosphoinositide 3-phosphate (PI-3P), an endosomally enriched
phospholipid localized to the cytosolic surface (Raiborg et al., 2001; Stenmark, Aasland,
& Driscoll, 2002). The FYVE domain contains a cysteine rich zinc finger that binds
directly with high selectivity to PI-3P compared to other phospholipids. The FYVEdomain is named after four proteins in which it was originally discovered: Fab1, YOTB,
Vac1 and early endosome antigen-1 EEA1 (Burd & Emr, 1998; He et al., 2009). We
explored the possibility that DTX3L modulates the steady state levels of PI-3P as a
mechanism for controlling ESCRT-0 localization to endosomes. In order to determine
this, we employed fixed cell confocal immunofluorescence microscopy in HeLa cells
transfected with the fluorescent-tagged FYVE domain fusion (YFP-2"FYVE) construct
as a means to monitor PI-3P levels similar to published approaches (Gillooly et al.,
2000). In particular, we examined the effect DTX3L depletion has on YFP-2"FYVE
localization to early endosomes following CXCR4 activation. Images were acquired
under equal acquisition settings between parallel experiments as detailed in Methods
Section 2.7. To control for binding to endosomes, we utilized wortmannin a potent
inhibitor of phosphoinositide (PI) 3-kinase. Wortmannin is a non-selective PI-3K
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inhibitor that disrupts the synthesis of PI-3Ps and, therefore, can disrupt the binding of
proteins on endosomes that depend on the interaction with endosomally enriched PI-3Ps
(Wymann et al., 1996).
In both control and DTX3L siRNA-treated cells, YFP-2"FYVE was highly colocalized to early endosomes following CXCL12 stimulation as determined by Pearson
analysis (Figures 3.15A and 3.16B). However, pre-treatment of both control and DTX3L
depleted cells with the PI-3P inhibitor, wortmannin, prevented YFP-2"FYVE localization
to early endosomes. Additionally, there was a reduction in EEA1 staining upon
wortmannin pre-treatment indicating a disruption of EEA1 binding to PI 3-P enriched
endosomes (Figures 3.15A). This coincides with previously published literature that
demonstrated that wortmannin treatment disrupts EEA1 binding to PI-3P membranes
(Patki et al., 1997). Together, these data demonstrate that DTX3L ability to regulate the
endosomal localization of ESCRT-0 is not due to a change in steady-state levels of
endosomally localized PI-3P.
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Figure 3.15 DTX3L does not reduce phosphatidylinositol 3-phosphate levels. A. HeLa cells were
transiently co-transfected with YFP-2"FYVE and either control or DTX3L siRNA. Media was aspirated
and cells were serum starved for 3h, followed by pre-treatment with either DMSO or wortmannin (100 nM)
for 30 min prior to stimulation with CXCL12 (10 nM) for 1 h. Cells were fixed, permeabilized and costained for EEA1 and DTX3L. YFP-2"FYVE is in green, EEA1 is in red and DTX3L is in blue. White in
the “merge” panel indicates co-localization between YFP-2"FYVE, EEA1 and DTX3L whereas yellow
indicates co-localization between YFP-2"FYVE and EEA1. Differential interference (DIC) contrast images
are shown.
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Figure 3.16 YFP-FYVE puncta and localization to endosomes is reduced upon reduction in
phosphatidylinositol 3-phosphate by wortmannin. A. Quantification of the average YFP-2"FYVE
puncta per cell using the ImageJ Function “Analyze Particles.” Data represent 3 independent experiments,
35-40 cells. Threshold was set at a minimum of 130 and maximum of 255. Wortmannin treatment
significantly prevents YFP-2"FYVE localization to early endosomes in both control and DTX3L siRNAtreated cells in contrast to DMSO control. Data were analyzed by one-way ANOVA (p < 0.0001) and error
bars represent the standard error of the mean. B. Quantification of average co-localization between YFPFYVE and EEA1 using the Pearson product moment correlation co-efficient. Correlation was determined
using the ImageJ plug-in “Colocalization Finder.” Data represent 3 independent experiments. Data were
analyzed by one-way ANOVA (p < 0.0001) and error bars represent the standard error of the mean.

DTX3L PREVENTS AIP4 SELF-UBIQUITINATION IN VITRO
Given that DTX3L and AIP4 interact directly and have opposing effects on
ESCRT-0 ubiquitination (Figures 3.7 and 3.11) (Holleman & Marchese, 2014; Malik &
Marchese, 2010; Marchese et al., 2003), we hypothesized that DTX3L may modulate
AIP4 E3 ligase activity. In order to determine this, we performed in vitro ubiquitination
assays using purified AIP4, His-DTX3L and their catalytically inactive mutants (AIP4-
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C830A; His-3C/A). In general, E3 ubiquitin ligases including AIP4 and DTX3L are
activated through self-ubiquitination (Takeyama et al., 2003 Scialpi et al., 2008). Thus,
these reactions were designed to examine AIP4 and DTX3L self-ubiquitination alone and
in combination. The catalytically inactive mutants are mutated within their active site
HECT (AIP4-C830A) or RING (His-3C/A) domain and are unable to mediate direct or
indirect transfer of ubiquitin to substrates (Chastagner et al., 2006; Marchese & Benovic,
2001). Specifically, the DTX3L-RING-3C/A mutant was designed based on the DTX1
mutant previously reported in which cysteine residues 561, 596 and 599 within the RING
domain were mutated to alanine residues. This mutation prevents E2 enzyme mediated
transfer of ubiquitin by disrupting the E2 binding site (Chastagner et al., 2006).
Therefore, these ‘ligase-dead’ mutants serve as negative controls since they are unable to
promote ubiquitination. Incubation of AIP4 and DTX3L alone results in selfubiquitination, which is common among E3 ubiquitin ligases (Scialpi et al., 2008;
Takeyama et al., 2003). Briefly, reactions were performed at room temperature for 1 h 30
min. Reaction conditions were based on previously described in vitro ubiquitin reactions
and optimized by titrating amount of ligase used in the reaction as well as performing
reactions at different temperatures (RT and 37˚C) and/or times (15, 30 or 60 min) in order
to determine optimal activity of either ligase (Laney & Hochstrasser, 2011).
Ubiquitination of substrates is determined by immunoblot analysis and is represented by
either the accumulation or smearing of higher molecular weight bands above the
predicted molecular weight of the unmodified substrate as compared to input.
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As seen in Figure 3.17, AIP4 self-ubiquitination is more robust than DTX3L with
AIP4 accumulating higher molecular species (Figure 3.17, lane 6 vs. 8). In contrast,
incubation of either catalytically inactive mutant (AIP4-C830A or His-3C/A) did not
exhibit self-ubiquitination (Figure 3.17, lane 7 and 9). Combination of AIP4 and DTX3L
resulted in a robust decrease in the level of AIP4 self-ubiquitination when compared to
AIP4 alone, indicating that the co-incubation of DTX3L with AIP4 inhibits AIP4 selfubiquitination (Figure 3.17, lane 10). A small decrease in DTX3L ubiquitination was also
apparent in these reactions as seen in the DTX3L immunoblot (Figure 3.17, lane 10). In
addition, co-incubation of AIP4 with the catalytically inactive mutant of DTX3L
(DTX3L-3C/A) also resulted in a decrease in AIP4 self-ubiquitination demonstrating that
the catalytic integrity of the DTX3L RING domain is not necessary to inhibit AIP4 selfubiquitination (Figure 3.17, lane 11). In contrast, neither co-incubation of AIP4-C830A
with DTX3L nor AIP4-C830A with DTX3L-3C/A resulted in AIP4-C830A
ubiquitination due to the inability of AIP4-C830A mutant to load ubiquitin (Figure 3.17,
lane 12 and 13). Thus, DTX3L-3C/A and AIP4-C830A mutants both act as negative
controls since both are unable to mediate ubiquitination. Altogether, these data show that
DTX3L, independent of the RING domain activity, inhibits AIP4 self-ubiquitination.

Figure 7. Holleman and Marchese
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Figure 3.17 DTX3L inhibits AIP4 ligase activity. A. Ubiquitination reactions containing purified AIP4,
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To further confirm that the inhibition of AIP4 self-ubiquitination is specific to DTX3L
acting upon AIP4 and not due simply to non-specific sequestration of ubiquitin by
DTX3L, we examined the effect of the E3 ubiquitin ligase Parkin on AIP4 selfubiquitination. Parkin belongs to the RING-between-RING (RBR) E3 ligases, which
possess features of both HECT and RING domain ligases and are termed RING-HECT
hybrids. In addition, Parkin shows self-ubiquitination activity with the E2 enzymes
UbcH7 and UbcH5c (Wenzel, Lissounov, Brzovic, & Klevit, 2011). As shown in Figure
17B, co-incubation of AIP4 with Parkin robustly promoted AIP4 self-ubiquitination
when compared to AIP4 alone (Figure 3.17B, lanes 5 vs. 9). As expected co-incubation
of AIP4 and DTX3L reduced AIP4 self-ubiquitination (Figure 3.17B, lanes 5 vs. 8).
Parkin co-incubation with AIP4 promoted a different pattern of AIP4 ubiquitination than
seen with AIP4 alone indicating that either the presence of Parkin increases the ability of
AIP4 to self-ubiquitinate or that Parkin may mediate AIP4 ubiquitination (Figure 3.17B,
lane 5 vs. 9). Furthermore, DTX3L self-ubiquitination was robustly reduced in the
presence of Parkin, whereas co-incubation with AIP4 slightly reduced DTX3L selfubiquitination consistent with the previous panel (Figures 3.17B, lane 10 and 8, and
3.17A, lane 10). Moreover, co-incubation of AIP4 or DTX3L with Parkin did not prevent
Parkin self-ubiquitination (Figure 3.18B, lane 9 and 10). These results indicate that the
decrease in AIP4 ubiquitination in the presence of DTX3L in these reactions is specific.
Although both DTX3L and Parkin belong to the RING-type ligase family, either ligase
differentially regulates AIP4 self-ubiquitination in vitro. The importance of Parkin in
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mediating differential changes in both AIP4 and DTX3L self-ubiquitination will remain
to be investigated by future studies.

DTX3L ANTAGONIZES AIP4-MEDIATED UBIQUITINATION OF HRS
Given that DTX3L inhibits AIP4 self-ubiquitination in vitro, we next wanted to
determine whether DTX3L could prevent AIP4 ligase activity toward its substrates. To
this end, we examined the effect of DTX3L on inhibiting the ubiquitination of a known
AIP4 substrate, HRS, in HeLa cells (Malik & Marchese, 2010; Marchese et al., 2003).
HeLa cells were depleted of DTX3L, AIP4 or the combination and the level of HRS
ubiquitination was determined by immunoprecipitation followed by immunoblot analysis.
As seen in Figure 3.18, depletion of DTX3L results in hyper-ubiquitination of HRS
confirming results shown in Figure 3.11A. In contrast, either AIP4 depletion alone or the
combination of AIP4 and DTX3L siRNA resulted in a reduction in HRS ubiquitination.
Although in these experiments we noted that AIP4 knockdown efficiency was not as
great when co-transfected with DTX3L siRNA as seen with AIP4 knockdown alone.
Nonetheless given that the degree of HRS hyper-ubiquitination was reduced in the
combined lanes than with DTX3L knockdown alone, these data indicate that DTX3L
counteracts AIP4 activity in cells namely the hyper-ubiquitination of HRS. Thus, we have
defined that not only does DTX3L regulate CXCR4 endosomal to lysosomal degradation
but also DTX3L does so by promoting ESCRT-0 activity while counteracting AIP4
activity on early endosomes.
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Figure 3.18 DTX3L counteracts AIP4-mediated HRS ubiquitination. A. HeLa cells were first
transfected with siRNA against control, DTX3L, AIP4 or the combination, followed by co-transfected with
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DTX3L

DOES

NOT

PREVENT

AGONIST-PROMOTED

CXCR4

UBIQUITINATION
AIP4 mediates CXCR4 agonist-promoted ubiquitination at the plasma membrane
(Marchese et al., 2003). Given that DTX3L counteracts AIP4 mediated ubiquitination of
HRS, we next assessed the effect DTX3L depletion has on AIP4 agonist-promoted
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ubiquitination of CXCR4. To examine this, HeLa cells were depleted of DTX3L and the
level

of

agonist-promoted

ubiquitination

of

CXCR4

was

determined

by

immunoprecipitation followed by immunoblot analysis. As shown in Figure 3.19,
depletion of DTX3L did not prevent CXCR4 ubiquitination. The level of CXCR4
ubiquitination in DTX3L siRNA-treated cells was even greater than in control. These
data indicate that DTX3L counters AIP4 agonist-promoted ubiquitination of CXCR4
such that depletion of DTX3L increases AIP4-mediated ubiquitination of CXCR4.
Altogether, we have established that DTX3L is a bona fide inhibitor of AIP4
modification of CXCR4 and ESCRT-0 in the context of CXCR4 trafficking and
degradation.

Figure S3. Holleman and Marchese
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Figure 3.19 DTX3L does not prevent agonist-promoted CXCR4 ubiquitination. A. HeLa lysates were
co-transfected with FLAG-ubiquitin and HA-CXCR4 plus control or DTX3L siRNA. Serum starved cells

ilencing does not prevent agonist-promoted ubiquitination of CXCR4. Cleared HeLa cell lysates transfected with HAwere treated with 10 nM CXCL12 for 30 min followed by immunoprecipitation with the anti-HA
control or DTX3L siRNA were subjected to immunoprecipitation of HA-CXCR4 under denaturing conditions. Sample
DS-PAGE and immunoblotted
for the under
indicated
proteins.
polyclonal antibody
denaturing
conditions. Samples were resolved by 7% SDS-PAGE followed by
immunoblotting for indicated proteins. Data represent 7 independent experiments.

CHAPTER IV
DISCUSSION
The findings in this current study have provided further mechanistic insight into the
regulation of CXCR4 signaling and trafficking. Our study highlights a novel role for the
E3 ubiquitin ligase DTX3L in regulating the extent of CXCR4 degradation. We
demonstrate that silencing of DTX3L results in accumulation of CXCR4 on early
endosomes preventing its lysosomal degradation. We also show that AIP4 interacts with
the RING domain ligase Deltex-3L (DTX3L) upon CXCR4 activation. Furthermore,
DTX3L interacts directly with AIP4 and inhibits AIP4 self-ubiquitination in vitro.
Additionally, DTX3L interacts with the ESCRT-0 components HRS and STAM and
regulates ESCRT-0 complex integrity. Our data show that DTX3L regulates AIP4mediated ubiquitination of ESCRT-0 to regulate the extent of CXCR4 degradation
(Holleman & Marchese, 2014). Altogether this study has provided conceptual advances
in understanding both the regulation of CXCR4 signaling as well as expands upon current
knowledge into GPCR regulation in general.

ROLE OF DTX3L IN CXCR4 DEGRADATION
Deltex-3-like (DTX3L; also known as B lymphoma and BAL associated protein,
BBAP) belongs to the RING domain ligase family of Deltex proteins (Takeyama et al.,
2003). While DTX1 and DTX2 have been widely studied as regulators of Notch
!
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signaling, the function of DTX3 and DTX3L are less defined in the literature (Mazaleyrat
et al., 2003; Takeyama et al., 2003). DTX3L was first identified in a subset of DLBCLs
as a binding partner to the gene BAL (B aggressive lymphoma). The interaction of BAL
with DTX3L enables BAL nuclear localization and is implicated in regulating the DNA
damage response through DTX3L-mediated monoubiquitination of histone H4 (Yan et
al., 2009; Yan et al., 2013). Here in this work, we have defined a novel role for DTX3L
in regulating the membrane trafficking of CXCR4 (Figure 4.1). We show that siRNAmediated knockdown of DTX3L significantly prevented CXCR4 degradation, revealing a
novel function of DTX3L as a positive regulator of CXCR4 degradation (Figure 3.1). To
our knowledge, this present study is the first to define a role for DTX3L in membrane
trafficking of a GPCR.
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Figure 4.1 Proposed model for the role of DTX3L in CXCR4 trafficking. Upon CXCR4 activation,
endogenous DTX3L is recruited to early endosomes where it interacts directly with AIP4. On early
endosomes, DTX3L antagonizes AIP4 ubiquitin ligase activity and ability to bridge to the ESCRT-0
subunits through binding to Arrestin-2. This limits the extent to which ESCRT-0 subunits (HRS and
STAM-1) are ubiquitinated (green arrows). This promotes ESCRT-0 function on early endosomes such that
it is able to interact with ubiquitinated CXCR4 and sort it for lysosomal degradation. Taken together our
data are consistent with a model whereby DTX3L acts as a inhibitor of AIP4 activity to promote CXCR4
downregulation.
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DTX3L REGULATES CXCR4 TRAFFICKING INTO THE DEGRADATIVE
PATHWAY
Our study highlights that DTX3L subcellular distribution to early endosomes is
influenced upon CXCR4 activation. The distribution of endogenous DTX3L in HeLa
cells is mostly diffuse in the cytosol with few puncta aggregating on early endosomes and
lysosomes (Figure 3. 4). Following CXCR4 activation, DTX3L co-localization onto early
endosomes increases significantly whereas DTX3L localization to lysosomes remains
relatively unchanged (Figure 3.4A,C and D). The precise mechanisms governing DTX3L
recruitment onto endosomes and lysosomes remain to be determined. Yet given the
uncharacterized unique N-terminal region of DTX3L, we speculate that perhaps a noncanonical motif within this N-terminal region may be required for recruitment to
endosomes and lysosomes. Alternatively, DTX3L through binding to such proteins as
AIP4 or ESCRT-0 may act to recruit DTX3L to these structures.
Moreover, we have demonstrated that DTX3L functions to regulate the endosomal
to lysosomal trafficking of CXCR4 since siRNA depletion of DTX3L increases the
number of CXCR4 puncta that localize to early endosomes following 3 h of CXCL12
treatment in contrast to control (Figure 3.4A and B). Since DTX3L knockdown prevents
CXCR4 degradation, we can speculate that in DTX3L CXCR4 may be trafficked through
recycling pathways. Preliminary CXCR4 recycling experiments suggest that indeed
DTX3L knockdown promotes CXCR4 recycling back to the plasma membrane.
Additionally, the receptor that recycles back to the plasma membrane is able to evoke
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agonist-promoted signaling responses. Overall the findings in this study and preliminary
data suggest that DTX3L functions to promote ESCRT-dependent trafficking of CXCR4
into the degradative pathway and the removal of DTX3L antagonizes CXCR4
degradation in favor of recycling.
Given that a small subset of endogenous DTX3L does localize to early endosomes
and lysosomes prior to CXCL12 stimulation, it is plausible that DTX3L may have
additional roles in regulating membrane trafficking not exclusive to ESCRT-0. For
instance, DTX3L may regulate the recruitment and ubiquitin modification of the other
ESCRT proteins to facilitate the concentration of receptors into the limiting membrane of
the endosome to form the MVBs. Preliminary binding experiments demonstrated that
GST-DTX3L not only interacts with the endosomally localized ESCRT-0 components
HRS and STAM-1 but in addition DTX3L can bind to the ESCRT-I component Tsg101,
ESCRT-II component EAP45 as well as Arrestin-2 (!-Arrestin-1). Given that previous
literature suggests that the STAM1/Arrestin-2 complex may recruit AIP4 to endosomes
where it can bind ESCRT-0 and ubiquitinate the subunit HRS, it is plausible that DTX3L
may inhibit AIP4 from interacting with STAM-1/Arrestin-2 to promote ESCRTdependent targeting of CXCR4 for degradation (Malik & Marchese, 2010). Preliminary
data demonstrate that DTX3L can in fact bind to Arrestin-2 directly albeit at a lower
affinity than that of DTX3L with AIP4 when compared in parallel binding experiments.
Thus, DTX3L may antagonize AIP4 activity by inhibiting AIP4 interaction with STAM1/Arrestin-2 complex. DTX3L may play a general role in endosomal to lysosomal
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targeting of other ESCRT-dependent GPCRs through general regulation of the ESCRT
machinery or function of Arrestin-2. To this end, whether other GPCR ligands can
promote increased DTX3L localization to endosomes remains to be determined.

INTERACTION OF DTX3L AND AIP4
Previously our lab demonstrated that siRNA mediated knockdown of AIP4
significantly inhibits CXCR4 degradation to a similar degree seen with DTX3L siRNA
treatment in the current study (Marchese et al., 2003). Given the propensity of AIP4 to
interact with RING domain ligases (Chastagner, Israel, & Brou, 2006; Courbard et al.,
2002; Kitching et al., 2003), we found in the present study that AIP4 could interact with
DTX3L by several complementary approaches (Figure 3.7-3.10). Domain mapping
studies also reveal that the N-terminal unique region of DTX3L binds stronger than the
C-terminal RING domain to AIP4. In addition, the C2 and HECT domains of AIP4 bind
strongly to DTX3L. However, it will be important in future studies to further determine
the precise amino acid binding regions between DTX3L and AIP4. This information
could provide insight into creating a mini-gene to inhibit or mimic this interaction and
help establish more precisely the importance of this interaction in cells.
Given that AIP4 belongs to the Nedd4 family of HECT domain ligases that are
highly homologous within their HECT domain sequences, it is intriguing to speculate that
DTX3L may bind to and regulate the ligase activity of other members of the Nedd4
family. In line with this, preliminary interaction studies reveal that DTX3L can bind to
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the Nedd4 family members AIP2, AIP5 and Nedd4L in addition to AIP4 (data not
shown). Future studies will be necessary to establish the general importance of DTX3L
interactions with Nedd4 ligases.

DTX3L PREVENTS AIP4 E3 LIGASE ACTIVITY
Our lab has demonstrated that AIP4 spatially regulates CXCR4 both at the plasma
membrane as well as on early endosomes. Given that DTX3L directly interacts and
localizes onto early endosomes with AIP4, we hypothesized that the DTX3L and AIP4
interaction could regulate ligase activity. Indeed, we show that DTX3L inhibits AIP4
self-ubiquitination activity in vitro independent of its RING domain activity (Figure
3.17). We did not determine in our experiments the predominant ubiquitin linkage be
formed on AIP4. However, based on previous literature which demonstrated that AIP4
self-ubiquitination reactions predominately form K63 poly-ubiquitin chains and that this
had a non-degradative role in regulating AIP4 function, we can speculate that K63 polyubiquitination may be the predominate linkage form in our in vitro ubiquitin reactions
(Scialpi et al., 2008). Overall, we have defined DTX3L as an inhibitor of AIP4 ubiquitin
dependent self-activation.
The mechanism of this interaction is in contrast to previously published
interactions of AIP4 with RING domain ligases whereby AIP4 could act as a positive or
negative regulator of RING ligase activity. In the case of DTX1, it was shown that AIP4
could mediate K29-polyubiquitination of DTX1 leading to DTX1 lysosomal degradation
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(Chastagner et al., 2006). Therefore, it was concluded that AIP4 acts to inhibit DTX1
function in ligand-independent Notch signaling (Chastagner et al., 2006). Interestingly,
DTX3L has also been shown to interact with DTX1, however, the function of this
interaction in cells remains to be determined. The interaction of AIP4 with RING domain
ligase Cbl-c was demonstrated to act synergistically to regulate ubiquitination and
lysosomal degradation of the epidermal growth factor receptor (EGFR) (Courbard et al.,
2002). To our knowledge, our study is the first to demonstrate that a RING ligase
(DTX3L) is an inhibitor of HECT domain ligase (AIP4) self-ubiquitination. Whether the
effect DTX3L has on AIP4 activity regulates other AIP4 substrates remains to be
established. For instance, DTX3L by inihibiting AIP4 may also prevent AIP4-mediated
ubiquitination of DTX1 in the context of Notch signaling or Cbl-c in the context of
EGFR. Thus, the importance of DTX3L in other receptor pathways will be important to
address.

DTX3L ANTAGONIZES AIP4-MEDIATED UBIQUITINATION OF ESCRT-0
It has previously been shown that CXCR4 is degraded via ESCRT dependent
sorting on early endosomes. Following CXCR4 activation, the ESCRT-0 subunits HRS
and STAM-1 are ubiquitinated by AIP4 (Malik & Marchese, 2010; Marchese et al.,
2003). It was further defined that Arrestin-2 has a role in this AIP4-mediated
ubiquitination of HRS. Specifically, AIP4 is recruited by the STAM-1/Arrestin-2
complex to endosomes and, thereby, ubiquitinates HRS. HRS ubiquitination regulates the
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extent of receptor degradation. Importantly, recent work from our lab has demonstrated
that CXCR4 sorting to lysosomes is enhanced when HRS ubiquitination is blocked
(Malik & Marchese, 2010). However, the precise mechanism underlying CXCR4
ESCRT-dependent sorting remains poorly defined. In addition, previous studies have
shown that the DUBs USP8 and AMSH indirectly promote the trafficking of CXCR4 by
counteracting the AIP4-mediated ubiquitination of ESCRT-0 "#$%&'()! *'++'(,-./01)!
2'3$)!4'$%%0)!5!603/)!7898:.
Our current study provides further insight into AIP4 mediated ubiquitination of
ESCRT-0 and its implications in targeting CXCR4 for degradation. We show that
DTX3L negatively regulates ESCRT-0 ubiquitination by antagonizing AIP4 (Figure
3.11; 4.2). We also show that DTX3L is also an important regulator of ESCRT-0
complex formation on early endosomes following CXCR4 activation (3.12-3.14). Taken
into account previous studies, it could be the case that DTX3L also has effects on the
function or localization of DUBs, like USP8 and AMSH, to facilitate CXCR4
downregulation. Future studies aimed at characterizing the effect DTX3L has on DUBs
will be important to address. Furthermore whether DTX3L inhibits the ability of the
STAM-1/Arrestin-2 to recruit AIP4 remains to be determined. Preliminary studies have
revealed that DTX3L can bind to both Arrestin-2 and STAM-1. In addition, DTX3L
binds to Arrestin-2 directly in a purified binding assay. Thus DTX3L not only counteracts
AIP4 activity itself, but may also interact with the STAM-1/Arretin-2 complex
preventing the interaction of AIP4 and, hence, promoting CXCR4 downregulation. This
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idea will be important to address in the future. Altogether this current study expands our
knowledge on the regulation of CXCR4 downregulation by demonstrating that DTX3L
by antagonizing AIP4 function promotes ESCRT activity on early endosomes and, hence,
sorting of CXCR4 for degradation (Figure 4.2).
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Figure 4.2 Proposed model for DTX3L antagonism of AIP4-mediated ubiquitination of ESCRT-0. In
model one (1), AIP4 undergoes self-ubiquitination through its interaction with its cognate E2 conjugating
enzyme. This self-ubiquitination is required for AIP4 activation and results in the hyperubiquitination of
ESCRT-0, which prevents CXCR4 lysosomal degradation. In model two (2), activation of DTX3L by its
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cognate E2 promotes DTX3L binding to AIP4, thereby, preventing AIP4 E2-mediated self-ubiquitination.
As a result, ESCRT-0 is moderately ubiquitinated and, therefore, functions to sort CXCR4 for lysosomal
degradation.

Although ubiquitin modification of ESCRT-0 seems to regulate ESCRTdependent sorting of CXCR4, the cellular relevance of ESCRT-0 ubiquitination in
mediating receptor sorting remains to be confirmed. In yeast, fusion of ESCRT-0 or
ESCRT-I to a DUB was shown to prevent their ubiquitination, but does not effect their
sorting of ubiquitinated cargoes into the intraluminal vesicles (ILVs) (Stringer & Piper,
2011). These data demonstrate that receptor ubiquitination is required to promote ESCRT
activity on endosomes leading to concentration of receptors into ILVs, however, ESCRT
modification by ubiquitination is not necessary to the sorting process. Thus, ubiquitin
modified cargos play an essential role in ILV formation and cooperation between
ubiquitin cargo and ESCRTs help facilitate ILV formation (Shields & Piper, 2011). In
contrast to yeast, in mammalian cells ESCRT ubiquitination has been proposed to play a
role in receptor trafficking. CXCR4 trafficking for degradation is proposed to be
dependent upon ubiquitination of ESCRT-0. AIP4 counteracts ESCRT-0 activity via
poly-ubiquitination (Marchese et al., 2003). This is thought to displace HRS and STAM
from early endosomes and perhaps result in an auto-inhibitory conformation. In this study
we have further identified that the E3 ligase DTX3L antagonizes the effect AIP4 has on
ESCRT-0 ubiquitination by preventing AIP4 self-ubiquitination activity (Holleman &
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Marchese, 2014). Although there seems to be a clear effect on ESCRT-0 ubiquitination
downstream of CXCR4 activation, whether this plays a direct role in receptor trafficking
remains to be determined. Moreover, it has yet to be proven that poly-ubiquitination of
HRS or STAM1 leads to either protein being placed in an auto-inhibitory conformation.
This could be address by fusing either ESCRT-0 protein to a DUB similar to a published
approach used in yeast (Stringer & Piper, 2011). Expression of a fusion of ESCRT-0 to a
DUB in cells should remove any ubiquitin modification of the fusion and, therefore based
on our study, should promote ESCRT-dependent downregulation opposite to that seen
with DTX3L knockdown. This will be important to establish in future studies. Although
previous data highlight that monoubiquitination of ESCRT-0 is predicted to place HRS in
auto-inhibitory conformation, thereby, preventing HRS interaction with STAM1 and the
ability to sort ubiquitinated receptors (Hoeller et al., 2006). Another recent study suggests
that HRS ubiquitination also effects the extent by which the RTK receptor EGFR is
degraded (Sun, Hedman, Tan, Schill, & Anderson, 2013).
One reason for this difference between yeast and mammalian cells may be due to
that fact that mammalian cells have evolved to be more complex than yeast. For example
mammalian cells are more compartmentalized with mammalian cells requiring both
endosomes and lysosomes to sort cargo, whereas in yeast cargos are sorted into the
vacuole (the homolog to the mammalian lysosome). Another reason for the difference
between yeast and mammalian cells could be due to the necessity of additional adaptor
proteins in facilitating the downregulation of mammalian GPCRs. For example, the
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downregulation of mammalian CXCR4 is dependent upon the adaptor protein Arrestin-2
(Bhandari, Trejo, Benovic, & Marchese, 2007; Malik & Marchese, 2010). Arrestin-2 can
form a complex with STAM-1, negatively regulating the ESCRT-dependent
downregulation CXCR4. Additionally, the STAM-1/Arrestin-2 complex binds and
localizes AIP4 on early endosomes enabling AIP4 to mediate ubiquitination the ESCRT0 component HRS, thereby, modulating ESCRT-0 function. Thus, Arrestin-2 may act to
bridge AIP4 with ESCRT-0 to regulate the extent of ESCRT-0 ubiquitination and, hence,
targeting of CXCR4 for degradation. Given the vast complexity of mammalian cells, it is
not surprising that perhaps ESCRT ubiquitination may have a direct role on GPCR
trafficking distinct from yeast.

DTX3L NEGATIVELY REGULATES CXCR4 UBIQUITINATION
It has been previously demonstrated that AIP4 mediates agonist-promoted
ubiquitination of CXCR4 at the plasma membrane to facilitate downstream sorting and
degradation (Marchese & Benovic, 2001; Marchese et al., 2003). In this study, we also
demonstrate that silencing of DTX3L enhances both basal and agonist promoted CXCR4
ubiquitination (Figure 3.19). These data are consistent with the observation that DTX3L
inhibits AIP4 ligase activity. Thus, DTX3L inhibition of AIP4 may not be restricted to
early endosome although preliminary data demonstrate that DTX3L is not localized to the
plasma membrane at early time points following CXCR4 activation (data not shown).
Given that DTX3L and AIP4 complex basally and optimally at 15 min of CXCL12
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treatment (Figures 3.7C and 3.8), it is possible DTX3L may sequester a fraction of AIP4
early on from mediating CXCR4 ubiquitination at the plasma membrane. Future studies
will be required to determine whether this is indeed the case.

SUMMARY AND FIGURE DIRECTIONS
The findings of this present study are summarized in Figures 4.1 and 4.2. We
have identified a novel role for the E3 ubiquitin ligase DTX3L in regulating CXCR4
degradation through inhibition of the activity of AIP4 on early endosomes. Our findings
demonstrate that upon CXCR4 activation, DTX3L displays enhanced localization to early
endosomes where it directly interacts with AIP4. Through its interaction with AIP4,
DTX3L inhibits the ubiquitination of ESCRT-0 and, therefore, promotes ESCRT sorting
function on early endosomes. We believe this mechanism serves to regulate the extent to
which CXCR4 is sorted for degradation in lysosomes.

DTX3L AS A GENERAL REGULATOR OF RECEPTOR DOWNREGULATION
In this study we found that DTX3L regulates CXCR4 downregulation, however,
whether DTX3L also regulates the ESCRT-dependent downregulation of other GPCRs or
RTKs remains unknown. However, preliminary data suggest that DTX3L does not seem
to regulate the ESCRT-dependent sorting of the receptor tyrosine kinase receptor EGFR
(data not shown). Even though DTX3L may not have role in EGFR degradation, this
could be due to the fact that EGFR sorting by ESCRTs is mediated by a different
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mechanism. Recently, it has been shown that EGFR trafficking is dependent upon both
Smad anchor for receptor activation (SARA) an endocytically enriched FYVE-domain
containing protein as well as the RING domain ligase RNF11 (Kostaras et al., 2013).
This study demonstrated that both SARA and RNF11 interact with ESCRT-0 to regulate
the extent by which EGFR is degraded. In particular, SARA was shown to interact with
clathrin and the ESCRT-I subunit Tsg101 similar to HRS indicating that SARA may
function with or is a part of an alternative ESCRT-0 in the EGFR pathway. Whether
SARA plays a role in GPCR trafficking remains to be studied. However to the best of our
knowledge, the need for additional ESCRT adaptors seen for EGFR degradation such as
Eps15b appears to be specific to EGFR. EGFR ubiquitination upon EGF stimulation is
also dependent upon the RING ligase Cbl-c. Interestingly, AIP4 has been shown to act
synergistically to promote Cbl-c mediated ubiquitination and degradation of EGFR
(Courbard et al., 2002). Our study demonstrates that CXCL12 activation of CXCR4
promotes DTX3L localization to early endosomes where we believe that DTX3L inhibits
AIP4 activity to promote ESCRT function. Although DTX3L does not regulate
downregulation of EGFR, DTX3L localization to early endosomes and the effect on
AIP4 as well as ESCRT function may be dependent on a specific a ligand (i.e. CXCL12)
or additional yet to be identified ligands. Altogether, whether DTX3L plays a role in the
ESCRT-dependent sorting of other GPCRs remains to be determined, however, it
plausible to suggest that DTX3L may have a general role in GPCR sorting.
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MECHANISM OF DTX3L INHIBITION OF AIP4 SELF-UBIQUITINATION
While this study demonstrates that DTX3L antagonizes AIP4 activity in the
context of CXCR4 downregulation, the precise mechanism by which DTX3L prevents
AIP4 self-ubiquitination remains unclear. Our data show DTX3L inhibition of AIP4
ubiquitination is independent of its ability to bind to the E2 since the RING mutant of
DTX3L still prevents AIP4 ubiquitination in vitro (Figure 3.17). Moreover, interaction
studies suggest that DTX3L binds to the HECT domain of AIP4 (Figure 3.10) and
preliminary competition assays suggest DTX3L does not compete with E2 for binding to
AIP4. Therefore based on these observations, we can speculate that DTX3L occludes E2mediated transfer of ubiquitin to AIP4, but not the ability of the E2 to bind to AIP4.
Additionally, it is conceivable that the inability of AIP4 to self-ubiquitinate in the
presence of DTX3L may be due to an inability to adopt an active conformation
structurally. To confirm this will require further and more rigorous study. Nonetheless,
this study establishes DTX3L as a bona fide antagonist of AIP4 activity in the context of
CXCR4 trafficking.

TARGETING THE DTX3L/AIP4 INTERACTION IN CXCR4 PATHOLOGIES
The findings from this study leave the possibility of further exploring the DTX3L
and AIP4 interaction as a potential therapeutic option in treating CXCR4 pathologies. For
instance, the progression of many cancers is correlated to a high expression of CXCR4.
Specifically in HER2/neu positive breast cancers, CXCR4 levels are increased due in part
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to inhibition of receptor ubiquitination and downregulation (Li et al., 2004).
Overexpression of AIP4, but not the catalytically inactive mutant of AIP4 (C830A),
could promote downregulation in these cancer cells. However, the status of DTX3L in
the HER2/neu subtype of breast has yet to be determined. Based on this study, one
strategy to promote AIP4 activity is to increase AIP4 levels in these cells to promote
CXCR4 ubiquitination at the plasma membrane. Yet given the dual functions of AIP4 at
both the plasma and early endosome, it would important to promote CXCR4
ubiquitination at the plasma membrane while also ensuring a level of endosomal
downregulation. Based on our data if DTX3L is overexpressed in these cancers, it should
prevent AIP4 activity on endosomes and, thereby, promote CXCR4 downregulation.
However if DTX3L is expressed at a low levels, a combinational therapy that promotes a
balance of AIP4 as well as DTX3L function may be efficacious. Therapies that could
promote function could include gene therapy or delivery (i.e. PEGylation, PLGA
microspheres, nanoparticle) of a drug that promotes activity. A recent study described the
creation of small bicyclic peptides that could target the E2 binding site that is crucial for
ubiquitin transfer within the HECT domains of Nedd4, Smurf2, WWP1 and Mule/Huwe1
(Mund, T. et al. 2014). This approach could inhibit the auto-ubiquitination of these
ligases as well as prevent transfer of ubiquitin to substrates. An approach similar to this
could be utilized to target the catalytic HECT domain of AIP4, however, it would be
necessary to ensure that endosomally localized AIP4 would be specifically targeted in
order to promote CXCR4 downregulation. More detailed analysis in the future will be

!
156

required to determine whether these strategies would be useful in order to promote
CXCR4 downregulation in HER2/neu cancers.
Whether altered CXCR4 ubiquitination is implicated in other cancers where
CXCR4 is overexpressed or whether this is specific to HER2/neu cancers remains to be
investigated. Though one could speculate, given the importance of CXCR4 ubiquitination
in CXCR4 endosomal to lysosomal downregulation, that defective CXCR4 ubiquitination
could underlie other CXCR4 related pathologies. Additionally, a defect in ESCRTdependent targeting of CXCR4 for degradation may promote increased CXCR4
expression. For instanced, increased ubiquitination of ESCRT-0 by AIP4 prevents
CXCR4 targeting for degradation and, thereby, may promote CXCR4 recycling (Malik &
Marchese, 2010; Marchese et al., 2003). Thus, targeting key regulators in the CXCR4
degradative pathway, including those interactions defined in this dissertation, may prove
efficacious in treating this subtype of breast cancer where CXCR4 is overexpressed.
In terms of hematological malignancies, both DTX3L and CXCR4 have
prominent roles in DLCBLs. Analysis of the gene expression profile from the Brune
Lymphoma Dataset (Oncomine database) reveals that the increased expression of DTX3L
(fold change above 0) is correlated with a decrease in AIP4 levels (fold change below 0)
in 10 out of 11 samples from DLBCLs (Brune et al., 2008). The reduction in AIP4 levels
may be attributed to the DTX3L-mediated inhibition of AIP4. However, whether DTX3L
also regulates AIP4 expression remains to be defined. Interestingly, in all of these
samples HRS levels were increased (fold change between 0.79 – 1.81) while STAM-1
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levels were elevated in 9 out of the 11 samples (fold change between 0.07 – 1.7). The
increase in both ESCRT-0 components HRS and STAM-1 seen in these DLBCLs could
be correlated to high levels of DTX3L, which we believe promotes ESCRT-0 function.
Consistent with our study, this data reveals that high expression of DTX3L may be
correlated to increased ESCRT-0 activity possibly through a reduction in AIP4 levels.
More variation is seen in the levels of CXCR4 in these DLBCLs samples ranging from a
fold change between -0.54 to 0.63. This variation may reflect differential functions of
CXCR4 in DLBCLs subtypes.
A recent study has established that loss of CXCR4 expression is a prognostic
marker for the development and progression of gastric extranodal DLBCLs originating
from mucosa-associated lymphoid tissue (MALT) (Deutsch et al., 2013). While decrease
expression of CXCR4 has been implicated in progression of gastric extranodal DLBCLs,
an increase in CXCR4 has been associated with increased dissemination in de novo
germinal-center B-cell-like (GCB)-DLBCLs (Chen et al., 2015). The latter study assessed
CXCR4 expression in 743 patient biopsies. Another study demonstrated that in cell lines
derived from 94 DLBCL biopsies, high levels of CXCR4 correlated to increased
migration and increased engraftment as well as dissemination in a NOD/SCID xenograft
mouse model (Moreno et al., 2015). Treatment of these mice with the CXCR4 antagonist
AMD3100 significantly reduced dissemination. Thus, CXCR4 expression and role in
progression varies between different DLBCLs sub-types.
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Overexpression of DTX3L and B-aggressive lymphoma 1 (BAL1) are a risk
factor for the host response (HR) subtype of DLBCLs signified by increased IFN- !
production and immune/inflammatory infiltrate (Juszczynski et al., 2006). In particular,
DTX3L has been shown to bind to the nuclear protein BAL1. The DTX3L/BAL complex
shuttles from the cytoplasm to nucleus where DTX3L mediates monoubiquitination of
Histone H4 to modulate the DNA damage response (Yan et al., 2009). It will be
interesting to establish within different subtypes of DLBCLs whether CXCR4 expression
correlates to DTX3L levels. For example in line with our study, high levels of DTX3L
should correlate to an overall reduction in CXCR4 levels due to increased receptor
downregulation. Therefore, in DLBCL subtypes where low levels of CXCR4 drive
disease progression, reducing DTX3L activity to promote CXCR4 recycling may prove
advantageous. One strategy to reduce DTX3L levels therapeutically could be to prevent
DTX3L interaction with AIP4 using a mini-gene that would mimic the minimal binding
region on AIP4 to occlude DTX3L binding. Based on the present study by preventing
DTX3L interaction with AIP4, this should prevent ESCRT-dependent sorting of CXCR4
for degradation and instead promote CXCR4 recycling and resensitization at the plasma
membrane. Conversely, in DLBCLs where high levels of CXCR4 are implicated as a
prognostic marker, promoting DTX3L activity by gene therapy to drive CXCR4
downregulation could be an ideal therapeutic strategy. Although our study did not focus
on the role DTX3L may have on CXCR4-mediated signaling and migration, it will be
important in future studies to establish whether DTX3L regulates these processes in

!
159

addition to receptor downregulation. Altogether understanding the molecular mechanisms
regulating CXCR4 downregulation and signaling may provide insight into treating
different sub-types of DLBCLs.
In addition to studying the therapeutic potential of targeting the DTX3L/AIP4
interaction in the context of CXCR4 related pathologies, future studies may highlight
DTX3L as general regulator of ESCRT-dependent sorting of GPCRs (i.e. B2AR, PAR2,
DOR) providing further implications for studying DTX3L in the context of a therapeutic
treatment. Given that preliminary data (not shown) demonstrate that DTX3L can interact
with other Nedd4 E3 ligases in addition to AIP4 raises the possibility that DTX3L may
regulate these ligases in the context of other GPCR trafficking pathways.

E2 ENZYMES IN CXCR4 DOWNREGULATION
Ubiquitination plays a major role in the lysosomal downregulation of CXCR4. It
has been established here and in previous work that the E3 ligases AIP4 and DTX3L are
key regulators of this process (Holleman & Marchese, 2014; Marchese et al., 2003). AIP4
mediates agonist-induced ubiquitination of CXCR4 at the plasma membrane (Marchese
et al., 2003). However on early endosomes, AIP4 acts to limit the extent of CXCR4
sorted for degradation by ubiquitin modification of ESCRT-0 subunits HRS and STAM-1
(Bhandari, Trejo, Benovic, & Marchese, 2007; Malik & Marchese, 2010; Marchese et al.,
2003). Work from this dissertation has demonstrated that DTX3L acts to antagonize
AIP4 activity on early endosomes to promote CXCR4 downregulation. Given that
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ubiquitination of substrates is dependent upon three enzymes (E1, E2 and E3), whether
specific E2 conjugating enzymes regulate CXCR4 degradation through their interactions
with the E3 ligases AIP4 and DTX3L remains unknown. The function of the E2 enzyme
is to link the ATP-dependent activation of ubiquitin by the E1 activating enzyme to the
final covalent modification of protein substrates through the activities of E3 ubiquitin
ligases. Based on phylogenetic analyses, the E2 enzymes are sub-grouped into 17
families (Wenzel, Stoll, & Klevit, 2011). In contrast, there are over 600 E3 ubiquitin
ligases sub-grouped into the RING and HECT domain families (Metzger, Hristova, &
Weissman, 2012; Metzger & Weissman, 2010; Pickart, 2001). Given the ratio of E2:E3
enzymes, it is often the case that one particular E3 ligase can work with several E2
enzymes and conversely one particular E2 can interact with several E3 ligases.
The role of specific E2 enzymes in conjunction with their E3 ligases in regulating
GPCR downregulation remains unknown. Prior data on the downregulation of the RTK
receptor EGFR demonstrated that the E2 enzymes UbcH5b and UbcH5c could regulate
EGFR ubiquitin-dependent downregulation. This ubiquitination event is mediated
through the interaction of UbcH5b and UbcH5c with the RING domain ligase Cbl-c
(Umebayashi, Stenmark, & Yoshimori, 2008). This was the first study to our knowledge
that provided insight into the specificity of E2 enzymes in the regulation of receptor
trafficking. The precise role for specific subsets of E2 enzymes in GPCR regulation
remains elusive.
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Previous studies have demonstrated that DTX3L activity is dependent upon UbcH5
members (Takeyama et al., 2003) while AIP4 activity is mediated through either UbcH5
or UbcH7 (Kim & Huibregtse, 2009; Schwarz, Rosa, & Scheffner, 1998; Scialpi et al.,
2008; Wenzel et al., 2011).

Whether CXCR4 activation promotes the binding of

particular E2 enzymes to either DTX3L or AIP4 remain to be determined. Future studies
aimed at assessing the subcellular localization of these E2 enzymes with AIP4 and
DTX3L upon CXCR4 activation can provide further mechanistic insight into E2 and E3
regulation of CXCR4 trafficking. Although previous literature has shown that UbcH5c
can localize to both the plasma membrane as well as the early endosome with the E3
ligase Cbl-c following EGF stimulation (Umebayashi et al., 2008). Whether this
localization pattern is true following CXCR4 activation remains to be determined.
Though given the E2 specificities for DTX3L and AIP4 defined in the literature, we can
speculate that UbcH5c and UbcH7 can localize to similar compartments as AIP4 and
DTX3L such as the plasma membrane and early endosome. Understanding the particular
E2:E3 interactions in the CXCR4 trafficking pathway may help determine differential
specificities of these enzymes in regulating ubiquitination of CXCR4, ESCRT-0 as well
as the self-ubiqutination of AIP4 and DTX3L, thereby, providing further mechanistic
insight into CXCR4 ubiquitin dependent regulation.
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ROLE OF UbcH5c IN DTX3L-MEDIATED INHIBITION OF AIP4 SELF
UBIQUITINATION
It has been well documented that self-ubiquitination of some ubiquitin ligases like
AIP4 is essential to their function and this may also be the case for DTX3L in CXCR4
trafficking (Scialpi et al., 2008). In particular, our in vitro ubiquitination assays utilized
the E2 enzyme UbcH5c. Whether UbcH5c has a functional role in the cellular context in
mediating DTX3L inhibition of AIP4 self-ubiquitination will be interesting to address in
future study. One could speculate that UbcH5c may influence both the activity and
subcellular distribution of either AIP4 or DTX3L to promote endosomal trafficking of
CXCR4.
A recent study of the E3 ligase Parkin has demonstrated that specific E2 enzymes
(UbcH5b, UbcH5c, UbcH7 and UbcH13) are important regulators of Parkin translocation
from the cytoplasm to the mitochondria upon mitochondrial stress (Fiesel, MoussaudLamodiere, Ando, & Springer, 2014). Depletion of the identified E2 enzymes reduced
Parkin localization to the damaged mitochondria and prevented Parkin mediated
ubiquitination of substrates at the mitochondria. Additionally, in the Parkin study it was
demonstrated that E2 enzymes UbcH5b, UbcH5c and UbcH7 function redundantly to
activate and charge Parkin with ubiquitin. However, whether these E2 enzymes regulate
Parkin stability and degradation was not assessed. Based on these studies, it is intriguing
to speculate that particular E2 enzymes may also regulate the activation and localization
of AIP4 and/or DTX3L within the CXCR4 degradation pathway. Yet given the broad role
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of E2 enzymes in the ubiquitination process, whether we may see effects attributed
directly or indirectly to AIP4-mediated ubiquitination may be one caveat.

CONCLUSION
Overall, this study provides increased knowledge on the ubiquitin-dependent
regulation of CXCR4 signaling and downregulation (Figure 4.1). We have discovered the
RING domain ligase DTX3L as a novel endogenous antagonist of AIP4 in the context of
CXCR4 trafficking. This interaction may prove beneficial in developing strategies in
modulating CXCR4 expression. Furthermore, the details of this study can be used in
future studies aimed at creating potential therapies for CXCR4 pathologies, such as breast
cancer and DLBCLs, and may even be broadly applicable to other GPCRs.

APPENDIX A:
BUFFER AND REAGENT RECIPES

[164]

[165]
Polyethylenimine (1mg/ml PEI)
In a 50 mL conical tube, dissolve 0.01 grams of PEI (Sigma-Aldrich) in 3 ml of 100%
ethanol. Vortex solution and heat in 37°C water bath for 5 -10 min (vortex 2-3 times)
until PEI is dissolved. Dilute PEI solution in 7 ml of DEPC treated (RNAase/DNAase
free) H2O (Invitrogen; final volume of 30% ethanol). In a biological safety cabinet,
syringe filter the solution with a 0.2 µm filter and make 100 µl aliquots. Store aliquots at
-80°C.

Short-duration ECL solution
Solution 1

Solution 2

2.5 mM luminol

0.02% Hydrogen Peroxide

0.45 mM p-Coumaric Acid

0.1 M Tris pH 8.8

0.1 M Tris pH 8.8

To make Solution 1, dissolve 112.5 mg of luminol in 2.5 ml of DMSO. Dissolve 18.5 mg
p-Coumaric acid in 1.25 ml DMSO. Add 0.1 M Tris-HCl pH 8.8 in final volume of 250
ml. To make Solution 2, combine 167 µl of Hydrogen peroxide to 250 ml of 0.1 M TrisHCl pH 8.8. Store each solution at 4°C. To use, combine equal volumes of solution 1 and
solution 2. Incubate with immunoblot for 1 min before exposure.

Protease Inhibitor Cocktail

[166]
Make 10 mg/ml stocks of aprotinin, leupeptin and pepstatin. To 50 mg of aprotinin
and leupeptin, add 5 ml of dH2O on ice and vortex. Make 1 mL aliquots. Add 1 mL
DMSO to 10 mg of pepstatin. Aliquot 50 µl of each protease inhibitor into a sterile
microcentrifuge tube. Store at -20°C.

Acrylamide Running Gels
10 % Acrylamide Running Gel
Sterile, filtered dH2O
0.75 M Tris-HCl, pH 8.8
10 % SDS
30 % Acrylamide
10% APS
TEMED

Volume for 2 gels
1.54 ml
5.0 ml
100 µl
3.3 ml
60 µl
10 µl

7 % Acrylamide Running Gel
Sterile, filtered dH2O
0.75 M Tris-HCl, pH 8.8
10 % SDS
30 % Acrylamide
10% APS
TEMED

Volume for 2 gels
2.5 ml
5 ml
100 µl
2.33 ml
60 µl
10 µl

12 % Acrylamide Running Gel
Sterile, filtered dH2O
0.75 M Tris-HCl, pH 8.8
10 % SDS
30 % Acrylamide
10% APS
TEMED

Volume for 2 gels
830 µl
5 ml
100 µl
4.0 ml
60 µl
10 µl

3 % Acrylamide Stacking Gel
Sterile, filtered dH2O
0.75 M Tris-HCl, pH 8.8
10 % SDS
30 % Acrylamide
10% APS
TEMED

Volume for 2 gels
2.0 ml
500 µl
45 µl
400 µl
50 µl
5 µl

[167]
Mix together desired percentage of resolving acrylamide gel ingredients in a 50 ml
conical tube (add Acrylamide, APS and TEMED last). Vortex and pipet into glass plates
leaving about a ! inch space from top of short plate. Fill remaining space with
isopropanol. Let resolving gel solidify at room temperature for about 20 min. To pour the
stacking gel, first rinse away isopropanol from resolving gel with dH2O and then combine
stacking ingredients in a 50 ml conical tube (add Acrylamide, APS and TEMED last).
Vortex and pipet into remaining space between glass plates. Place comb of desired size
(i.e. 10 sample or 15 sample comb) into stacking liquid. Let solidify at room temperature
for about 10 min. To load gel, remove comb and place gel into running apparatus (BioRad). Fill tank with 1! SDS Running Buffer prior to loading samples.

SDS Running Buffer (10!)
0.25 mM Tris Base
0.192 M Glycine
1% (w/v) SDS
dH2O 4 L to final volume

To 3 L dH2O, combine Tris Base and Glycine. Once dissolved, add SDS and dH2O to 4 L
final volume. To make 1! Running Buffer, dilute 400 ml of 10 X SDS Running Buffer
with 3.6 L of dH2O.

Transfer Buffer (10!)
0.25 mM

Tris Base

[168]
0.192 M

Glycine

dH2O

4 L to final volume

To 3 L dH2O, combine Tris Base and Glycine. Once dissolved, add dH2O to 4 L final
volume. To make 1!Transfer Buffer, combine 400 ml of 10 X Transfer Buffer with 800
ml of methanol (20% vol/vol) and 2.8 L of dH2O. Store at 4°C.

Western Blot Stripping Buffer
10% SDS

200 ml

0.75 M Tris-HCl, pH 6.5

83.4 ml

14.3 M "-mercaptoethanol

7 ml

dH2O

709.6 ml

Combine SDS, Tris HCl and dH2O. Add "-mercaptoethanol in biological safety cabinet.
Store at room temperature. To strip immunoblots, incubate immunoblots with ~100 ml of
Stripping Buffer for 30 min at 60°C. After stripping, wash blots 10 X with d dH2O. Block
immunoblots with 5% TBST-milk for 30 min at room temperature and add primary
overnight at 4°C. Develop blots as described above.

0.75 M Tris-HCl pH 8.8 or 6.5
0.75 M Tris Base

45.41 g

Concentrated HCl

Drop-wise to desired pH

dH2O

500 ml final volume

[169]
Stir together Tris Base with 300 ml dH2O in glass beaker. Add pH monitor (calibrate if
necessary). Once Tris Base is dissolved, add HCl drop-wise until desired pH obtained.
Add dH2O to final volume of 500 ml.

1 M Tris-HCl pH 7.5
1 M Tris Base

193.76 g

Concentrated HCl

Drop-wise to pH 7.5

dH2O

1.6 L

In a 2 L beaker with a stir bar, dissolve Tris Base in 1.2 L of dH2O. Add pH monitor to
beaker (calibrate if necessary). Add HCl drop-wise until pH 7.5 is achieved. Bring
solution to final volume of 1.6 L with dH2O.

TBS-T (20X)
3 M NaCl

2.4 L

1 M Tris-HCl, pH 7.5 1.6 L
Tween

40 ml

dH2O

4L final volume

In a 4 L beaker with a stir bar, combine NaCl, Tris-HCl and Tween in 4 L of dH2O (final
volume). Store at 4°C. To make 1! TBS-T, combine 200 ml 10! TBS-T with 3.8 L of
dH2O. Store at 4°C until use.

[170]
2! Sample Buffer (8% SDS)
8% SDS
10% glycerol
0.7 M "-mercaptoethanol
37.5 mM Tris-HCl, pH 6.5
0.003% bromophenol blue

To a 500 ml flask with a stir bar, combine SDS, Tris-HCl and glycerol. In a biological
safety cabinet, add the "-mercaptoethanol. Lastly, add the bromophenol blue. Once
dissolved, make aliquots and store at -20°C.

Co-immunoprecipitation Buffer
50 mM Tris-HCl
150 mM NaCl
2 mM EDTA
1% Triton-X 100
20 mM NEM
10 µg/ml Protease Inhibitor cocktail
dH2O to final volume

Combine all ingredients except protease inhibitor cocktail. Place at 4°C and let NEM
dissolve for 30 min. Then add protease inhibitor cocktail on ice before adding to cells.

[171]
GST-fusion Purification Lysis Buffer
50 mM Tris-HCl, pH 7.5
300 mM NaCl
1% Triton X 100
1 mM DTT
10 µg/ml Protease Inhibitor cocktail
dH2O to final volume

Combine all ingredients except protease inhibitor cocktail. Store at 4°C. Then add
protease inhibitor cocktail on ice before adding to bacterial pellets.

His-fusion Purification Buffer
50 mM Tris-HCl, pH 7.5
300 mM NaCl
1% Triton X 100
10 µg/ml Protease Inhibitor cocktail
dH2O to final volume

Combine all ingredients except protease inhibitor cocktail. Store at 4°C. Then add
protease inhibitor cocktail on ice before adding to bacterial pellets.

Binding Buffer

[172]
50 mM Tris-HCl, pH 7.5
300 mM NaCl
1% Triton X 100
20 mM NEM
10 µg/ml Protease Inhibitor cocktail
dH2O to final volume

Combine all ingredients except protease inhibitor cocktail. Place at 4°C and let NEM
dissolve for 30 min. Then add protease inhibitor cocktail on ice before adding to cells.

Ubiquitination Buffer
150 mM NaCl
50 mM Tris-HCl, pH 7.5
1% SDS
5 mM EDTA
1% Triton X 100
20 mM NEM
10 µg/ml Protease Inhibitor cocktail
dH2O to final volume

Combine all ingredients except protease inhibitor cocktail. Place at 4°C and let NEM
dissolve for 30 min. Then add protease inhibitor cocktail on ice before adding to cells.

[173]
Ubiquitin Dilution Buffer
150 mM NaCl
50 mM Tris-HCl, pH 7.5
5 mM EDTA
1% Triton X 100
dH2O to final volume

Combine all ingredients and place at 4°C until use.

Immunofluorescence Reagents:
3.7% Paraformaldehyde (PFA) Fixing solution
Dilute 1 ml of 37 % PFA (Sigma-Aldrich) into 9 ml of cold, 1!PBS

Permeabilization Buffer
Combine 1!PBS plus 0.05% w/v saponin

Blocking Buffer
Combine 1!PBS plus 1% BSA and 0.05% w/v saponin

APPENDIX B:
PLASMID CONSTRUCT MAPS

[174]

[175]
Plasmid Name: FLAG-DTX3L-Full Length
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma)
Insert Size: ~2.0 kb
Vector Size: 6.4 kb
Constructed by: Justine Holleman
Construction Date: 10-12-2011
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
IMAGE clone ID: 4339554
GenBank No.: BC042191.1
Construction Details:
FLAG-Deltex-3-Like (DTX3L) was PCR amplified from pCMV-SPORT6-DTX3L
template (Thermo Scientific). Primers used are listed below. Briefly, the forward primer
carried a NotI restriction site and started at amino acid residue Ala2, in frame with the
3xFLAG epitope. The reverse primer carried a XbaI site and an in frame stop codon and
ended at E740. The PCR fragment was digested with NotI and XbaI and cloned into the
NotI and XbaI sites of p3xFLAG-CMV10.
DTX3L-pCMV10 F: 5’ATATGCGGCCGCG GCC TCC CAC CTG CGC CCG CCG TC
NotI
A
S
H
L
R
P
P
DTX3L-pCMV10 R: 5’ ATATTCTAGA TTA CTC AAT TCC TTT GGC TTT C
XbaI
stop E
I
G
K
A K

[176]
Plasmid Name: FLAG-DTX3L-C561A
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma)
Insert Size: ~2.2 kb
Vector Size: 6.4 kb
Constructed by: Justine Holleman
Construction Date: 03-12-2012
Location: Mini Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
To generate the single mutant FLAG-DTX3L-C561A we first amplified FLAG-DTX3L
template DNA using FLAG-DTX3L-Forward and FLAG-DTX3L-C561A-Reverse
primer in one tube and FLAG-DTX3L-Reverse and FLAG-DTX3L-C561A Forward
primer in tube two. The product of PCR reaction one was then used as a template to
anneal the C561A mutant strands. The forward primer carried a NotI restriction site and
started at amino acid residue Ala2, in frame with the 3xFLAG epitope. The reverse
primer carried a XbaI site and an in frame stop codon and ended at E740. The PCR
fragment was digested with NotI and XbaI and cloned into the NotI and XbaI sites of
3xFLAG-CMV10.
DTX3L-C561A-F: 5’ GAAGGAAAAGGGCATCGCTGTCATCTGTATGGACACC
C561A
DTX3L-C561A-R: 5’ GGTGTCCATACAGATGACAGCGATGCCCTTTTCCTTC
C561A
DTX3L-pCMV10 R: 5’ ATATTCTAGATTACTCAATTCCTTTGGCTTTC
XbaI
DTX3L-pCMV10 F: 5’ATATGCGGCCGCGGCCTCCCACCTGCGCCCGCCGTC
NotI

[177]
Plasmid Name: FLAG-DTX3L-3C/A
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma)
Insert Size: ~2.2 kb
Vector Size: 6.4 kb
Constructed by: Justine Holleman
Construction Date: 03-12-2012
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
FLAG-DTX3L-3C/A was PCR amplified using FLAG-DTX3L-C561A (single mutant)
template DNA extended with DTX3L- C596/599A -Forward oligo in PCR reaction 1.
Product of reaction 1 was then subjected to a second round of PCR using the DTX3LC596/599A -Reverse/pcmv10-R in tube two. The product of PCR reaction one was used
as a template to anneal the DTX3L-3C/A triple mutant strands and extended using
pcmv10-DTX3L-Forward/Reverse primers. The forward primer carried a NotI restriction
site and started at amino acid residue Ala2, in frame with the 3xFLAG epitope. The
reverse primer carried a XbaI site and an in frame stop codon and ended at E740. The
PCR fragment was digested with NotI and XbaI and cloned into the NotI and XbaI sites
of 3xFLAG-CMV10.
DTX3L-C596/599A-Forward:
5’ CATGTCATATAAGCCAATCGCTCCCACAGCCCAGACTTCCTATGGTATTC
C596A
C599A
DTX3L-C596/599A-Reverse:
5’GAATACCATAGGAAGTCTGGGCTGTGGGAGCGATTGGCTTATATGACATG
C599A
C596A
DTX3L-pCMV10 R: 5’ ATATTCTAGATTACTCAATTCCTTTGGCTTTC
XbaI
DTX3L-pCMV10 F: 5’ATATGCGGCCGCGGCCTCCCACCTGCGCCCGCCGTC
NotI

[178]
Plasmid Name:GST-DTX3L
Vector Backbone: pGEX-6p-1
Insert Size: ~2 kb
Vector Size: 5 kb
Constructed by: Justine Holleman
Construction Date: 10-24-2011
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
GST-DTX3L was PCR amplified from pCMV-SPORT6-DTX3L template (Thermo). The
forward primer carried a BamHI restriction site and started at amino acid residue Ala2, in
frame with the pGEX6p1 epitope. The reverse primer carried a XhoI site and an in frame
stop codon and ended at E740. The PCR fragment was digested with BamHI and XhoI
and cloned into the BamHI and XbaI sites of pGEX6p1.
F: 5’-ATAT GGA TCC GCC TCC CAC CTG CGC CCG CCG TC
Bam HI
R: 5’-ATAT CTC GAG TTA CTC AAT TCC TTT GGC TTT C
XhoI

[179]
Plasmid Name:GST-DTX3L-N-term
Vector Backbone: pGEX-6p-1
Insert Size: ~1.68 kb
Vector Size: 5 kb
Constructed by: Justine Holleman
Construction Date: 10-24-2011
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
GST-DTX3L was PCR amplified from pCMV-SPORT6-DTX3L template (Thermo). The
forward primer carried a BamHI restriction site and started at amino acid residue Ala2, in
frame with the pGEX6p1 epitope. The reverse primer carried a XhoI site and an in frame
stop codon and ended at I560. The PCR fragment was digested with BamHI and XhoI
and cloned into the BamHI and XbaI sites of pGEX6p1.
DTX3L-pGEX- F: 5’ ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC
BamHI
DTX3L-Nterm-GEX- R:
5’ ATATCTCGAGTCAGATGCCCTTTTCCTTCTTGTCCAGTTCAAAGC
XhoI STOP

[180]
Plasmid Name:GST-DTX3L-N-term
Vector Backbone: pGEX-6p-1
Insert Size: ~0.6 kb
Vector Size: 5 kb
Constructed by: Justine Holleman
Construction Date: 10-24-2011
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
GST-DTX3L was PCR amplified from pCMV10- DTX3L template. The forward primer
carried a BamHI restriction site and started at amino acid residue D529, in frame with the
3xFLAG epitope. The reverse primer carried a XhoI site and an in frame stop codon and
ended at E740. The PCR fragment was digested with BamHI and XhoI and cloned into
the BamHI and XbaI sites of pGEX6p1.
DTX3L-Cterm-GEX- F: 5’ ATATGGATCCGACATTGATAGCGATGATTCC
BamHI
DTX3L-pGEX- R: 5’ ATATCTCGAGTTACTCAATTCCTTTGGCTTTC
XhoI

[181]
Plasmid name: His-DTX3L
Vector Backbone: pET-21a(+) (Katherine Knight lab)
Insert size: ~2.1 kb
Vector size: 5.4 kb
Constructed by: Justine Holleman
Construction Date: 08-23-12
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
Full-length DTX3L was cloned into BamHI and XhoI sites pET-21a(+) vector using
below oligos and FLAG-DTX3L as a template:
DTX3L-pGEX- F: 5’ ATATGGATCC GCC TCC CAC CTG CGC CCG CCG TC
BamHI
pET-21a-DTX3L- R: 5’ ATAT CTCGAG CTC AAT TCC TTT GGC TTT CAG CTC
XhoI

pET-21a(+)
- DTX3L

[182]
Plasmid name: His-DTX3L-3C/A
Vector Backbone: pET-21a(+) (Katherine Knight lab)
Insert size: ~2.1 kb
Vector size: 5.4 kb
Constructed by: Justine Holleman
Construction Date: 08-23-12
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
DTX3L-3C/A was cloned into BamHI and XhoI sites pET-21a(+) vector using below
primers and Flag-DTX3L-3C/A as a template:
DTX3L-pGEX- F: 5’ ATATGGATCC GCC TCC CAC CTG CGC CCG CCG TC
BamHI
pET-21a-DTX3L- R: 5’ ATAT CTCGAGCTC AAT TCC TTT GGC TTT CAG CTC
XhoI

pET-21a(+)
- DTX3L

[183]
Plasmid Name: FLAG-AIP4-C830A ligase mutant
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma)
Insert Size: ~656 kb
Vector Size: 6.4 kb
Constructed by: Justine Holleman
Construction Date: 07-14-2011
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
FLAG-AIP4-C830A was amplified from myc-AIP4-C830A. Primers used are listed
below. Briefly, the forward primer carried a BamHI restriction site and started at amino
acid residue Gly2, in frame with the 3xFLAG epitope. The reverse primer carried a XhoI
restriction site and an in-frame stop codon and ended at E862. The PCR fragment was
digested with BamHI and XhoI and cloned into the BamHI and XhoI sites of p3xFLAGCMV10.
F: 5’- ATATGGATCC GGT AGT CTG ACC ATG AAA TCT TC
BamHI
R: 5’ - ATATTCTAGA TTA CTC TTG TCC AAA TCC TTC TGT TTC
XhoI

[184]
Plasmid Name: GST-AIP4-C830A
Vector Backbone: pGEX-6p-1
Insert Size: ~2.6 kb
Vector Size: 5 kb
Constructed by: Justine Holleman
Construction Date: 4-29-12
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
Construction Details:
GST-AIP4-C830A was PCR amplified from FLAG-AIP4-C830A template DNA and
sub-cloned into the BamHI-SmaI sites of pGEX6p1 using the below primers:
F: 5’-ATAT GGA TCC GGT AGT CTG ACC ATG AAA TCT TC
Bam HI
R: 5’-ATAT CCC GGG TTA CTC TTG TCC AAA TCC TTC TGT TTC
SmaI

BamHI
GST

AIP4-C830A
SmaI
pGEX6p1-AIP4C830A
~7.6 kb
AMP

[185]
Plasmid Name: FLAG-DTX1-Full Length
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma)
Insert Size: ~1.9 kb
Vector Size: 6.4 kb
Constructed by: Justine Holleman
Construction Date: 10-12-2011
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
IMAGE clone ID: 5931062
GenBank No.: BC048216
Construction Details:
FLAG-DTX1 was PCR amplified from human Deltex 1 (DTX1) DNA template. Primers
used are listed below. Briefly, the forward primer carried a HindIII restriction site and
started at amino acid residue S2, in frame with the 3xFLAG epitope. The reverse primer
carried a XbaI site and an in frame stop codon and ended at A620. The PCR fragment
was digested with HindIII and XbaI and cloned into the HindIII and XbaI sites of
p3xFLAG-CMV10.
DTX1-met-F: 5’-ATAT AAGCTT TCA CGG CCA GGC CAC GGT GGG C
HindIII S2
R
P
G
H
G
G
DTX1-stop-R2: 5’-ATAT TCTAGA TCA AGC CTG GTG TCG ACT CCG GC
XbaI
stop A620 K
A
A
A
E

[186]
Plasmid Name: FLAG-DTX2-Full Length
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma)
Insert Size: ~1.9 kb
Vector Size: 6.4 kb
Constructed by: Justine Holleman
Construction Date: 10-12-2011
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C
IMAGE clone ID: 4107018
GenBank No.: BC008856
Construction Details:
FLAG-DTX2 was PCR amplified from human Deltex 2 (DTX2) DNA template. Primers
used are listed below. Briefly, the forward primer carried a HindIII restriction site and
started at amino acid residue A2, in frame with the 3xFLAG epitope. The reverse primer
carried a XbaI site and an in frame stop codon and ended at Q622. The PCR fragment
was digested with HindIII and XbaI and cloned into the HindIII and XbaI sites of
p3xFLAG-CMV10.
DTX2-Met-F: 5’-ATAT AAGCTT GCC ATG GCC CCA AGC CCT TCC C
HindIII A2
M
A
P
S
P
S
DTX2-stop-R2: 5’-ATAT TCTAGA TCA CTG CTG CTC CAG GCA GTC
XbaI
stop Q622 Q
E L
C
D
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